

    <!DOCTYPE html>
<html class="">

        
<head>
    <title>Protecting the heart in cancer therapy | F1000Research</title>
    <meta charset="utf-8">
    <!--<meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>-->
    <!--<meta lang="$locale">-->
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="google-site-verification" content="9-QVycOO2_ob3Z9QzRmXv2CF08A9oyYXqWyTiVdKPlU" />
    <!-- This is commented out to fix display problems on mobile devices.
    We may use it again once we implement a responsive design that supports native device resolutions.
    <meta name="viewport" content="width=device-width"> -->

    <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">



    <link rel="alternate" title="Recent articles published in F1000Research" href="/rss" type="application/rss+xml">
            <link rel="alternate" type="application/pdf" title="PDF" href="https://f1000research.com/articles/7-1566/pdf"/>
        <link rel="canonical" href="https://f1000research.com/articles/7-1566" />
    
            <meta name="description" content="Read the original article in full on F1000Research: Protecting the heart in cancer therapy" />
    
            <meta name="og:title" content="F1000Research Article: Protecting the heart in cancer therapy.">
            <meta name="og:description" content="Read the latest article version by J. Emanuel Finet, W. H. Wilson Tang, at F1000Research.">
            <meta name="og:image" content="/img/sharing/og_research.png">
            <meta name="version-id" content="16550">
            <meta name="article-id" content="15190">
            <meta name="dc.title" content="Protecting the heart in cancer therapy">
            <meta name="dc.description" content="Recent advances in cancer prevention and management have led to an exponential increase of cancer survivors worldwide. Regrettably, cardiovascular disease has risen in the aftermath as one of the most devastating consequences of cancer therapies. In this work, we define cancer therapeutics-induced cardiotoxicity as the direct or indirect cardiovascular injury or injurious effect caused by cancer therapies. We describe four progressive stages of this condition and four corresponding levels of prevention, each having a specific goal, focus, and means of action. We subsequently unfold this didactic framework, surveying mechanisms of cardiotoxicity, risk factors, cardioprotectants, biomarkers, and diagnostic imaging modalities. Finally, we outline the most current evidence-based recommendations in this area according to multidisciplinary expert consensus guidelines.">
            <meta name="dc.subject" content="Cardiovascular disease, cancer, heart, cardioprotection, cardiotoxicity, prevention, biomarkers">
            <meta name="dc.creator" content="Finet, J. Emanuel">
            <meta name="dc.creator" content="Tang, W. H. Wilson">
            <meta name="dc.date" content="2018/09/28">
            <meta name="dc.identifier" content="doi:10.12688/f1000research.15190.1">
            <meta name="dc.source" content="F1000Research 2018 7:1566">
            <meta name="dc.format" content="text/html">
            <meta name="dc.language" content="en">
            <meta name="dc.publisher" content="F1000 Research Limited">
            <meta name="dc.rights" content="https://creativecommons.org/licenses/by/3.0/igo/">
            <meta name="dc.type" content="text">
            <meta name="prism.keyword" content="Cardiovascular disease">
            <meta name="prism.keyword" content="cancer">
            <meta name="prism.keyword" content="heart">
            <meta name="prism.keyword" content="cardioprotection">
            <meta name="prism.keyword" content="cardiotoxicity">
            <meta name="prism.keyword" content="prevention">
            <meta name="prism.keyword" content="biomarkers">
            <meta name="prism.publication.Name" content="F1000Research">
            <meta name="prism.publicationDate" content="2018/09/28">
            <meta name="prism.volume" content="7">
            <meta name="prism.number" content="1566">
            <meta name="prism.versionIdentifier" content="1">
            <meta name="prism.doi" content="10.12688/f1000research.15190.1">
            <meta name="prism.url" content="https://f1000research.com/articles/7-1566">
            <meta name="citation_title" content="Protecting the heart in cancer therapy">
            <meta name="citation_abstract" content="Recent advances in cancer prevention and management have led to an exponential increase of cancer survivors worldwide. Regrettably, cardiovascular disease has risen in the aftermath as one of the most devastating consequences of cancer therapies. In this work, we define cancer therapeutics-induced cardiotoxicity as the direct or indirect cardiovascular injury or injurious effect caused by cancer therapies. We describe four progressive stages of this condition and four corresponding levels of prevention, each having a specific goal, focus, and means of action. We subsequently unfold this didactic framework, surveying mechanisms of cardiotoxicity, risk factors, cardioprotectants, biomarkers, and diagnostic imaging modalities. Finally, we outline the most current evidence-based recommendations in this area according to multidisciplinary expert consensus guidelines.">
            <meta name="citation_description" content="Recent advances in cancer prevention and management have led to an exponential increase of cancer survivors worldwide. Regrettably, cardiovascular disease has risen in the aftermath as one of the most devastating consequences of cancer therapies. In this work, we define cancer therapeutics-induced cardiotoxicity as the direct or indirect cardiovascular injury or injurious effect caused by cancer therapies. We describe four progressive stages of this condition and four corresponding levels of prevention, each having a specific goal, focus, and means of action. We subsequently unfold this didactic framework, surveying mechanisms of cardiotoxicity, risk factors, cardioprotectants, biomarkers, and diagnostic imaging modalities. Finally, we outline the most current evidence-based recommendations in this area according to multidisciplinary expert consensus guidelines.">
            <meta name="citation_keywords" content="Cardiovascular disease, cancer, heart, cardioprotection, cardiotoxicity, prevention, biomarkers">
            <meta name="citation_journal_title" content="F1000Research">
            <meta name="citation_author" content="J. Emanuel Finet">
            <meta name="citation_author_institution" content="Section of Heart Failure and Transplantation Medicine, Robert and Suzanne Tomsich Department of Cardiovascular Medicine, and Sydell and Arnold Miller Family Heart and Vascular Institute, Cleveland Clinic, Cleveland, USA">
            <meta name="citation_author" content="W. H. Wilson Tang">
            <meta name="citation_author_institution" content="Section of Heart Failure and Transplantation Medicine, Robert and Suzanne Tomsich Department of Cardiovascular Medicine, and Sydell and Arnold Miller Family Heart and Vascular Institute, Cleveland Clinic, Cleveland, USA">
            <meta name="citation_author_institution" content="Cleveland Clinic Lerner College of Medicine at Case Western Reserve University; Center for Clinical Genomics; Cleveland Clinic, Cleveland, USA">
            <meta name="citation_publication_date" content="2018/09/28">
            <meta name="citation_volume" content="7">
            <meta name="citation_publication_number" content="1566">
            <meta name="citation_version_number" content="1">
            <meta name="citation_doi" content="10.12688/f1000research.15190.1">
            <meta name="citation_firstpage" content="1566">
            <meta name="citation_pdf_url" content="https://f1000research.com/articles/7-1566/v1/pdf">
    

    
    <link href="/img/favicon-research.ico" rel="shortcut icon" type="image/ico">
    <link href="/img/favicon-research.ico" rel="icon" type="image/ico">

        <link rel="stylesheet" href="/1597255280893/css/mdl/material-design-lite.css" type="text/css" media="all" />
    <link href="https://fonts.googleapis.com/icon?family=Material+Icons" rel="stylesheet">
    <link href="https://fonts.googleapis.com/css?family=Roboto:100,100i,300,300i,400,400i,500,500i,700,700i,900,900i" rel="stylesheet">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/MaterialDesign-Webfont/2.2.43/css/materialdesignicons.min.css" />

        
            
    <link rel="stylesheet" href="/1597255280893/css/F1000Research.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/animation.css" type="text/css" media="all" />

        <!--[if IE 7]><link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons-ie7.css" media="all" /><![endif]-->

                    <script>dataLayer = [];</script>
        <!-- Google Tag Manager -->
        <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
        new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
        j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
        'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
        })(window,document,'script','dataLayer','GTM-54Z2SBK');</script>
        <!-- End Google Tag Manager -->
    
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.8.1/jquery.min.js"></script>
    <script>window.jQuery || document.write('<script src="/js/vendor/jquery-1.8.1.min.js"><\/script>')</script>
    <script src="/1597255280893/js/vendor/modernizr-2.6.1-respond-1.1.0.min.js"></script>
    <script src="/1597255280893/js/shared_scripts/sticky.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/shared_scripts/menu.js"></script>
    <script src="/1597255280893/js/shared_scripts/navbar.js"></script>
    <script src="/1597255280893/js/shared_scripts/platforms.js"></script>
    <script src="/1597255280893/js/shared_scripts/object-polyfills.js"></script>
            <script src="/1597255280893/js/vendor/lodash.min.js"></script>
        <script>CKEDITOR_BASEPATH='https://f1000research.com/js/ckeditor/'</script>
    <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/plugins.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/app/research.js"></script>
    <script>window.reactTheme = 'research';</script>
    <script src="/1597255280893/js/public/bundle.js"></script>

    <script src="/1597255280893/js/app/research.ui.js"></script>
    <script src="/1597255280893/js/app/login.js"></script>
    <script src="/1597255280893/js/app/main.js"></script>
    <script src="/1597255280893/js/app/js-date-format.min.js"></script>
    <script src="/1597255280893/js/app/search.js"></script>
    <script src="/1597255280893/js/app/cookies_warning.js"></script>
    <script src="/1597255280893/js/mdl/mdl.min.js"></script>

    <script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
                <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/ckeditor.js"></script>
            <script src="/js/ckeditor/adapters/jquery.js"></script>
                <script src="/js/article/article_scrolling_module.js"></script>
            <script src="/js/article/article_stats.js"></script>
            <script src="/js/article/article.js"></script>
            <script src="/js/shared_scripts/referee_timeline_pagination.js"></script>
            <script src="/js/app/text_editor_controller.js"></script>
            <script src="//s7.addthis.com/js/250/addthis_widget.js#pubid=ra-503e5e99593dc42c"></script>
            <script src="/js/article/article_metrics.js"></script>
        
                                                                            <script>
            if (window.location.hash == '#_=_'){
                window.location = window.location.href.split('#')[0]
            }
        </script>

                    
        
    <!-- pixelId: 1641728616063202 :: assetPixelId: 6034867600215 :: funderPixelId:  -->

            <!-- Facebook pixel code (merged with EP GTM code) -->
        <script>
            !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function()

            {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}
            ;if(!f._fbq)f._fbq=n;
            n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0;
            t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
            document,'script','https://connect.facebook.net/en_US/fbevents.js');

            fbq('init', '1641728616063202');

            
            fbq('track', "PixelInitialized", {});
        </script>

        <noscript><img height="1" width="1" style="display:none"
            src="https://www.facebook.com/tr?id=1641728616063202&noscript=1&amp;ev=PixelInitialized"
        /></noscript>
        <!-- End Facebook Pixel Code -->
    
                <script>
            (function(h,o,t,j,a,r){
                h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)};
                h._hjSettings={hjid:917825,hjsv:6};
                a=o.getElementsByTagName('head')[0];
                r=o.createElement('script');r.async=1;
                r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv;
                a.appendChild(r);
            })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv=');
        </script>
    
</head>
<body  class="o-page-container no-js p-article o-layout-reset   ">

    
                            <!-- Google Tag Manager (noscript) -->
        <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54Z2SBK"
        height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
        <!-- End Google Tag Manager (noscript) -->
    
        
    <div class="o-page">

        <div id="notify-container"></div>
        <div id="pageWarning"></div>
        <div id="pageMessage"></div>
        <div id="pageFooterMessage"></div>

                                <div id="f1r-ga-data" data-name="f1r-ga-data" class="f1r-ga-data"
                data-user-registered="false"
                data-user-module=""
                data-current-path=""
                data-location=""
                data-website="F1000Research"
                data-websiteDisplayName="F1000Research">
            </div>
        
                
        
        <div class="header-wrapper   js-navbar-space ">
                            


    










        
                            
    
            



<nav class="c-navbar js-navbar js-mini-nav js-sticky c-navbar--js-sticky c-navbar--userSite c-navbar__platform-bgcolor  c-navbar--bg-f1000research ">

    <div class="c-navbar__content">

                                <div class="c-navbar__extras">
            <div class="o-wrapper">
                <div class="o-actions o-actions--middle c-navbar__extras-row">
                    <div class="o-actions__primary">
                        
                                            </div>
                                    </div>
            </div>
        </div>

        <div class="o-wrapper t-inverted js-sticky-start">

            <div class="c-navbar__branding-row">
                <div class="c-navbar__row">


                                        
                    <div class="c-navbar__primary u-mr--2">

                                                                                                                                                                                                    <a href="/" class="c-navbar__branding u-ib u-middle"   data-test-id="nav_branding"  >
                                <img class="u-ib u-middle" src="/img/research/F1000Research_white_solid.svg" alt="F1000Research">
                            </a>
                                            </div>

                    <div class="c-navbar__secondary c-navbar__row">


                                                
                                                    <form action="/search" class="-navbar__secondary u-mr--2 c-search-form js-search-form u-hide u-show@navbar">
                                <label for="searchInput" class="c-search-form__label _mdl-layout">
                                    <input name="q" type="search" class="c-search-form__input" id="searchInput" placeholder="Search">
                                    <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                </label>
                            </form>
                        
                                                
                                                    <div class="c-navbar__primary u-hide u-show@navbar">
                                <div class="_mdl-layout c-navbar__cta">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--no-shadow mdl-button--multi-line mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                            </div>
                        

                                                
                        <span class="u-hide@navbar _mdl-layout u-nowrap">

                                                            <button type="button" class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" data-focus="#navbar_mob_search_input" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_search_mob"  ><i class="material-icons">search</i></button>
                            
                                                            <button class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon mdl-button--multi-line c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" type="button" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_toggle_mob"  >
                                    <i class="material-icons c-navbar__toggle-open">menu</i>
                                    <i class="material-icons c-navbar__toggle-close">close</i>
                                </button>
                                                    </span>
                    </div>

                </div>
            </div>

                        
                            <div class="c-navbar__menu-row js-navbar-block is-collapsed" id="navbarMenu">

                                                                                                                                                
                                                                    
                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                            

                                                                
                                                                                                                                                                                                                                
                                            
                    <div class="c-navbar__menu-row-content">

                                                                            <div class="u-hide@navbar c-navbar__menu-bar-spacing">
                                <form action="/search" class="c-search-form js-search-form">
                                    <label for="navbar_mob_search_input" class="c-search-form__label _mdl-layout">
                                        <input id="navbar_mob_search_input" name="q" type="search" class="c-search-form__input" placeholder="Search">
                                        <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                    </label>
                                </form>
                            </div>
                        
                        <div class="o-actions o-actions--middle">

                            <div class="o-actions__primary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="main-menu"   role="menubar" aria-label="Main Navigation"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/browse/articles" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="0"
                              data-test-id="nav_browse"                              >Browse</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/gateways" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_gatewaysViewAndBrowse"                              >Gateways & Collections</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="2"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_for-authors"                              >How to Publish</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="How to Publish">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_submit-manuscript"                      href="/for-authors/publish-your-research"
                    role="menuitem"
                    tabindex="0">Submit your Research</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/for-authors/my-submissions"
                    role="menuitem"
                    tabindex="-1">My Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines"                      href="/for-authors/article-guidelines"
                    role="menuitem"
                    tabindex="-1">Article Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines-new-versions"                      href="/for-authors/article-guidelines-new-versions"
                    role="menuitem"
                    tabindex="-1">Article Guidelines (New Versions)</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_data-guidelines"                      href="/for-authors/data-guidelines"
                    role="menuitem"
                    tabindex="-1">Data Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_asset-guidelines"                      href="/for-authors/posters-and-slides-guidelines"
                    role="menuitem"
                    tabindex="-1">Posters and Slides Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_document-guidelines"                      href="/for-authors/document-guidelines"
                    role="menuitem"
                    tabindex="-1">Document Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-processing-charges"                      href="/for-authors/article-processing-charges"
                    role="menuitem"
                    tabindex="-1">Article Processing Charges</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_finding-referees"                      href="/for-authors/tips-for-finding-referees"
                    role="menuitem"
                    tabindex="-1">Finding Article Reviewers</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="3"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_about-contact"                              >About</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="About">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_about-page"                      href="/about"
                    role="menuitem"
                    tabindex="0">How it Works</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_referee-guidelines"                      href="/for-referees/guidelines"
                    role="menuitem"
                    tabindex="-1">For Reviewers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_advisoryPanel"                      href="/advisors"
                    role="menuitem"
                    tabindex="-1">Our Advisors</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_policy-page"                      href="/about/policies"
                    role="menuitem"
                    tabindex="-1">Policies</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_glossary-page"                      href="/glossary"
                    role="menuitem"
                    tabindex="-1">Glossary</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_faqs-page"                      href="/faqs"
                    role="menuitem"
                    tabindex="-1">FAQs</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              u-hide u-show@navbar"
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      u-hide u-show@navbar"
                                          data-test-id="nav_for-developers"                      href="/developers"
                    role="menuitem"
                    tabindex="-1">For Developers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_newsroom-page"                      href="/newsroom"
                    role="menuitem"
                    tabindex="-1">Newsroom</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_contact-page"                      href="/contact"
                    role="menuitem"
                    tabindex="-1">Contact</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="4"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="https://blog.f1000.com/blogs/f1000research/" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                             target="_blank"                                                         tabindex="-1"
                              data-test-id="nav_blog"                              >Blog</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                            <div class="o-actions__secondary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="secondary-items"   role="menubar" aria-label="My Account"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="0"
                              data-test-id="nav_my-research"                              >My Research</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="My Research">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/login?originalPath=/my/submissions"
                    role="menuitem"
                    tabindex="0">Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-email-alerts"                      href="/login?originalPath=/my/email-alerts"
                    role="menuitem"
                    tabindex="-1">Content and Tracking Alerts</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-user-details"                      href="/login?originalPath=/my/user-details"
                    role="menuitem"
                    tabindex="-1">My Details</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/login?originalPath=/articles/7-1566.html" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_sign-in"                              >Sign In</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                                                                                        <div class="_mdl-layout c-navbar__cta u-hide@navbar c-navbar__menu-bar-spacing">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--multi-line mdl-button--no-shadow mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research_mob"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                                                    </div>

                    </div>

                </div>
            
        </div>

    </div>

</nav>
                    </div>

        <div class="content-wrapper o-page__main row ">
            <div id="highlight-area" class="content ">
                





<div id=article-metadata class=hidden> <input type=hidden name=versionId value=16550 /> <input type=hidden id=articleId name=articleId value=15190 /> <input type=hidden id=xmlUrl value="/articles/7-1566/v1/xml"/> <input type=hidden id=xmlFileName value="-7-1566-v1.xml"> <input type=hidden id=article_uuid value=6187c644-06df-464f-8554-a8942e79cdcc /> <input type=hidden id=referer value=""/> <input type=hidden id=meta-article-title value="Protecting the heart in cancer therapy"/> <input type=hidden id=workspace-export-url value="https://sciwheel.com/work/api/import/external?doi=10.12688/f1000research.15190.1"/> <input type=hidden id=versionDoi value="10.12688/f1000research.15190.1"/> <input type=hidden id=usePmcStats value=true /> </div> <main class="o-wrapper p-article__wrapper js-wrapper"> <script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "ScholarlyArticle",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://f1000research.com/articles/7-1566"
  },
  "headline": "Protecting the heart in cancer therapy",
  "datePublished": "2018-09-28T09:19:51",
  "dateModified": "2018-09-28T09:19:51",
  "author": [
    {
      "@type": "Person",
      "name": "J. Emanuel Finet"
    },    {
      "@type": "Person",
      "name": "W. H. Wilson Tang"
    }  ],
  "publisher": {
    "@type": "Organization",
    "name": "F1000Research",
    "logo": {
      "@type": "ImageObject",
      "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
      "height": 480,
      "width": 60
    }
  },
  "image": {
    "@type": "ImageObject",
    "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
    "height": 1200,
    "width": 150
  },
  "description": "Recent advances in cancer prevention and management have led to an exponential increase of cancer survivors worldwide. Regrettably, cardiovascular disease has risen in the aftermath as one of the most devastating consequences of cancer therapies. In this work, we define cancer therapeutics-induced cardiotoxicity as the direct or indirect cardiovascular injury or injurious effect caused by cancer therapies. We describe four progressive stages of this condition and four corresponding levels of prevention, each having a specific goal, focus, and means of action. We subsequently unfold this didactic framework, surveying mechanisms of cardiotoxicity, risk factors, cardioprotectants, biomarkers, and diagnostic imaging modalities. Finally, we outline the most current evidence-based recommendations in this area according to multidisciplinary expert consensus guidelines."
}
</script> <div class="o-layout o-layout--right-gutter"> <div id=article_secondary-column class="p-article__main o-layout__item u-font-size--legal u-2/3@article not-expanded "> <div class=float-left> <script type="application/ld+json">
  {
    "@context": "http://schema.org",
    "@type": "BreadcrumbList",
    "itemListElement": [
              {
          "@type": "ListItem",
          "position": "1",
          "item": {
            "@id": "https://f1000research.com/",
            "name": "Home"
          }
        },              {
          "@type": "ListItem",
          "position": "2",
          "item": {
            "@id": "https://f1000research.com/browse/articles",
            "name": "Browse"
          }
        },              {
          "@type": "ListItem",
          "position": "3",
          "item": {
            "@id": "https://f1000research.com/articles/7-1566.html",
            "name": "Protecting the heart in cancer therapy"
          }
        }          ]
  }
  </script> <div class="breadcrumbs js-breadcrumbs"> <a href="/" class=f1r-standard-link>Home</a> <span class=item_separator></span> <a href="/browse/articles" class=f1r-standard-link>Browse</a> <span class=item_separator></span> Protecting the heart in cancer therapy </div> </div> <div class="article-badges-container u-mb--2"> <div class=crossmark-new> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script> <a data-target=crossmark><img height=30 width=150 src="https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_Color_horizontal.svg"/></a> </div> <div id=crossmark-dialog style="display: none;" title=""> <iframe id=crossmark-dialog-frame frameborder=0></iframe> </div> <div class=clearfix></div> </div> <div class=article-interaction-container> <div id=main-article-count-box class=article-count-box> <div class="article-metrics-wrapper metrics-icon-wrapper" data-version-id=16550 data-id=15190 data-downloads="" data-views="" data-scholar="10.12688/f1000research.15190.1" data-recommended="" data-doi="10.12688/f1000research.15190.1" data-f1r-ga-helper="Article Page Metrics (Desktop)"> <span class="metrics-on-browse article-metrics-icon f1r-icon icon-89_metrics"></span> <div class="count-title article-metrics-text">ALL Metrics</div> <div class=js-article-metrics-container></div> </div> <div> <div class=count-delimiter></div> <div title="Total views from F1000Research and PubMed Central"> <div class="count-container view-count js-views-count">-</div> <div class=count-title><span class="count-title-icon count-title-views-icon"></span>Views</div> </div> <div class=download-counts hidden> <div class=count-delimiter></div> <div title="Total downloads from F1000Research and PubMed Central"> <div class="count-container js-downloads-count"></div> <div class=count-title><span class="count-title-icon f1r-icon icon-76_download_file"></span>Downloads</div> </div> </div> </div> </div> <div id=main-article-interaction-box class="article-interaction-box has-control-tab"> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-102_download_pdf"></span> <a href="https://f1000research.com/articles/7-1566/v1/pdf?article_uuid=6187c644-06df-464f-8554-a8942e79cdcc" title="Download PDF" class="button-link download pdf-download-helper" target=_blank>Get PDF</a> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-103_download_xml"></span> <a id=download-xml href="#" class="button-link download" title="Download XML">Get XML</a> </div> </div> <div class="article-interaction-info article-page"> <div class="cite-article-popup-wrapper article-page-interaction-box"> <div class="article-interaction-button cite-article-button" title="Cite this article" data-windowref=cite-article-popup-15190-1> <span class="f1r-icon icon-82_quote"></span> <a href="#" class="button-link cite-article-popup-link" title="Cite Article">Cite</a> </div> <div id=cite-article-popup-15190-1 class="popup-window-wrapper is-hidden"> <div class=cite-popup-background></div> <div class="popup-window top-popup cite-this-article-box research-layout"> <div class="popup-window-title small cite-title">How to cite this article</div> <span id=cite-article-text-15190-1 data-test-id=copy-citation_text> <span class="article-title-and-info in-popup">Finet JE and Tang WHW. Protecting the heart in cancer therapy [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2018, <b>7</b>(F1000 Faculty Rev):1566 (<a class=new-orange href="https://doi.org/10.12688/f1000research.15190.1" target=_blank>https://doi.org/10.12688/f1000research.15190.1</a>) </span> <div class="popup-window-title small margin-top-20 margin-bottom-20 note"> <strong>NOTE:</strong> it is important to ensure the information in square brackets after the title is included in all citations of this article. </div> <div class=float-right> <button class="secondary no-fill orange-text-and-border margin-right-20 close-cite-popup uppercase">Close</button> <button id=copy-citation-details class="secondary orange copy-cite-article-version uppercase js-clipboard" title="Copy the current citation details to the clipboard." data-clipboard-target="#cite-article-text-15190-1" data-test-id=copy-citation_button>Copy Citation Details</button> </div> </div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-76_download_file"></span> <a id=export-citation href="#" class="button-link download" title="Export Citation">Export</a> </div> <div class="modal-window-wrapper is-hidden"> <div id=export-citation-popup class="modal-window padding-20"> <div class=modal-window-close-button></div> <div class=modal-window-title>Export Citation</div> <div class=modal-window-row> <div> <input type=radio name=export-citation-option value=WORKSPACE /> <span class=radio-label>Sciwheel</span> </div> <div> <input type=radio name=export-citation-option value=ENDNOTE /> <span class=radio-label>EndNote</span> </div> <div> <input type=radio name=export-citation-option value=REF_MANAGER /> <span class=radio-label>Ref. Manager</span> </div> <div> <input type=radio name=export-citation-option value=BIBTEX /> <span class=radio-label>Bibtex</span> </div> <div> <input type=radio name=export-citation-option value=PROCITE /> <span class=radio-label>ProCite</span> </div> <div> <input type=radio name=export-citation-option value=SENTE /> <span class=radio-label>Sente</span> </div> </div> <div class=modal-window-footer> <button class=general-white-orange-button id=export-citation-submit>EXPORT</button> </div> <div class=default-error style="display: none;">Select a format first</div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-90_track"></span> <a class="button-link track-article" data-article-id=15190 id=track-article-signin-15190 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/15190?target=/articles/7-1566.html">Track</a> </div> </div> <div class="article-interaction-info article-page"> <div class="article-interaction-button email-article"> <span class="f1r-icon icon-6_email"></span> <a href="#" class=button-link title="Email this article">Email</a> </div> <div class="email-article-version-container small-tooltip _chrome-fix"> <div class=close-icon><span class="f1r-icon icon-3_close_big"></span></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=16550 /> <input name=articleId type=hidden value=15190 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-34_share"></span> <a href="#" class="button-link last addthis_button share-article" title="Share this article">Share</a> </div> </div> </div> <div id=article-interaction-control-tab class=article-interaction-control-tab> <div id=hide-article-interaction class=article-interaction-control title="Hide Toolbox">&#9644;</div> <div id=show-article-interaction class="article-interaction-control open" title="Show Toolbox">&#10010;</div> </div> </div> <div class="article-header-information article-page"> <div class="f1r-article-mobile article-heading-bar"></div> <div class="article-type article-display">Review </div> <div class="article-title-and-info article-view highlighted-article" id=anchor-title> <h1>Protecting the heart in cancer therapy</h1><span class=other-info> [version 1; peer review: 2 approved]</span> </div> <div class=article-subtitle></div> <div class=f1r-article-desk> <div class="authors _mdl-layout"><span class=""><a href="mailto:finetj@ccf.org" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>J. Emanuel Finet</span></a><sup>1</sup>,&nbsp;</span><span class=""><a href="mailto:tangw@ccf.org" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>W. H. Wilson Tang</span></a><a href="https://orcid.org/0000-0002-8335-735X" target=_blank id=author-orcid-1><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=author-orcid-1><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0002-8335-735X</div><sup>1,2</sup></span></div> </div> <div class=f1r-article-mobile> <div class="authors _mdl-layout"><span class=""><a href="mailto:finetj@ccf.org" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>J. Emanuel Finet</span></a><sup>1</sup>,&nbsp;</span><span class=""><a href="mailto:tangw@ccf.org" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>W. H. Wilson Tang</span></a><a href="http://orcid.org/0000-0002-8335-735X" target=_blank id=mauthor-orcid-1><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=mauthor-orcid-1><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0002-8335-735X</div><sup>1,2</sup></span></div> </div> <div class=f1r-article-mobile> <div class=article-pubinfo-mobile> PUBLISHED 28 Sep 2018 </div> </div> <span class=Z3988 title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft_id=info:doi/10.12688%2Ff1000research.15190.1"></span> <div class=f1r-article-desk> <div class="contracted-details first"> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> Section of Heart Failure and Transplantation Medicine, Robert and Suzanne Tomsich Department of Cardiovascular Medicine, and Sydell and Arnold Miller Family Heart and Vascular Institute, Cleveland Clinic, Cleveland, USA<br/> <sup>2</sup> Cleveland Clinic Lerner College of Medicine at Case Western Reserve University; Center for Clinical Genomics; Cleveland Clinic, Cleveland, USA<br/> <p> <div class=margin-bottom> J. Emanuel Finet <br/> <span>Roles: </span> Conceptualization, Data Curation, Writing – Original Draft Preparation </div> <div class=margin-bottom> W. H. Wilson Tang <br/> <span>Roles: </span> Conceptualization, Funding Acquisition, Writing – Review & Editing </div> </p> </div> </div> </div> <div class=f1r-article-mobile> <div class="article-page-section-box margin-bottom-40 research-layout"> <span class=box-title> <span class="f1r-icon icon-85_peer_review"></span> OPEN PEER REVIEW </span> <button class="tertiary grey float-right" data-scrollto=article-reports>DETAILS</button> <div class="status-row referee-reports-container"> REVIEWER STATUS <span class=status-icons> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=39294-38452></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=39295-38453></span> </span> </div> </div> </div> </div> <h2 class="article-headings article-page-abstract" id=anchor-abstract> <span class="f1r-article-mobile-inline abstract-heading-border"></span> Abstract </h2> <div class="article-abstract article-page-general-text-mobile research-layout"> <div class="abstract-text is-expanded"> Recent advances in cancer prevention and management have led to an exponential increase of cancer survivors worldwide. Regrettably, cardiovascular disease has risen in the aftermath as one of the most devastating consequences of cancer therapies. In this work, we define cancer therapeutics-induced cardiotoxicity as the direct or indirect cardiovascular injury or injurious effect caused by cancer therapies. We describe four progressive stages of this condition and four corresponding levels of prevention, each having a specific goal, focus, and means of action. We subsequently unfold this didactic framework, surveying mechanisms of cardiotoxicity, risk factors, cardioprotectants, biomarkers, and diagnostic imaging modalities. Finally, we outline the most current evidence-based recommendations in this area according to multidisciplinary expert consensus guidelines. </div> <div class=abstract-for-mobile> <div class="margin-top-30 padding-bottom-30 research-layout is-centered"> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border show" style="display: none;"> READ ALL <span class="f1r-icon icon-14_more_small orange vmiddle big"></span> </button> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border hide"> READ LESS <span class="f1r-icon icon-10_less_small orange vmiddle big"></span> </button> </div> </div> </div> <div class=clearfix></div> <div class="article-context no-divider"> <div class="article-abstract article-page-general-text-mobile research-layout generated-article-body"> <h2 class=main-title>Keywords</h2> <p class="u-mb--0 u-pb--2"> Cardiovascular disease, cancer, heart, cardioprotection, cardiotoxicity, prevention, biomarkers </p> </div> </div> <div class=article-information> <span class="info-separation padding-bottom"> <div id=corresponding-author-icon class="email-icon float-left"> <span class="f1r-icon icon-6_email orange"></span> <div id=corresponding-author-window class="margin-top-20 popup-window-wrapper is-hidden"> <div class="popup-window corresponding-authors-popup"> <div class=corresponding-author-container> <div class="popup-window-title small">Corresponding Author(s)</div> <div class=authors> J. Emanuel Finet (<a href="mailto:finetj@ccf.org">finetj@ccf.org</a>) <br> W. H. Wilson Tang (<a href="mailto:tangw@ccf.org">tangw@ccf.org</a>) </div> </div> <div class="margin-top margin-bottom float-left"> <button id=close-popup-window class=general-white-orange-button>Close</button> </div> </div> </div> </div> <span class="icon-text float-left" data-test-id=box-corresponding-author> <b>Corresponding authors:</b> J. Emanuel Finet, W. H. Wilson Tang </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom competing-interests-display"> <span class=competing-interests-title>Competing interests:</span> No competing interests were disclosed. </span> <div class="info-separation padding-bottom grant-information-display"> <span class=grant-information-title>Grant information:</span> W. H. Wilson Tang is supported by grants from the National Institutes of Health (R01HL103866, P20HL113452, R01DK106000, and R01HL126827). <br/> <i>The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</i> </div> <span class="f1r-article-desk info-separation padding-bottom"> <span class="copywrite-icon float-left"> <span class="f1r-icon icon-100_open_access"></span> </span> <span class="icon-text float-left" data-test-id=box-copyright-text> <b>Copyright:</b>&nbsp; © 2018 Finet JE and Tang WHW. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom" data-test-id=box-how-to-cite> <b>How to cite:</b> <span class="article-title-and-info in-article-box"> Finet JE and Tang WHW. Protecting the heart in cancer therapy [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2018, <b>7</b>(F1000 Faculty Rev):1566 (<a href="https://doi.org/10.12688/f1000research.15190.1" target=_blank>https://doi.org/10.12688/f1000research.15190.1</a>) </span> <span class=info-separation data-test-id=box-first-published><b>First published:</b> 28 Sep 2018, <b>7</b>(F1000 Faculty Rev):1566 (<a href="https://doi.org/10.12688/f1000research.15190.1" target=_blank>https://doi.org/10.12688/f1000research.15190.1</a>)</span> <span class=info-separation data-test-id=box-latest-published><b>Latest published:</b> 28 Sep 2018, <b>7</b>(F1000 Faculty Rev):1566 (<a href="https://doi.org/10.12688/f1000research.15190.1" target=_blank>https://doi.org/10.12688/f1000research.15190.1</a>)</span> </div> <div class=clearfix></div> <div id=article-context class=article-context> <div id=article1-body class=generated-article-body><h2 class=main-title id=d17740e176>Introduction</h2><p class="" id=d17740e179>Recent advances in cancer prevention and management have led to an exponential increase of cancer survivors worldwide<sup><a href="#ref-1">1</a></sup>. Regrettably, cardiovascular disease (CVD) has risen in the aftermath as one of the most devastating consequences of cancer therapies<sup><a href="#ref-2">2</a>,<a href="#ref-3">3</a></sup>, being most prevalent in adult survivors of breast cancer and hematological malignancies<sup><a href="#ref-1">1</a>,<a href="#ref-4">4</a>,<a href="#ref-5">5</a></sup>.</p><p class="" id=d17740e203>In this work, we define cancer therapeutics-induced cardiotoxicity (CTIC) as the direct or indirect cardiovascular injury or injurious effect caused by cancer therapies, such as mediastinal radiotherapy<sup><a href="#ref-6">6</a></sup> and/or some chemotherapeutic agents<sup><a href="#ref-7">7</a></sup>. These incipient toxic changes (e.g. cardiomyocyte apoptosis, cardiac ion-channel alteration, endothelial damage, etc.) can further develop into complex cardiovascular conditions, such as heart failure (HF), valvular heart disease, coronary artery disease (CAD), pericardial disease, systemic and pulmonary hypertension, arrhythmias, and thromboembolic disease, among others<sup><a href="#ref-8">8</a>,<a href="#ref-9">9</a></sup>. Concomitant pre-existent cardiovascular risk factors have been shown to foment this pathogenesis<sup><a href="#ref-10">10</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d17740e228>Pathogenesis of cancer therapeutics-induced cardiotoxicity</h2><div class=section><a name=d17740e231 class=n-a></a><h3 class=section-title>Cardiotoxic chemotherapy</h3><p class="" id=d17740e236>Doxorubicin (and other agents in the anthracycline family) is the archetype chemotherapeutic leading to CTIC, historically called anthracycline-induced cardiotoxicity or anthracycline-induced cardiomyopathy (AIC)<sup><a href="#ref-11">11</a></sup>. The hallmark of this condition is a HF syndrome arising from dilated cardiomyopathy (DCM)<sup><a href="#ref-11">11</a></sup>; supraventricular and ventricular arrhythmias have also been described during anthracycline administration but seldom require intervention<sup><a href="#ref-12">12</a></sup>. Its prevalence has not been thoroughly studied owing to lack of a uniform definition, inconsistent diagnostic criteria, and underreporting; in modern times, it is thought to affect 17–23% of survivors of pediatric hematological malignancies<sup><a href="#ref-13">13</a>–<a href="#ref-15">15</a></sup> and accounts for 2.6% of all patients with non-ischemic cardiomyopathy undergoing cardiac transplantation<sup><a href="#ref-16">16</a></sup>.</p><p class="" id=d17740e262>In addition to anthracyclines, an increasing number of chemotherapeutic agents have been labeled as “cardiotoxic”, with particular mechanisms of action that lead to distinctive cardiovascular effects, and in turn various degrees of frequency and severity (see <a href="#T1">Table 1</a> for a list of the most important cardiotoxic chemotherapeutic agents currently available in the US)<sup><a href="#ref-7">7</a>,<a href="#ref-8">8</a>,<a href="#ref-17">17</a></sup>. Because historical cardiotoxicity was mediated by non-specific agents such as anthracycline and alkylating agents, it was believed that the novel “targeted therapeutics” (e.g. monoclonal antibodies, tyrosine kinase inhibitors, etc.) would provide fewer off-target adverse effects. However, an increasingly systematic evaluation and reporting of cardiovascular safety, along with a concomitant explosion of basic<sup><a href="#ref-18">18</a></sup>, translational<sup><a href="#ref-19">19</a></sup>, and clinical research in the area of CTIC<sup><a href="#ref-20">20</a></sup>, have progressively revealed that a large number of these targeted agents are mechanistically determined to cause cardiotoxicity<sup><a href="#ref-21">21</a></sup>. Based on the weight of the evidence, the US Food and Drug Administration has recently issued several cardiovascular box warnings for some of these agents, such as myocardial toxicity for anthracyclines, cardiomyopathy for ERBB2 inhibitors, QT prolongation and sudden cardiac death for certain tyrosine kinase inhibitors, and immune-mediated adverse reactions (i.e. myocarditis) for CTLA-4 inhibitors, among others (see <a href="#T1">Table 1</a>)<sup><a href="#ref-17">17</a></sup>.</p><a name=T1 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 1. Chemotherapy agents associated with cancer therapeutics-induced cardiotoxicity.</h3><p id=d17740e312>Text in bold represents US Food and Drug Administration box warnings. 5-FU, 5-fluorouracil; ALK, anaplastic lymphoma kinase; CSF-1R, colony-stimulating factor 1 receptor; ECG, electrocardiogram; EGFR, epidermal growth factor receptor; FKBP, FK506-binding protein; FGFR, fibroblast growth factor receptor; FLT3, FMS-like tyrosine kinase 3; GIST, gastrointestinal stromal tumor; GVHD, graft-versus-host disease; LT3, Lymphotoxin 3; HDAC, histone deacetylase; HGFR, hepatocyte growth factor receptor; HIF-1, hypoxia-inducible factor-1; Ig, immunoglobulin; IGF-1R, insulin-like growth factor 1-receptor; IL, interleukin; LAK, lymphokine-activated killer; mTOR, mammalian target of rapamycin; NK, natural killer; PD-1, programmed death 1; PDGFR, platelet-derived growth factor receptor; PD-L1, programmed death ligand 1; PNET, primitive neuroectodermal tumor; SCD, sudden cardiac death; TdP, Torsades de Pointes; TIL, tumor-infiltrating lymphocyte; VEGF; vascular endothelial growth factor; VEGFR, vascular endothelial growth factor receptor.</p></div><table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d17740e316 class=n-a></a><thead><a name=d17740e318 class=n-a></a><tr><a name=d17740e320 class=n-a></a><th align=center colspan=5 rowspan=1><a name=d17740e322 class=n-a></a>Chemotherapy agents associated with cancer therapeutics-induced cardiotoxicity</th></tr><tr><a name=d17740e326 class=n-a></a><th align=center colspan=1 rowspan=1><a name=d17740e328 class=n-a></a>Family</th><th align=center colspan=1 rowspan=1><a name=d17740e331 class=n-a></a>Agent</th><th align=center colspan=1 rowspan=1><a name=d17740e334 class=n-a></a>Approved uses</th><th align=center colspan=1 rowspan=1><a name=d17740e337 class=n-a></a>Mechanism of action</th><th align=center colspan=1 rowspan=1><a name=d17740e340 class=n-a></a>Cardiovascular toxicities</th></tr></thead><tbody><a name=d17740e345 class=n-a></a><tr><a name=d17740e347 class=n-a></a><td align=center colspan=1 rowspan=5 valign=middle><a name=d17740e349 class=n-a></a>Anthracyclines</td><td align=center colspan=1 rowspan=1><a name=d17740e352 class=n-a></a>Doxorubicin</td><td align=center colspan=1 rowspan=1><a name=d17740e355 class=n-a></a> <i>Breast cancer, non-Hodgkin lymphoma, Burkitt</i><br class=br><i>lymphoma, mantle cell lymphoma, Hodgkin</i><br class=br><i>lymphoma, Waldenstrom macroglobulinemia,</i><br class=br><i>acute lymphocytic leukemia, small cell lung cancer, multiple</i><br class=br><i>myeloma, gastric cancer, bladder cancer, Wilms’</i><br class=br><i>tumor, bone sarcoma, soft tissue sarcoma, thymoma,</i><br class=br><i>neuroblastoma, hepatoblastoma, endometrial cancer</i> </td><td align=center colspan=1 rowspan=5 valign=middle><a name=d17740e380 class=n-a></a>Anthracyclines bind directly to DNA<br class=br>(intercalation) and also inhibit DNA repair<br class=br>(via topoisomerase II inhibition), resulting<br class=br>in blockade of DNA and RNA synthesis<br class=br>and fragmentation of DNA. Doxorubicin<br class=br>is also a p53 inhibitor and powerful iron<br class=br>chelator; the iron–doxorubicin complex<br class=br>binds to DNA and cell membranes,<br class=br>producing free radicals that cleave the<br class=br>DNA and cell membranes.</td><td align=center colspan=1 rowspan=5 valign=middle><a name=d17740e402 class=n-a></a>Acute myocarditis, cardiomyopathy,<br class=br>heart failure, bradyarrhythmias and<br class=br>tachyarrhythmias, non-specific ST or<br class=br>T wave changes. <b>BOX WARNING:</b><br class=br><b>MYOCARDIAL TOXICITY</b> </td></tr><tr><a name=d17740e418 class=n-a></a><td align=center colspan=1 rowspan=1><a name=d17740e420 class=n-a></a>Daunorubicin</td><td align=center colspan=1 rowspan=1><a name=d17740e423 class=n-a></a> <i>Acute myelocytic leukemia, acute lymphocytic</i><br class=br><i>leukemia, Kaposi sarcoma, non-Hodgkin lymphoma</i> </td></tr><tr><a name=d17740e433 class=n-a></a><td align=center colspan=1 rowspan=1><a name=d17740e435 class=n-a></a>Idarubicin</td><td align=center colspan=1 rowspan=1><a name=d17740e438 class=n-a></a> <i>Acute promyelocytic leukemia, acute myelocytic</i><br class=br><i>leukemia</i> </td></tr><tr><a name=d17740e448 class=n-a></a><td align=center colspan=1 rowspan=1><a name=d17740e450 class=n-a></a>Epirubicin</td><td align=center colspan=1 rowspan=1><a name=d17740e453 class=n-a></a> <i>Breast cancer, soft tissue sarcoma, bone sarcoma,</i><br class=br><i>gastric cancer, esophageal cancer</i> </td></tr><tr><a name=d17740e463 class=n-a></a><td align=center colspan=1 rowspan=1><a name=d17740e465 class=n-a></a>Mitoxantrone</td><td align=center colspan=1 rowspan=1><a name=d17740e468 class=n-a></a> <i>Non-Hodgkin lymphoma, Hodgkin lymphoma,</i><br class=br><i>prostate cancer, breast cancer, acute promyelocytic</i><br class=br><i>leukemia, acute myelocytic leukemia</i> </td></tr><tr><a name=d17740e482 class=n-a></a><td align=center colspan=1 rowspan=6 valign=middle><a name=d17740e484 class=n-a></a>Alkylating agents</td><td align=center colspan=1 rowspan=1><a name=d17740e487 class=n-a></a>Cyclophosphamide</td><td align=center colspan=1 rowspan=1><a name=d17740e490 class=n-a></a> <i>Breast cancer, non-Hodgkin lymphoma, mantle cell</i><br class=br><i>lymphoma, follicular lymphoma, Burkitt lymphoma,</i><br class=br><i>Hodgkin lymphoma, Waldenstrom macroglobulinemia,</i><br class=br><i>acute lymphocytic leukemia, small cell lung cancer,</i><br class=br><br class=br><i>lymphoma, AL amyloidosis, multiple myeloma, gastric</i><br class=br><i>cancer, esophageal cancer, soft tissue sarcoma,</i><br class=br><i>Wilms’ tumor, gestational trophoblastic tumor,</i><br class=br><i>neuroblastoma, bone sarcoma, brain tumor, ovarian</i><br class=br><i>cancer, thymoma</i> </td><td align=center colspan=1 rowspan=6 valign=middle><a name=d17740e522 class=n-a></a>Alkylating agents prevent cell division by<br class=br>cross-linking DNA strands and binding<br class=br>with nucleic acids and other intracellular<br class=br>structures, inhibiting protein synthesis and<br class=br>DNA synthesis, resulting in cell death.</td><td align=center colspan=1 rowspan=3 valign=middle><a name=d17740e533 class=n-a></a>Atrial tachyarrhythmias or<br class=br>bradyarrhythmias, capillary<br class=br>leak syndrome, cardiac arrest,<br class=br>cardiomyopathy, heart failure,<br class=br>cardiogenic shock, hemopericardium,<br class=br>hemorrhagic myocarditis.</td></tr><tr><a name=d17740e547 class=n-a></a><td align=center colspan=1 rowspan=1><a name=d17740e549 class=n-a></a>Ifosfamide</td><td align=center colspan=1 rowspan=1><a name=d17740e552 class=n-a></a> <i>Hodgkin lymphoma, non-Hodgkin lymphoma, Burkitt</i><br class=br><i>lymphoma, neuroblastoma, small cell lung cancer,</i><br class=br><i>penile cancer, testicular cancer, hepatoblastoma,</i><br class=br><i>bone sarcoma, soft tissue sarcoma</i> </td></tr><tr><a name=d17740e568 class=n-a></a><td align=center colspan=1 rowspan=1><a name=d17740e570 class=n-a></a>Mitomycin</td><td align=center colspan=1 rowspan=1><a name=d17740e573 class=n-a></a> <i>Gastric cancer, anal cancer, pancreatic cancer, lung</i><br class=br><i>cancer, mesothelioma, bladder cancer, breast cancer</i> </td></tr><tr><a name=d17740e583 class=n-a></a><td align=center colspan=1 rowspan=1><a name=d17740e585 class=n-a></a>Bleomycin</td><td align=center colspan=1 rowspan=1><a name=d17740e588 class=n-a></a> <i>Hodgkin lymphoma, testicular cancer, ovarian cancer</i> </td><td align=center colspan=1 rowspan=1><a name=d17740e594 class=n-a></a>Phlebitis, pericarditis, chest pain,<br class=br>myocardial ischemia</td></tr><tr><a name=d17740e600 class=n-a></a><td align=center colspan=1 rowspan=1><a name=d17740e602 class=n-a></a>Cisplatin</td><td align=center colspan=1 rowspan=1><a name=d17740e605 class=n-a></a> <i>Bladder cancer, ovarian cancer, testicular cancer,</i><br class=br><i>breast cancer, cervical cancer, endometrial cancer,</i><br class=br><i>esophageal cancer, gastric cancer, head and neck</i><br class=br><i>cancer, Hodgkin lymphoma, mesothelioma, non-</i><br class=br><i>Hodgkin lymphoma, non-small cell lung cancer,</i><br class=br><i>osteosarcoma, penile cancer, small cell lung cancer</i> </td><td align=center colspan=1 rowspan=1><a name=d17740e627 class=n-a></a>Arrhythmias, myocardial ischemia and<br class=br>infarction, ischemic cardiomyopathy,<br class=br>Raynaud’s phenomenon, hypertension,<br class=br>stroke</td></tr><tr><a name=d17740e637 class=n-a></a><td align=center colspan=1 rowspan=1><a name=d17740e639 class=n-a></a>Trabectedin</td><td align=center colspan=1 rowspan=1><a name=d17740e642 class=n-a></a> <i>Soft tissue sarcoma, ovarian cancer</i> </td><td align=center colspan=1 rowspan=1><a name=d17740e648 class=n-a></a>Cardiomyopathy, heart failure, cardiac<br class=br>arrest, peripheral edema, pulmonary<br class=br>embolism</td></tr><tr><a name=d17740e657 class=n-a></a><td align=center colspan=1 rowspan=4 valign=middle><a name=d17740e659 class=n-a></a>Antimetabolites</td><td align=center colspan=1 rowspan=1><a name=d17740e662 class=n-a></a>5-FU</td><td align=center colspan=1 rowspan=1><a name=d17740e665 class=n-a></a> <i>Breast cancer, anal cancer, gastric cancer,</i><br class=br><i>esophageal cancer, colorectal cancer, cervical</i><br class=br><i>cancer, bladder cancer, head and neck cancer,</i><br class=br><i>pancreatic cancer</i> </td><td align=center colspan=1 rowspan=4 valign=middle><a name=d17740e680 class=n-a></a>Antimetabolites inhibit DNA polymerase,<br class=br>interfering with DNA and, to a lesser<br class=br>degree, RNA synthesis. Some agents also<br class=br>inhibit ribonucleotide reductase, DNA<br class=br>primase, and DNA ligase I.</td><td align=center colspan=1 rowspan=4 valign=middle><a name=d17740e691 class=n-a></a>Angina pectoris, vasospasm, myocardial<br class=br>infarction, non-specific ECG changes,<br class=br>atrial and ventricular bradyarrhythmias<br class=br>and tachyarrhythmias, cardiomyopathy,<br class=br>heart failure, pericardial effusion,<br class=br>cerebrovascular accident, local<br class=br>thrombophlebitis, pericarditis</td></tr><tr><a name=d17740e708 class=n-a></a><td align=center colspan=1 rowspan=1><a name=d17740e710 class=n-a></a>Capecitabine</td><td align=center colspan=1 rowspan=1><a name=d17740e713 class=n-a></a> <i>Colorectal cancer, breast cancer, biliary cancer,</i><br class=br><i>esophageal cancer, pancreatic cancer, gastric cancer</i> </td></tr><tr><a name=d17740e723 class=n-a></a><td align=center colspan=1 rowspan=1><a name=d17740e725 class=n-a></a>Fludarabine</td><td align=center colspan=1 rowspan=1><a name=d17740e728 class=n-a></a> <i>Chronic lymphocytic leukemia, acute myeloid</i><br class=br><i>leukemia, hematopoietic stem cell transplant, non-</i><br class=br><i>Hodgkin lymphoma, Waldenstrom macroglobulinemia</i> </td></tr><tr><a name=d17740e741 class=n-a></a><td align=center colspan=1 rowspan=1><a name=d17740e743 class=n-a></a>Cytarabine</td><td align=center colspan=1 rowspan=1><a name=d17740e746 class=n-a></a> <i>Acute myelocytic leukemia, acute promyelocytic</i><br class=br><i>leukemia, acute lymphocytic leukemia, chronic</i><br class=br><i>lymphocytic leukemia, primary central nervous</i><br class=br><i>system lymphoma, Hodgkin lymphoma, non-Hodgkin</i><br class=br><i>lymphoma, meningeal leukemia</i> </td></tr><tr><a name=d17740e765 class=n-a></a><td align=center colspan=1 rowspan=3 valign=middle><a name=d17740e767 class=n-a></a>Anti-ERBB<br class=br>monoclonal<br class=br>antibodies</td><td align=center colspan=1 rowspan=1><a name=d17740e774 class=n-a></a>Trastuzumab</td><td align=center colspan=1 rowspan=2 valign=middle><a name=d17740e777 class=n-a></a> <i>Breast cancer and gastric cancer (ERBB2+)</i> </td><td align=center colspan=1 rowspan=3 valign=middle><a name=d17740e783 class=n-a></a>Binds to ERBB1 (EGFR) or ERBB2 (HER-<br class=br>2), mediating antibody-dependent cellular<br class=br>cytotoxicity of cells that overexpress EGFR<br class=br>or HER-2 proteins.</td><td align=center colspan=1 rowspan=2 valign=middle><a name=d17740e792 class=n-a></a>Cardiomyopathy, heart failure, peripheral<br class=br>edema, hypertension, arrhythmias. <b>BOX</b><br class=br><b>WARNING: CARDIOMYOPATHY</b> </td></tr><tr><a name=d17740e804 class=n-a></a><td align=center colspan=1 rowspan=1><a name=d17740e806 class=n-a></a>Pertuzumab</td></tr><tr><a name=d17740e811 class=n-a></a><td align=center colspan=1 rowspan=1><a name=d17740e813 class=n-a></a>Necitumumab</td><td align=center colspan=1 rowspan=1><a name=d17740e816 class=n-a></a> <i>Non-small cell lung cancer (ERBB1+)</i> </td><td align=center colspan=1 rowspan=1><a name=d17740e822 class=n-a></a>Arrhythmias, venous and arterial<br class=br>thomboembolism, ischemia. <b>BOX</b><br class=br><b>WARNING: CARDIOPULMONARY</b><br class=br><b>ARREST</b> </td></tr><tr><a name=d17740e837 class=n-a></a><td align=center colspan=1 rowspan=3 valign=middle><a name=d17740e839 class=n-a></a>Anti-VEGF<br class=br>monoclonal<br class=br>antibodies</td><td align=center colspan=1 rowspan=1><a name=d17740e846 class=n-a></a>Bevacizumab</td><td align=center colspan=1 rowspan=1><a name=d17740e849 class=n-a></a> <i>Non-small cell lung cancer, cervical cancer, ovarian</i><br class=br><i>cancer, breast cancer, endometrial cancer, renal cell</i><br class=br><i>cancer, glioblastoma, soft tissue sarcoma, colorectal</i><br class=br><i>cancer</i> </td><td align=center colspan=1 rowspan=1><a name=d17740e864 class=n-a></a>Binds to and neutralizes VEGF-A,<br class=br>preventing its association with the<br class=br>endothelial receptors VEGFR1 and<br class=br>VEGFR2, inhibiting angiogenesis and<br class=br>thus retarding the growth of all tissues<br class=br>(including metastatic tissue).</td><td align=center colspan=1 rowspan=3 valign=middle><a name=d17740e877 class=n-a></a>Hypertension, cardiomyopathy, heart<br class=br>failure, peripheral edema, hypotension,<br class=br>venous and arterial thromboembolism,<br class=br>syncope, pulmonary embolism</td></tr><tr><a name=d17740e887 class=n-a></a><td align=center colspan=1 rowspan=1><a name=d17740e889 class=n-a></a>Aflibercept</td><td align=center colspan=1 rowspan=1><a name=d17740e892 class=n-a></a> <i>Colorectal cancer</i> </td><td align=center colspan=1 rowspan=1><a name=d17740e898 class=n-a></a>Inhibits VEGFR1 and VEGFR2</td></tr><tr><a name=d17740e902 class=n-a></a><td align=center colspan=1 rowspan=1><a name=d17740e904 class=n-a></a>Ramucirumab</td><td align=center colspan=1 rowspan=1><a name=d17740e907 class=n-a></a> <i>Colorectal cancer, gastric cancer, non-small cell lung</i><br class=br><i>cancer</i> </td><td align=center colspan=1 rowspan=1><a name=d17740e916 class=n-a></a>Inhibits VEGFR2</td></tr><tr><a name=d17740e920 class=n-a></a><td align=center colspan=1 rowspan=6 valign=middle><a name=d17740e922 class=n-a></a>Immune checkpoint<br class=br>inhibitors<br class=br>(monoclonal<br class=br>antibodies)</td><td align=center colspan=1 rowspan=1><a name=d17740e931 class=n-a></a>Ipilimumab</td><td align=center colspan=1 rowspan=1><a name=d17740e934 class=n-a></a> <i>Melanoma, small cell lung cancer</i> </td><td align=center colspan=1 rowspan=1><a name=d17740e940 class=n-a></a>Human IgG1 that blocks CTLA-4, which<br class=br>is a downregulator of T-cell activation<br class=br>pathways, enhancing their activation and<br class=br>proliferation</td><td align=center colspan=1 rowspan=1><a name=d17740e949 class=n-a></a>Acute myocarditis, cardiogenic shock.<br class=br><b>BOX WARNING: IMMUNE-MEDIATED</b><br class=br><b>ADVERSE REACTIONS (including</b><br class=br><b>autoimmune myocarditis)</b> </td></tr><tr><a name=d17740e963 class=n-a></a><td align=center colspan=1 rowspan=1><a name=d17740e965 class=n-a></a>Nivolumab</td><td align=center colspan=1 rowspan=2 valign=middle><a name=d17740e968 class=n-a></a> <i>Head and neck cancer, Hodgkin lymphoma,</i><br class=br><i>melanoma, non-small cell lung cancer, renal cell</i><br class=br><i>cancer, urothelial carcinoma, small cell lung cancer</i> </td><td align=center colspan=1 rowspan=2 valign=middle><a name=d17740e980 class=n-a></a>Human IgG4 that inhibits PD-1, enhancing<br class=br>T-cell activation and proliferation. It<br class=br>potentiates the effects of CTLA-4 inhibitors</td><td align=center colspan=1 rowspan=2 valign=middle><a name=d17740e987 class=n-a></a>Peripheral edema, acute myocarditis,<br class=br>cardiogenic shock, pulmonary embolism</td></tr><tr><a name=d17740e994 class=n-a></a><td align=center colspan=1 rowspan=1><a name=d17740e996 class=n-a></a>Pembrolizumab</td></tr><tr><a name=d17740e1000 class=n-a></a><td align=center colspan=1 rowspan=1><a name=d17740e1002 class=n-a></a>Atezolizumab</td><td align=center colspan=1 rowspan=1><a name=d17740e1005 class=n-a></a> <i>Non-small cell lung cancer, urothelial carcinoma</i> </td><td align=center colspan=1 rowspan=3 valign=middle><a name=d17740e1011 class=n-a></a>Human IgG1 that inhibits PD-L1 and<br class=br>CD80, enhancing T-cell activation and<br class=br>proliferation. It potentiates the effects of<br class=br>CTLA-4 inhibitors</td><td align=center colspan=1 rowspan=1><a name=d17740e1020 class=n-a></a>Peripheral edema, venous<br class=br>thromboembolism</td></tr><tr><a name=d17740e1026 class=n-a></a><td align=center colspan=1 rowspan=1><a name=d17740e1028 class=n-a></a>Avelumab</td><td align=center colspan=1 rowspan=1><a name=d17740e1031 class=n-a></a> <i>Merkel cell carcinoma, urothelial carcinoma</i> </td><td align=center colspan=1 rowspan=1><a name=d17740e1037 class=n-a></a>Peripheral edema, hypertension</td></tr><tr><a name=d17740e1041 class=n-a></a><td align=center colspan=1 rowspan=1><a name=d17740e1043 class=n-a></a>Durvalumab</td><td align=center colspan=1 rowspan=1><a name=d17740e1046 class=n-a></a> <i>Urothelial carcinoma</i> </td><td align=center colspan=1 rowspan=1><a name=d17740e1052 class=n-a></a>Peripheral edema, myocarditis</td></tr><tr><a name=d17740e1056 class=n-a></a><td align=center colspan=1 rowspan=7 valign=middle><a name=d17740e1058 class=n-a></a>Multi-targeted<br class=br>(VEGFR) tyrosine<br class=br>kinase inhibitors</td><td align=center colspan=1 rowspan=1><a name=d17740e1065 class=n-a></a>Sunitinib</td><td align=center colspan=1 rowspan=1><a name=d17740e1068 class=n-a></a> <i>Renal cell cancer, soft tissue sarcoma, GIST</i> </td><td align=center colspan=1 rowspan=7 valign=middle><a name=d17740e1074 class=n-a></a>Inhibits multiple receptor tyrosine kinases<br class=br>(VEGFR1, VEGFR2, and VEGFR3 mainly;<br class=br>also inhibits PDGFRα/β; <span style="color:#FF0000">LT3</span>; FLT3; CSF-<br class=br>1R; RET; FGFR-1/3; cKIT; IL-2R; Lck; c-<br class=br>Fms; RET/PTC; CRAF; BRAF), preventing<br class=br>tumor growth and angiogenesis.</td><td align=center colspan=1 rowspan=7 valign=middle><a name=d17740e1091 class=n-a></a>Hypertension, QTc prolongation,<br class=br>bradycardia, peripheral edema,<br class=br>cardiomyopathy, heart failure, chest pain,<br class=br>venous and arterial thromboembolim,<br class=br>ischemia, myocardial infarction,<br class=br>arrhythmias. <b>BOX WARNING: QTc</b><br class=br><b>PROLONGATION, TdP, AND SCD</b><br class=br><b>(vandetanib)</b> </td></tr><tr><a name=d17740e1115 class=n-a></a><td align=center colspan=1 rowspan=1><a name=d17740e1117 class=n-a></a>Pazopanib</td><td align=center colspan=1 rowspan=1><a name=d17740e1120 class=n-a></a> <i>Renal cell cancer, soft tissue sarcoma, thyroid cancer</i> </td></tr><tr><a name=d17740e1128 class=n-a></a><td align=center colspan=1 rowspan=1><a name=d17740e1130 class=n-a></a>Sorafenib</td><td align=center colspan=1 rowspan=1><a name=d17740e1133 class=n-a></a> <i>Renal cell cancer, hepatocellular cancer, soft tissue sarcoma, GIST, thyroid cancer</i> </td></tr><tr><a name=d17740e1140 class=n-a></a><td align=center colspan=1 rowspan=1><a name=d17740e1142 class=n-a></a>Axitinib</td><td align=center colspan=1 rowspan=1><a name=d17740e1145 class=n-a></a> <i>Renal cell cancer, thyroid cancer</i> </td></tr><tr><a name=d17740e1152 class=n-a></a><td align=center colspan=1 rowspan=1><a name=d17740e1154 class=n-a></a>Lenvatinib</td><td align=center colspan=1 rowspan=1><a name=d17740e1157 class=n-a></a> <i>Renal cell cancer, thyroid cancer</i> </td></tr><tr><a name=d17740e1164 class=n-a></a><td align=center colspan=1 rowspan=1><a name=d17740e1166 class=n-a></a>Regorafenib</td><td align=center colspan=1 rowspan=1><a name=d17740e1169 class=n-a></a> <i>Colorectal cancer, GIST, hepatocellular carcinoma</i> </td></tr><tr><a name=d17740e1176 class=n-a></a><td align=center colspan=1 rowspan=1><a name=d17740e1178 class=n-a></a>Vandetanib</td><td align=center colspan=1 rowspan=1><a name=d17740e1181 class=n-a></a> <i>Thyroid cancer (medullary)</i> </td></tr><tr><a name=d17740e1188 class=n-a></a><td align=center colspan=1 rowspan=5 valign=middle><a name=d17740e1190 class=n-a></a>Multi-targeted<br class=br>(BCR-ABL) tyrosine<br class=br>kinase inhibitors</td><td align=center colspan=1 rowspan=1><a name=d17740e1197 class=n-a></a>Imatinib</td><td align=center colspan=1 rowspan=1><a name=d17740e1200 class=n-a></a> <i>Acute lymphocytic leukemia, acute myelocytic</i><br class=br><i>leukemia, GIST</i> </td><td align=center colspan=1 rowspan=5 valign=middle><a name=d17740e1209 class=n-a></a>Inhibits multiple receptor tyrosine kinases<br class=br>(Bcr-Abl mainly; also VEGFRs, PDGFRβ;<br class=br>SRC; LCK; YES; FYN; cKIT; EPHA2,<br class=br>among others), inducing apoptosis.</td><td align=center colspan=1 rowspan=5 valign=middle><a name=d17740e1218 class=n-a></a>Edema (anasarca, ascites, pericardial<br class=br>and pleural effusion, peripheral edema,<br class=br>pulmonary edema, and superficial<br class=br>edema), hypertension, hypotension,<br class=br>chest pain, cardiomyopathy, heart failure,<br class=br>QTc prolongation, tachyarrhythmias<br class=br>and bradyarrhythmias, pulmonary<br class=br>hypertension, myocardial ischemia<br class=br>and infarction. <b>BOX WARNING: QTc</b><br class=br><b>PROLONGATION, TdP, AND SCD</b><br class=br><b>(nilotinib). BOX WARNING: HEART FAILURE; ARTERIAL AND VENOUS</b><br class=br><b>THROMBOEMBOLISM (ponatinib)</b> </td></tr><tr><a name=d17740e1253 class=n-a></a><td align=center colspan=1 rowspan=1><a name=d17740e1255 class=n-a></a>Dasatinib</td><td align=center colspan=1 rowspan=1><a name=d17740e1258 class=n-a></a> <i>Acute lymphocytic leukemia, chronic myelocytic leukemia, GIST</i> </td></tr><tr><a name=d17740e1265 class=n-a></a><td align=center colspan=1 rowspan=1><a name=d17740e1267 class=n-a></a>Nilotinib</td><td align=center colspan=1 rowspan=1><a name=d17740e1270 class=n-a></a> <i>Chronic myelocytic leukemia, GIST</i> </td></tr><tr><a name=d17740e1277 class=n-a></a><td align=center colspan=1 rowspan=1><a name=d17740e1279 class=n-a></a>Bosutinib</td><td align=center colspan=1 rowspan=1><a name=d17740e1282 class=n-a></a> <i>Chronic myelocytic leukemia</i> </td></tr><tr><a name=d17740e1289 class=n-a></a><td align=center colspan=1 rowspan=1><a name=d17740e1291 class=n-a></a>Ponatinib</td><td align=center colspan=1 rowspan=1><a name=d17740e1294 class=n-a></a> <i>Acute lymphocytic leukemia, chronic myelocytic</i><br class=br><i>leukemia</i> </td></tr><tr><a name=d17740e1304 class=n-a></a><td align=center colspan=1 rowspan=3 valign=middle><a name=d17740e1306 class=n-a></a>Multi-targeted<br class=br>(ALK) tyrosine<br class=br>kinase inhibitors</td><td align=center colspan=1 rowspan=1><a name=d17740e1313 class=n-a></a>Brigatinib</td><td align=center colspan=1 rowspan=3 valign=middle><a name=d17740e1316 class=n-a></a> <i>Non-small cell lung cancer (EML4-ALK)</i> </td><td align=center colspan=1 rowspan=3 valign=middle><a name=d17740e1322 class=n-a></a>Inhibits multiple receptor tyrosine kinases<br class=br>(ALK, HGFR, c-MET, ROS1, IGF-1R, FLT-3,<br class=br>EGFR, etc.), blocking cell proliferation.</td><td align=center colspan=1 rowspan=3 valign=middle><a name=d17740e1329 class=n-a></a>Sinus bradycardia, hypertension,<br class=br>QTc prolongation, edema, pulmonary<br class=br>embolism, syncope</td></tr><tr><a name=d17740e1337 class=n-a></a><td align=center colspan=1 rowspan=1><a name=d17740e1339 class=n-a></a>Crizotinib</td></tr><tr><a name=d17740e1344 class=n-a></a><td align=center colspan=1 rowspan=1><a name=d17740e1346 class=n-a></a>Ceritinib</td></tr><tr><a name=d17740e1350 class=n-a></a><td align=center colspan=1 rowspan=3 valign=middle><a name=d17740e1352 class=n-a></a>Multi-targeted<br class=br>(MEK) tyrosine<br class=br>kinase inhibitors</td><td align=center colspan=1 rowspan=1><a name=d17740e1359 class=n-a></a>Cobimetinib</td><td align=center colspan=1 rowspan=3 valign=middle><a name=d17740e1362 class=n-a></a> <i>Melanoma and non-small cell lung cancer (BRAF</i><br class=br><i>V600E and V600K mutations)</i> </td><td align=center colspan=1 rowspan=3 valign=middle><a name=d17740e1371 class=n-a></a>MEK1 and MEK2 inhibitors (BRAF<br class=br>pathway), causing decreased proliferation,<br class=br>cell cycle arrest and apoptosis. Some also<br class=br>inhibit RAS, RAF, and ERK.</td><td align=center colspan=1 rowspan=2 valign=middle><a name=d17740e1380 class=n-a></a>Cardiomyopathy, hypertension</td></tr><tr><a name=d17740e1384 class=n-a></a><td align=center colspan=1 rowspan=1><a name=d17740e1386 class=n-a></a>Trametinib</td></tr><tr><a name=d17740e1390 class=n-a></a><td align=center colspan=1 rowspan=1><a name=d17740e1392 class=n-a></a>Vemurafenib</td><td align=center colspan=1 rowspan=1><a name=d17740e1395 class=n-a></a>Peripheral edema, hypotension, atrial<br class=br>fibrillation, QTc prolongation, retinal vein<br class=br>occlusion, vasculitis</td></tr><tr><a name=d17740e1403 class=n-a></a><td align=center colspan=1 rowspan=2 valign=middle><a name=d17740e1405 class=n-a></a>Multi-targeted<br class=br>(ERBB) tyrosine<br class=br>kinase inhibitors</td><td align=center colspan=1 rowspan=1><a name=d17740e1412 class=n-a></a>Lapatinib</td><td align=center colspan=1 rowspan=1><a name=d17740e1415 class=n-a></a> <i>Breast cancer (ERBB2+)</i> </td><td align=center colspan=1 rowspan=1><a name=d17740e1421 class=n-a></a>Inhibits EGFR (ERBB1) and HER2<br class=br>(ERBB2), regulating cellular proliferation<br class=br>and survival</td><td align=center colspan=1 rowspan=1><a name=d17740e1428 class=n-a></a>Peripheral edema, cardiomyopathy, heart<br class=br>failure, hypertension, arrhythmias</td></tr><tr><a name=d17740e1434 class=n-a></a><td align=center colspan=1 rowspan=1><a name=d17740e1436 class=n-a></a>Osimertinib</td><td align=center colspan=1 rowspan=1><a name=d17740e1439 class=n-a></a> <i>Non-small cell lung cancer (ERBB1 T790M mutation)</i> </td><td align=center colspan=1 rowspan=1><a name=d17740e1445 class=n-a></a>Inhibits EGFR (ERBB1 T790M and L858R<br class=br>mutations), regulating cellular proliferation<br class=br>and survival</td><td align=center colspan=1 rowspan=1><a name=d17740e1452 class=n-a></a>Cardiomyopathy, QTc prolongation,<br class=br>venous thromboembolism, stroke</td></tr><tr><a name=d17740e1459 class=n-a></a><td align=center colspan=1 rowspan=2 valign=middle><a name=d17740e1461 class=n-a></a>Proteasome<br class=br>inhibitors</td><td align=center colspan=1 rowspan=1><a name=d17740e1466 class=n-a></a>Carfilzomib</td><td align=center colspan=1 rowspan=1><a name=d17740e1469 class=n-a></a> <i>Multiple myeloma</i> </td><td align=center colspan=1 rowspan=1><a name=d17740e1475 class=n-a></a>Inhibits the 20S proteasome, leading to cell cycle arrest and apoptosis</td><td align=center colspan=1 rowspan=2 valign=middle><a name=d17740e1478 class=n-a></a>Hypotension, acute pulmonary<br class=br>edema, cardiomyopathy, heart failure,<br class=br>cardiogenic shock, bradyarrhythmias<br class=br>and tachyarrhythmias, angina pectoris,<br class=br>cerebrovascular accident, venous<br class=br>thromboembolism, hemorrhagic stroke,<br class=br>myocardial infarction, pericardial<br class=br>effusion, pericarditis, peripheral edema,<br class=br>pulmonary embolism.</td></tr><tr><a name=d17740e1499 class=n-a></a><td align=center colspan=1 rowspan=1><a name=d17740e1501 class=n-a></a>Bortezomib</td><td align=center colspan=1 rowspan=1><a name=d17740e1504 class=n-a></a> <i>AL amyloidosis, follicular lymphoma, mantle cell</i><br class=br><i>lymphoma, Waldenstrom macroglobulinemia, multiple</i><br class=br><i>myeloma</i> </td><td align=center colspan=1 rowspan=1><a name=d17740e1516 class=n-a></a>Inhibits the 26S proteasome, leading to<br class=br>cell-cycle arrest, and apoptosis</td></tr><tr><a name=d17740e1522 class=n-a></a><td align=center colspan=1 rowspan=5 valign=middle><a name=d17740e1524 class=n-a></a>Antimicrotubule<br class=br>agents</td><td align=center colspan=1 rowspan=1><a name=d17740e1529 class=n-a></a>Vinblastine</td><td align=center colspan=1 rowspan=1><a name=d17740e1532 class=n-a></a> <i>Hodgkin lymphoma, testicular cancer, bladder</i><br class=br><i>cancer, melanoma, non-small cell lung cancer, soft</i><br class=br><i>tissue sarcoma</i> </td><td align=center colspan=1 rowspan=1><a name=d17740e1544 class=n-a></a>Binds to tubilin and inhibits microtubulin<br class=br>formation; it is specific of M and S phases.</td><td align=center colspan=1 rowspan=1><a name=d17740e1549 class=n-a></a>Angina, hypotension, myocardial<br class=br>ischemia and infarction, Raynaud’s<br class=br>phenomenon, limb ischemia</td></tr><tr><a name=d17740e1557 class=n-a></a><td align=center colspan=1 rowspan=1><a name=d17740e1559 class=n-a></a>Paclitaxel</td><td align=center colspan=1 rowspan=1><a name=d17740e1562 class=n-a></a> <i>Breast cancer, bladder cancer, cervical cancer,</i><br class=br><i>endometrial cancer, esophageal cancer, gastric</i><br class=br><i>cancer, head and neck cancer, non-small cell lung</i><br class=br><i>cancer, small cell lung cancer, testicular cancer, soft</i><br class=br><i>tissue sarcoma, thymoma/thymic carcinoma, penile</i><br class=br><i>cancer, ovarian cancer</i> </td><td align=center colspan=1 rowspan=1><a name=d17740e1584 class=n-a></a>Inhibits microtubule disassembly,<br class=br>interfering with the late G2 mitotic phase,<br class=br>and inhibits cell replication. In addition, it<br class=br>can distort mitotic spindles, resulting in the<br class=br>breakage of chromosomes.</td><td align=center colspan=1 rowspan=1><a name=d17740e1595 class=n-a></a>Edema, hypotension, arrhythmias,<br class=br>hypertension, syncope, cardiomyopathy,<br class=br>heart failure, venous thrombosis</td></tr><tr><a name=d17740e1603 class=n-a></a><td align=center colspan=1 rowspan=1><a name=d17740e1605 class=n-a></a>Docetaxel</td><td align=center colspan=1 rowspan=1><a name=d17740e1608 class=n-a></a> <i>Breast cancer, bladder cancer, bone sarcoma,</i><br class=br><i>esophageal cancer, gastric cancer, head and neck</i><br class=br><i>cancer, non-small cell lung</i><br class=br><i>cancer, small cell lung cancer, ovarian cancer, pancreatic cancer, prostate</i><br class=br><i>cancer, soft tissue sarcoma, uterine sarcoma</i> </td><td align=center colspan=1 rowspan=1><a name=d17740e1626 class=n-a></a>Inhibits microtubule disassembly,<br class=br>interfering with the M mitotic phase, and<br class=br>inhibits cell replication</td><td align=center colspan=1 rowspan=1><a name=d17740e1633 class=n-a></a>Hypotension, cardiomyopathy, heart<br class=br>failure. <b>BOX WARNING: FLUID</b><br class=br><b>RETENTION (including pulmonary</b><br class=br><b>edema)</b> </td></tr><tr><a name=d17740e1648 class=n-a></a><td align=center colspan=1 rowspan=1><a name=d17740e1650 class=n-a></a>Eribulin</td><td align=center colspan=1 rowspan=1><a name=d17740e1653 class=n-a></a> <i>Breast cancer, liposarcoma</i> </td><td align=center colspan=1 rowspan=1><a name=d17740e1659 class=n-a></a>Synthetic analogue of halichondrin B that<br class=br>inhibits polymerization of tubulin.</td><td align=center colspan=1 rowspan=1><a name=d17740e1664 class=n-a></a>Peripheral edema, hypotension, QTc<br class=br>prolongation</td></tr><tr><a name=d17740e1671 class=n-a></a><td align=center colspan=1 rowspan=1><a name=d17740e1673 class=n-a></a>Ixabepilone</td><td align=center colspan=1 rowspan=1><a name=d17740e1676 class=n-a></a> <i>Breast cancer</i> </td><td align=center colspan=1 rowspan=1><a name=d17740e1682 class=n-a></a>Epothilone B analog, inhibits tubulin (G2/M<br class=br>phase inhibitor)</td><td align=center colspan=1 rowspan=1><a name=d17740e1687 class=n-a></a>Peripheral edema, angina pectoris</td></tr><tr><a name=d17740e1691 class=n-a></a><td align=center colspan=1 rowspan=4 valign=middle><a name=d17740e1693 class=n-a></a>Immunomodulators</td><td align=center colspan=1 rowspan=1><a name=d17740e1696 class=n-a></a>IL-2</td><td align=center colspan=1 rowspan=1><a name=d17740e1699 class=n-a></a> <i>Melanoma, neuroblastoma, renal cell cancer</i> </td><td align=center colspan=1 rowspan=1><a name=d17740e1705 class=n-a></a>Promotes proliferation, differentiation, and<br class=br>recruitment of T and B cells, NK cells,<br class=br>thymocytes, LAK cells, and TILs, causing<br class=br>subsequent interactions between the<br class=br>immune system and malignant cells.</td><td align=center colspan=1 rowspan=1><a name=d17740e1716 class=n-a></a>Capillary leak syndrome, acute<br class=br>myocarditis, hypotension, peripheral<br class=br>edema, cardiomyopathy, heart failure,<br class=br>ventricular tachyarrhythmias, cardiac arrest, myocardial infarction. <b>BOX</b><br class=br><b>WARNING: CARDIOPULMONARY</b><br class=br><b>DISEASE, CAPILLARY LEAK</b><br class=br><b>SYNDROME (including</b><br class=br><b>supraventricular and ventricular</b><br class=br><b>arrhythmias and myocardial infarction)</b> </td></tr><tr><a name=d17740e1745 class=n-a></a><td align=center colspan=1 rowspan=1><a name=d17740e1747 class=n-a></a>Interferon</td><td align=center colspan=1 rowspan=1><a name=d17740e1750 class=n-a></a> <i>Melanoma, renal cell cancer</i> </td><td align=center colspan=1 rowspan=1><a name=d17740e1756 class=n-a></a>Inhibits cellular growth, alters cellular<br class=br>differentiation and cell surface antigen<br class=br>expression, interferes with oncogene<br class=br>expression, increases phagocytic<br class=br>activity of macrophages, and augments<br class=br>cytotoxicity of lymphocytes</td><td align=center colspan=1 rowspan=1><a name=d17740e1769 class=n-a></a>Chest pain, myocardial ischemia<br class=br>and infarction, atrial and ventricular<br class=br>tachyarrhythmias, edema, hypertension,<br class=br>cardiomyopathy, heart failure. <b>BOX</b><br class=br><b>WARNING: ISCHEMIC DISORDERS</b><br class=br><b>(including stroke and myocardial</b><br class=br><b>infarction)</b> </td></tr><tr><a name=d17740e1792 class=n-a></a><td align=center colspan=1 rowspan=1><a name=d17740e1794 class=n-a></a>Thalidomide</td><td align=center colspan=1 rowspan=1><a name=d17740e1797 class=n-a></a> <i>AL amyloidosis, Waldenstrom macroglobulinemia,</i><br class=br><i>multiple myeloma</i> </td><td align=center colspan=1 rowspan=1><a name=d17740e1806 class=n-a></a>Increases NK cell number and levels of<br class=br>IL-2 and interferon gamma. Also inhibits<br class=br>angiogenesis, increases cell-mediated<br class=br>cytotoxic effects, and alters the expression<br class=br>of cellular adhesion molecules.</td><td align=center colspan=1 rowspan=2 valign=middle><a name=d17740e1817 class=n-a></a>Edema, deep vein thrombosis,<br class=br>hypotension, hypertension, chest pain,<br class=br>atrial tachyarrhythmias, myocardial<br class=br>infarction, pulmonary embolism, syncope,<br class=br>stroke, angina pectoris, cardiomyopathy,<br class=br>heart failure, cardiac arrest, cardiogenic<br class=br>shock, increased cardiac enzymes. <b>BOX</b><br class=br><b>WARNING: ARTERIAL AND VENOUS</b><br class=br><b>THROMBOEMBOLISM</b> </td></tr><tr><a name=d17740e1843 class=n-a></a><td align=center colspan=1 rowspan=1><a name=d17740e1845 class=n-a></a>Lenalidomide</td><td align=center colspan=1 rowspan=1><a name=d17740e1848 class=n-a></a> <i>Mantle cell lymphoma, multiple myeloma, chronic</i><br class=br><i>lymphocytic leukemia, myelodisplastic syndrome,</i><br class=br><i>AL amyloidosis, renal cell cancer, non-Hodgkin</i><br class=br><i>lymphoma</i> </td><td align=center colspan=1 rowspan=1><a name=d17740e1863 class=n-a></a>Inhibits secretion of proinflammatory<br class=br>cytokines; enhances cell-mediated<br class=br>immunity by stimulating proliferation of<br class=br>anti-CD3 stimulated T cells (resulting in<br class=br>increased IL-2 and interferon gamma<br class=br>secretion); inhibits trophic signals to<br class=br>angiogenic factors in cells.</td></tr><tr><a name=d17740e1880 class=n-a></a><td align=center colspan=1 rowspan=3 valign=middle><a name=d17740e1882 class=n-a></a>mTOR inhibitors</td><td align=center colspan=1 rowspan=1><a name=d17740e1885 class=n-a></a>Sirolimus</td><td align=center colspan=1 rowspan=1><a name=d17740e1888 class=n-a></a> <i>GVHD, renal angiomyolipoma</i> </td><td align=center colspan=1 rowspan=3 valign=middle><a name=d17740e1894 class=n-a></a>Reduces protein synthesis and cell<br class=br>proliferation by binding to FKBP-12 and<br class=br>subsequently inhibiting mTOR activation,<br class=br>halting the cell cycle at the G1 phase. Also<br class=br>reduces angiogenesis by inhibiting VEGF<br class=br>and HIF-1 expression. Temsirolimus is the<br class=br>prodrug of sirolimus, the active metabolite.<br class=br>Everolimus is a sirolimus derivative.</td><td align=center colspan=1 rowspan=3 valign=middle><a name=d17740e1912 class=n-a></a>Peripheral edema, hypertension,<br class=br>angina pectoris, atrial fibrillation,<br class=br>cardiomyopathy, heart failure, deep vein<br class=br>thrombosis, hypotension, pulmonary<br class=br>embolism, renal artery thrombosis,<br class=br>syncope</td></tr><tr><a name=d17740e1927 class=n-a></a><td align=center colspan=1 rowspan=1><a name=d17740e1929 class=n-a></a>Everolimus</td><td align=center colspan=1 rowspan=1><a name=d17740e1932 class=n-a></a> <i>Breast cancer, renal cell cancer, astrocytoma, PNET</i> </td></tr><tr><a name=d17740e1939 class=n-a></a><td align=center colspan=1 rowspan=1><a name=d17740e1941 class=n-a></a>Temsirolimus</td><td align=center colspan=1 rowspan=1><a name=d17740e1944 class=n-a></a> <i>Renal cell cancer</i> </td></tr><tr><a name=d17740e1951 class=n-a></a><td align=center colspan=1 rowspan=2 valign=middle><a name=d17740e1953 class=n-a></a>Differentiation<br class=br>agents</td><td align=center colspan=1 rowspan=1><a name=d17740e1958 class=n-a></a>Tretinoin (ATRA)</td><td align=center colspan=1 rowspan=2 valign=middle><a name=d17740e1961 class=n-a></a> <i>Acute promyelocytic leukemia</i> </td><td align=center colspan=1 rowspan=1><a name=d17740e1967 class=n-a></a>Binds to nuclear receptors, decreasing<br class=br>proliferation and inducing differentiation of<br class=br>primitive promyelocytes</td><td align=center colspan=1 rowspan=1><a name=d17740e1974 class=n-a></a>Peripheral and facial edema, arrythmias,<br class=br>pericardial effusion/tamponade,<br class=br>myocardial ischemia and infarction,<br class=br>hypertension, cardiomyopathy, stroke,<br class=br>myocarditis, pericarditis, retinoic acid<br class=br>syndrome</td></tr><tr><a name=d17740e1988 class=n-a></a><td align=center colspan=1 rowspan=1><a name=d17740e1990 class=n-a></a>Arsenic trioxide</td><td align=center colspan=1 rowspan=1><a name=d17740e1993 class=n-a></a>Induces apoptosis of primitive<br class=br>promyelocytes via DNA fragmentation</td><td align=center colspan=1 rowspan=1><a name=d17740e1998 class=n-a></a>Tachycardia, QTc prolongation, angina,<br class=br>hypotension. <b>BOX WARNING: QTc</b><br class=br><b>PROLONGATION, TdP, AND SCD</b> </td></tr><tr><a name=d17740e2010 class=n-a></a><td align=center colspan=1 rowspan=3 valign=middle><a name=d17740e2012 class=n-a></a>HDAC inhibitors</td><td align=center colspan=1 rowspan=1><a name=d17740e2015 class=n-a></a>Vorinostat</td><td align=center colspan=1 rowspan=1><a name=d17740e2018 class=n-a></a> <i>Cutaneous T-cell lymphoma</i> </td><td align=center colspan=1 rowspan=3 valign=middle><a name=d17740e2024 class=n-a></a>Inhibits HDAC1, HDAC2, HDAC3, and<br class=br>HDAC6, resulting in the accumulation<br class=br>of acetyl groups, which alters chromatin<br class=br>structure and transcription factor<br class=br>activation, leading to cell growth arrest<br class=br>and apoptosis</td><td align=center colspan=1 rowspan=3 valign=middle><a name=d17740e2037 class=n-a></a>Peripheral edema, QTc prolongation,<br class=br>hypotension, tachyarrhythmias,<br class=br>pulmonary embolism, hypertension.<br class=br><b>BOX WARNING: SEVERE FATAL</b><br class=br><b>CARDIAC ISCHEMIC EVENTS AND</b><br class=br><b>ARRHYTHMIAS (panobinostat)</b> </td></tr><tr><a name=d17740e2055 class=n-a></a><td align=center colspan=1 rowspan=1><a name=d17740e2057 class=n-a></a>Romidepsin</td><td align=center colspan=1 rowspan=1><a name=d17740e2060 class=n-a></a><i>Cutaneous and peripheral T-cell lymphoma</i></td></tr><tr><a name=d17740e2066 class=n-a></a><td align=center colspan=1 rowspan=1><a name=d17740e2068 class=n-a></a>Panobinostat</td><td align=center colspan=1 rowspan=1><a name=d17740e2071 class=n-a></a><i>Multiple myeloma</i></td></tr></tbody></table></div></div><div class=section><a name=d17740e2080 class=n-a></a><h3 class=section-title>Cardiotoxic radiotherapy</h3><p class="" id=d17740e2085>The significant delay between exposure to mediastinal radiotherapy and manifestation of heart disease, reporting bias, and the frequent concomitant use of cardiotoxic chemotherapy precludes an accurate determination of the incidence of radiation-induced cardiotoxicity<sup><a href="#ref-8">8</a></sup>. Having said that, it is believed that cancer survivors who have undergone chest radiotherapy have a 23% increase in absolute risk of cardiovascular morbidity and mortality after 20 years<sup><a href="#ref-22">22</a></sup>. When considering the risk of radiotherapy-induced cardiomyopathy, for example, Hodgkin lymphoma survivors who received mediastinal radiotherapy have a fivefold increase after 30 years<sup><a href="#ref-23">23</a></sup>, whereas the greatest risk for breast cancer survivors belongs to those who received left-sided chest radiation and concomitant anthracycline chemotherapy<sup><a href="#ref-24">24</a></sup>. This laterality risk factor is likely related to the higher incidence of severe CAD in the mid and distal left anterior descending and distal diagonal arteries that is also present in this population, which could contribute to left ventricular (LV) dysfunction<sup><a href="#ref-25">25</a></sup>.</p><p class="" id=d17740e2108>Myocardial injury induced by radiotherapy has the hallmark of increased interstitial myocardial fibrosis<sup><a href="#ref-6">6</a></sup>, which in turn leads to diastolic LV dysfunction<sup><a href="#ref-26">26</a></sup> and subtle contractile impairment<sup><a href="#ref-27">27</a></sup>. These pathological changes may also account for the higher incidence of conduction abnormalities, cardiovascular autonomic dysfunction, impaired exercise performance, and overall mortality<sup><a href="#ref-28">28</a></sup>. Additionally, cardiac radiation is associated with complex stenotic and regurgitant valvular lesions<sup><a href="#ref-29">29</a></sup>, pericardial disease<sup><a href="#ref-6">6</a></sup>, and carotid artery disease<sup><a href="#ref-30">30</a></sup>, among other conditions.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d17740e2144>Stages of cancer therapeutics-induced cardiotoxicity</h2><p class="" id=d17740e2147>Patterned after an established classification of disease progression<sup><a href="#ref-31">31</a></sup>, we have divided CTIC into four distinct stages, i.e. A, B, C, and D (see <a href="#f1">Figure 1</a>). Stage A CTIC refers to cancer patients with cardiovascular health. Stage B CTIC designates cancer patients with high risk of developing CTIC. Risk factors for CTIC can be broadly divided into those pertaining to the patient and those pertaining to the cancer therapies implemented (see <a href="#T2">Table 2</a>)<sup><a href="#ref-5">5</a>,<a href="#ref-30">30</a>,<a href="#ref-32">32</a>,<a href="#ref-33">33</a></sup>. Stage C CTIC denotes “incipient” cardiotoxicity; this is the early stages of the cardiotoxic process before it becomes clinically apparent. This stage is characterized by the appearance of abnormal biomarkers that precede the clearly defined diseased entities (e.g. QTc prolongation precedes Torsade de Pointes and sudden cardiac death, and sarcomeric protein or natriuretic peptide serum elevations precede LV dysfunction and overt heart failure, etc.). Finally, stage D CTIC refers to established cardiotoxicity, which is manifested by cardiovascular syndromes in early or late stages, that requires standard diagnostic modalities and medical and surgical therapies derived from expert consensus guidelines<sup><a href="#ref-8">8</a>,<a href="#ref-31">31</a>,<a href="#ref-34">34</a>–<a href="#ref-36">36</a></sup>.</p><a name=f1 class=n-a></a><div class="fig panel clearfix"><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/16550/cca72747-2a69-4a6a-bb0d-ea7b12d983ff_figure1.gif"><img alt="cca72747-2a69-4a6a-bb0d-ea7b12d983ff_figure1.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/16550/cca72747-2a69-4a6a-bb0d-ea7b12d983ff_figure1.gif"></a><div class=caption><h3>Figure 1. Prevention of cancer therapeutics-induced cardiotoxicity.</h3><p id=d17740e2196>Prevention of cancer therapeutics-induced cardiotoxicity.</p></div></div><a name=T2 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 2. Risk factors of cancer therapeutics-induced cardiotoxicity.</h3><p id=d17740e2213>CAD, coronary artery disease; CVD, cardiovascular disease; HF, heart failure; LVEF, left ventricular ejection fraction; RT, radiotherapy; SCD, sudden cardiac death; US FDA, United States Food and Drug Administration.</p></div><table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d17740e2217 class=n-a></a><thead><a name=d17740e2219 class=n-a></a><tr><a name=d17740e2221 class=n-a></a><th align=center colspan=4 rowspan=1><a name=d17740e2223 class=n-a></a>Risk factors of cancer therapeutics-induced cardiotoxicity</th></tr></thead><tbody><a name=d17740e2228 class=n-a></a><tr><a name=d17740e2230 class=n-a></a><td align=center colspan=1 rowspan=15 valign=middle><a name=d17740e2231 class=n-a></a>Patient</td><td align=center colspan=3 rowspan=1><a name=d17740e2234 class=n-a></a>Age</td></tr><tr><a name=d17740e2237 class=n-a></a><td align=center colspan=3 rowspan=1><a name=d17740e2239 class=n-a></a>Sex</td></tr><tr><a name=d17740e2242 class=n-a></a><td align=center colspan=1 rowspan=12><a name=d17740e2244 class=n-a></a>Risk Factors of CVD</td><td align=center colspan=1 rowspan=4><a name=d17740e2247 class=n-a></a>Health behaviors</td><td colspan=1 rowspan=1><a name=d17740e2250 class=n-a></a>Smoking/tobacco use</td></tr><tr><a name=d17740e2253 class=n-a></a><td colspan=1 rowspan=1><a name=d17740e2255 class=n-a></a>Overweigth and obesity</td></tr><tr><a name=d17740e2258 class=n-a></a><td colspan=1 rowspan=1><a name=d17740e2260 class=n-a></a>Physical inactivity</td></tr><tr><a name=d17740e2264 class=n-a></a><td colspan=1 rowspan=1><a name=d17740e2266 class=n-a></a>Poor nutrition</td></tr><tr><a name=d17740e2269 class=n-a></a><td align=center colspan=1 rowspan=5><a name=d17740e2271 class=n-a></a>Health factors</td><td colspan=1 rowspan=1><a name=d17740e2274 class=n-a></a>Hypertension</td></tr><tr><a name=d17740e2277 class=n-a></a><td colspan=1 rowspan=1><a name=d17740e2279 class=n-a></a>Diabetes mellitus</td></tr><tr><a name=d17740e2282 class=n-a></a><td colspan=1 rowspan=1><a name=d17740e2284 class=n-a></a>Hyperlipidemia</td></tr><tr><a name=d17740e2287 class=n-a></a><td colspan=1 rowspan=1><a name=d17740e2289 class=n-a></a>Metabolic syndrome</td></tr><tr><a name=d17740e2292 class=n-a></a><td colspan=1 rowspan=1><a name=d17740e2294 class=n-a></a>Kidney disease</td></tr><tr><a name=d17740e2298 class=n-a></a><td align=center colspan=1 rowspan=3><a name=d17740e2300 class=n-a></a>Risk factors of SCD</td><td colspan=1 rowspan=1><a name=d17740e2303 class=n-a></a>QTc prolongation</td></tr><tr><a name=d17740e2306 class=n-a></a><td colspan=1 rowspan=1><a name=d17740e2308 class=n-a></a>Electrolyte abnormalities</td></tr><tr><a name=d17740e2311 class=n-a></a><td colspan=1 rowspan=1><a name=d17740e2313 class=n-a></a>Proarrhythmic drugs</td></tr><tr><a name=d17740e2316 class=n-a></a><td align=center colspan=2 rowspan=1><a name=d17740e2318 class=n-a></a>Pre-existent CVD</td><td colspan=1 rowspan=1><a name=d17740e2321 class=n-a></a>e.g. CAD, HF, arrhythmias, etc</td></tr><tr><a name=d17740e2324 class=n-a></a><td align=center colspan=1 rowspan=7 valign=middle><a name=d17740e2325 class=n-a></a>Cancer therapies</td><td align=center colspan=1 rowspan=4 valign=middle><a name=d17740e2328 class=n-a></a>Cardiotoxic<br class=br>chemotherapy</td><td align=center colspan=1 rowspan=1><a name=d17740e2333 class=n-a></a>High-dose anthracycline therapy</td><td colspan=1 rowspan=1><a name=d17740e2336 class=n-a></a>e.g. doxorubicin ≥250 mg/m<sup>2</sup> or epirubicin ≥600 mg/m<sup>2</sup></td></tr><tr><a name=d17740e2344 class=n-a></a><td align=center colspan=1 rowspan=1><a name=d17740e2346 class=n-a></a>Low-dose anthracycline or<br class=br>trastuzumab therapy in high-risk<br class=br>patients</td><td colspan=1 rowspan=1><a name=d17740e2353 class=n-a></a>e.g. low normal LVEF (&lt;53%), two or more general CVD risk<br class=br>factors, age 60 or over, established moderate to severe CVD</td></tr><tr><a name=d17740e2359 class=n-a></a><td align=center colspan=1 rowspan=1><a name=d17740e2361 class=n-a></a>Low-dose anthracycline and<br class=br>trastuzumab sequential therapy</td><td colspan=1 rowspan=1><a name=d17740e2366 class=n-a></a>e.g. doxorubicin &lt;250 mg/m<sup>2</sup> or epirubicin &lt;600 mg/m<sup>2</sup> +<br class=br>trastuzumab</td></tr><tr><a name=d17740e2377 class=n-a></a><td align=center colspan=1 rowspan=1><a name=d17740e2379 class=n-a></a>Other chemotherapy</td><td colspan=1 rowspan=1><a name=d17740e2382 class=n-a></a>e.g. US FDA box warning agents</td></tr><tr><a name=d17740e2385 class=n-a></a><td align=center colspan=1 rowspan=2 valign=middle><a name=d17740e2387 class=n-a></a>Cardiotoxic<br class=br>radiotherapy</td><td align=center colspan=1 rowspan=1><a name=d17740e2392 class=n-a></a>High-dose cardiac radiation<br class=br>therapy</td><td colspan=1 rowspan=1><a name=d17740e2397 class=n-a></a>e.g. cardiac RT ≥30 Gy or ≥2 Gy/day</td></tr><tr><a name=d17740e2400 class=n-a></a><td align=center colspan=1 rowspan=1><a name=d17740e2402 class=n-a></a>Inability of cardiac avoidance</td><td colspan=1 rowspan=1><a name=d17740e2405 class=n-a></a>e.g. anterior or left chest radiation, tumor in cardiac<br class=br>proximity, lack of shielding, etc.</td></tr><tr><a name=d17740e2410 class=n-a></a><td align=center colspan=1 rowspan=1><a name=d17740e2412 class=n-a></a>Combination of<br class=br>cardiotoxic cancer<br class=br>therapies</td><td align=center colspan=1 rowspan=1><a name=d17740e2419 class=n-a></a>Low-dose anthracycline + low-<br class=br>dose radiation therapy</td><td colspan=1 rowspan=1><a name=d17740e2424 class=n-a></a>e.g. doxorubicin &lt;250 mg/m<sup>2</sup> or epirubicin &lt;600 mg/m<sup>2</sup> +<br class=br>cardiac RT &lt;30 Gy</td></tr></tbody></table></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d17740e2441>Levels of prevention</h2><p class="" id=d17740e2444>Preventive strategies for CTIC can also be divided into four standard levels, i.e. primordial, primary, secondary, and tertiary, which correspond with the stages of CTIC; each level of prevention has a particular goal, focus, and means (see <a href="#f1">Figure 1</a>).</p><p class="" id=d17740e2450>Primordial prevention is principally focused on the education of both patients and providers and on the implementation of general best practices to impede the emergence and development of risk factors for CTIC. This is being accomplished by the explosion of expert consensus guidelines in the last decade (see “expert consensus guidelines” below) as well as a growing presence of cardio-oncology programs in major oncology and cardiology scientific meetings. Moreover, there has been an increasing number of continuing medical education materials and public health education programs in this topic, all serving to raise awareness and educate on the cardiovascular effects of cancer therapies. Furthermore, the International Cardio-Oncology Society and the Canadian Cardiac Oncology Network have recently partnered in the writing of a cardio-oncology multidisciplinary training proposal to formally educate physicians in this developing field<sup><a href="#ref-37">37</a></sup>.</p><p class="" id=d17740e2457>Primary prevention has the goal of impeding the emergence of CTIC. The diagnosis and control of modifiable risk factors (see <a href="#T2">Table 2</a>) and the promotion of cardiovascular health in the cancer population are of utmost importance. In addition, the administration of cardioprotective therapies to selected patients with unavoidable moderate and high risk of CTIC is a means of primary prevention (see “cardioprotectants” below).</p><p class="" id=d17740e2463>Secondary prevention is enforced once cardiac toxicity is incipient; early diagnosis and surveillance (see “blood biomarkers and diagnostic modalities” below), implementation of cardioprotective strategies, and administration of cardioprotective and basic therapies have the overarching goal to mitigate the progression of cardiotoxicity, restore cardiovascular health, and prevent complications. As in most health conditions, earlier diagnosis and treatment of CTIC seem to translate into improved outcomes<sup><a href="#ref-38">38</a></sup>. Inspired by the American Society of Clinical Oncology (ASCO) clinical practice guideline on the prevention and monitoring of cardiac dysfunction in survivors of adult cancers<sup><a href="#ref-5">5</a></sup>, as well as by other recent expert consensus guidelines that include recommendations on the prevention of CTIC<sup><a href="#ref-8">8</a>,<a href="#ref-32">32</a>,<a href="#ref-39">39</a>,<a href="#ref-40">40</a></sup>, we have constructed a table summarizing the general evidence-based recommendations for the prevention of cardiotoxicity before, during, and after cancer therapies (see <a href="#T3">Table 3</a>).</p><a name=T3 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 3. Preventive strategies for cancer therapeutics-induced cardiotoxicity.</h3><p id=d17740e2501>DM, diabetes mellitus; HL, hyperlipidemia; HTN, hypertension.</p></div><table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d17740e2505 class=n-a></a><thead><a name=d17740e2507 class=n-a></a><tr><a name=d17740e2509 class=n-a></a><th align=center colspan=4 rowspan=1><a name=d17740e2511 class=n-a></a>Preventive strategies for cancer therapeutics-induced cardiotoxicity</th></tr></thead><tbody><a name=d17740e2516 class=n-a></a><tr><a name=d17740e2518 class=n-a></a><td align=center colspan=1 rowspan=4 valign=middle><a name=d17740e2519 class=n-a></a>Before cardiotoxic cancer<br class=br>therapy</td><td colspan=2 rowspan=1><a name=d17740e2524 class=n-a></a>Prioritize non-cardiotoxic cancer therapies without compromising cancer-specific outcomes</td></tr><tr><a name=d17740e2527 class=n-a></a><td colspan=2 rowspan=1><a name=d17740e2529 class=n-a></a>Diagnosis and control of modifiable cardiovascular risk factors (e.g. HTN, DM, HL, etc.)</td></tr><tr><a name=d17740e2532 class=n-a></a><td colspan=2 rowspan=1><a name=d17740e2534 class=n-a></a>Establish cardiovascular health (e.g. clinical examination, imaging, biomarkers)</td></tr><tr><a name=d17740e2537 class=n-a></a><td colspan=2 rowspan=1><a name=d17740e2539 class=n-a></a>Referral to specialist as appropriate</td></tr><tr><a name=d17740e2542 class=n-a></a><td align=center colspan=1 rowspan=10 valign=middle><a name=d17740e2543 class=n-a></a>During cardiotoxic cancer<br class=br>therapy</td><td colspan=2 rowspan=1><a name=d17740e2548 class=n-a></a>Diagnosis and control of modifiable cardiovascular risk factors (e.g. HTN, DM, HL, etc.)</td></tr><tr><a name=d17740e2552 class=n-a></a><td colspan=2 rowspan=1><a name=d17740e2554 class=n-a></a>Evaluate and maintain cardiovascular health (e.g. clinical examination, imaging, biomarkers)</td></tr><tr><a name=d17740e2557 class=n-a></a><td colspan=2 rowspan=1><a name=d17740e2559 class=n-a></a>Referral to specialist as appropriate</td></tr><tr><a name=d17740e2562 class=n-a></a><td align=center colspan=1 rowspan=3 valign=middle><a name=d17740e2564 class=n-a></a>Cardiotoxic chemotherapy</td><td colspan=1 rowspan=1><a name=d17740e2567 class=n-a></a>Prioritize liposomal formulation and continuous infusion of doxorubicin</td></tr><tr><a name=d17740e2570 class=n-a></a><td colspan=1 rowspan=1><a name=d17740e2572 class=n-a></a>Prioritize the use of dexrazoxane administration when considered<br class=br>appropriate (e.g. high-dose anthracyclines)</td></tr><tr><a name=d17740e2577 class=n-a></a><td colspan=1 rowspan=1><a name=d17740e2579 class=n-a></a>Discontinue chemotherapy when considered appropriate</td></tr><tr><a name=d17740e2582 class=n-a></a><td align=center colspan=1 rowspan=4 valign=middle><a name=d17740e2584 class=n-a></a>Mediastinal radiotherapy</td><td colspan=1 rowspan=1><a name=d17740e2587 class=n-a></a>Prioritize lowest clinically effective radiation dose</td></tr><tr><a name=d17740e2591 class=n-a></a><td colspan=1 rowspan=1><a name=d17740e2593 class=n-a></a>Deep-inspiration breath holding radiotherapy techniques</td></tr><tr><a name=d17740e2596 class=n-a></a><td colspan=1 rowspan=1><a name=d17740e2598 class=n-a></a>Intensity-modulated radiotherapy</td></tr><tr><a name=d17740e2601 class=n-a></a><td colspan=1 rowspan=1><a name=d17740e2603 class=n-a></a>Discontinue radiotherapy when considered appropriate</td></tr><tr><a name=d17740e2606 class=n-a></a><td align=center colspan=1 rowspan=3 valign=middle><a name=d17740e2607 class=n-a></a>After cardiotoxic cancer<br class=br>therapy</td><td colspan=2 rowspan=1><a name=d17740e2612 class=n-a></a>Diagnosis and control of modifiable cardiovascular risk factors (e.g. HTN, DM, HL, etc.)</td></tr><tr><a name=d17740e2615 class=n-a></a><td colspan=2 rowspan=1><a name=d17740e2617 class=n-a></a>Monitor cardiovascular health (e.g. clinical examination, imaging, biomarkers)</td></tr><tr><a name=d17740e2620 class=n-a></a><td colspan=2 rowspan=1><a name=d17740e2622 class=n-a></a>Referral to specialist as appropriate</td></tr></tbody></table></div><p class="" id=d17740e2628>Lastly, once CTIC has progressed sufficiently to be manifest in cardiovascular syndromes (e.g. HF, arrhythmias, acute coronary syndromes, etc.), tertiary prevention aims to limit further progression and disability, and promote rehabilitation, by both basic and advanced cardiovascular therapeutics. The evaluation and management of these defined CTIC syndromes are similar to those encountered in non-cancer patients. There are several clinical practice guidelines for the evaluation and management of these conditions in the literature<sup><a href="#ref-31">31</a>,<a href="#ref-35">35</a>,<a href="#ref-36">36</a>,<a href="#ref-41">41</a>,<a href="#ref-42">42</a></sup>, and some specifically address the cancer population<sup><a href="#ref-8">8</a>,<a href="#ref-9">9</a></sup>; these tertiary prevention strategies will not be further detailed in this work.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d17740e2657>Expert panel consensus guidelines</h2><p class="" id=d17740e2660>As mentioned above, the prevention of cardiotoxicity induced by cancer therapies has increasingly been the focus of several clinical cardiovascular and oncological societies, demonstrating the increasing relevance that this field has taken in the latest decade. In 2012, the European Society for Medical Oncology published a basic set of clinical practice guidelines for the prevention, monitoring, and management of CTIC<sup><a href="#ref-40">40</a></sup>. The American Society of Echocardiography and the European Society of Cardiovascular Imaging joined forces to create expert consensus guidelines for the multimodality imaging evaluation of cardiovascular complications of radiotherapy in adult patients in 2013<sup><a href="#ref-30">30</a></sup> as well as evaluation during and after cancer therapies in 2014<sup><a href="#ref-43">43</a></sup>. These efforts aim to standardize the indications, acquisition protocols, definitions, limitations, and vendor variability for the different cardiac imaging modalities usually employed in the diagnosis and surveillance of CTIC. In 2016, the American Heart Association (AHA) released a comprehensive scientific statement describing the mechanism, magnitude, onset, and likelihood of direct myocardial toxicity of several anti-cancer medications, among other clinically approved drugs, “to assist healthcare providers in improving the quality of care for these patients”<sup><a href="#ref-7">7</a></sup>. In the same year, the Canadian Cardiovascular Society published a set of best practice guidelines for the management of cancer patients, focusing on the identification of the high-risk population and the detection and prevention of cardiotoxicity<sup><a href="#ref-39">39</a></sup>. This was followed by a position paper from the European Society of Cardiology summarizing the available evidence on the pathophysiology, prevention, diagnosis, therapeutic management, and long-term surveillance of the most common forms of cardiotoxicities induced by cancer therapies<sup><a href="#ref-8">8</a></sup>. Most recently, as mentioned above, the ASCO published a clinical practice guideline outlining general recommendations for the prevention of cardiac dysfunction in survivors of adult cancers<sup><a href="#ref-5">5</a></sup>. It was developed by an expert multidisciplinary physician panel using a systematic review (1996–2016) of 104 articles (meta-analyses, randomized clinical trials, and observational trials) and their clinical experience. Finally, the AHA has just published a scientific statement specifically and comprehensively dealing with the prevention of CVD in breast cancer patients, including that caused by cancer therapies<sup><a href="#ref-32">32</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d17740e2700>Cardioprotectants</h2><p class="" id=d17740e2703>The development and investigation of cardioprotective agents has been exponentially increasing since the early days of anthracycline cardiotoxicity. To date, only one cardioprotectant is approved for clinical use, i.e. dexrazoxane; many others have been tested in the clinical setting, and an even larger number are on preclinical stages of investigation (see <a href="#T4">Table 4</a> for a succinct list of cardioprotective agents for CTIC that have been shown to be useful at different stages of research). The vast majority of cardioprotectants have been tested in the setting of anthracycline administration, either alone or in combination with other chemotherapeutic agents; a small number has been tested in trastuzumab-only administration.</p><a name=T4 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 4. Cardioprotectants in cancer therapeutics-induced cardiotoxicity.</h3><p id=d17740e2719>ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; MRA, mineralocorticoid receptor antagonist; NSAID, non-steroidal anti-inflammatory drug; PC-SOD, lecithinized human recombinant super oxide dismutase.</p></div><table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d17740e2723 class=n-a></a><thead><a name=d17740e2725 class=n-a></a><tr><a name=d17740e2727 class=n-a></a><th colspan=4 rowspan=1><a name=d17740e2729 class=n-a></a>Cardioprotectants in cancer therapeutics-induced cardiotoxicity</th></tr></thead><tbody><a name=d17740e2734 class=n-a></a><tr><a name=d17740e2736 class=n-a></a><td align=center colspan=1 rowspan=17 valign=middle><a name=d17740e2738 class=n-a></a>Clinical</td><td align=center colspan=1 rowspan=2 valign=middle><a name=d17740e2741 class=n-a></a>Antidotes</td><td colspan=1 rowspan=1><a name=d17740e2744 class=n-a></a>Dexrazoxane</td><td colspan=1 rowspan=1><a name=d17740e2747 class=n-a></a>Lipshultz <i>et al</i>.<sup><a href="#ref-49">49</a></sup></td></tr><tr><a name=d17740e2756 class=n-a></a><td colspan=1 rowspan=1><a name=d17740e2758 class=n-a></a>N-acetylcysteine</td><td colspan=1 rowspan=1><a name=d17740e2761 class=n-a></a>Myers <i>et al</i>.<sup><a href="#ref-54">54</a></sup></td></tr><tr><a name=d17740e2770 class=n-a></a><td align=center colspan=1 rowspan=4 valign=middle><a name=d17740e2772 class=n-a></a>Beta-blockers</td><td colspan=1 rowspan=1><a name=d17740e2775 class=n-a></a>Carvedilol</td><td colspan=1 rowspan=1><a name=d17740e2778 class=n-a></a>Avila <i>et al</i>.<sup><a href="#ref-55">55</a></sup></td></tr><tr><a name=d17740e2787 class=n-a></a><td colspan=1 rowspan=1><a name=d17740e2789 class=n-a></a>Nebivolol</td><td colspan=1 rowspan=1><a name=d17740e2792 class=n-a></a>Kaya <i>et al</i>.<sup><a href="#ref-56">56</a></sup></td></tr><tr><a name=d17740e2801 class=n-a></a><td colspan=1 rowspan=1><a name=d17740e2803 class=n-a></a>Bisoprolol</td><td colspan=1 rowspan=1><a name=d17740e2806 class=n-a></a>Pituskin <i>et al</i>.<sup><a href="#ref-57">57</a></sup></td></tr><tr><a name=d17740e2816 class=n-a></a><td colspan=1 rowspan=1><a name=d17740e2818 class=n-a></a>Metoprolol</td><td colspan=1 rowspan=1><a name=d17740e2821 class=n-a></a>Georgakopoulos <i>et al</i>.<sup><a href="#ref-58">58</a></sup></td></tr><tr><a name=d17740e2830 class=n-a></a><td align=center colspan=1 rowspan=3 valign=middle><a name=d17740e2832 class=n-a></a>ACEIs</td><td colspan=1 rowspan=1><a name=d17740e2835 class=n-a></a>Enalapril</td><td colspan=1 rowspan=1><a name=d17740e2838 class=n-a></a>Cardinale <i>et al</i>.<sup><a href="#ref-59">59</a></sup></td></tr><tr><a name=d17740e2847 class=n-a></a><td colspan=1 rowspan=1><a name=d17740e2849 class=n-a></a>Ramipril</td><td colspan=1 rowspan=1><a name=d17740e2852 class=n-a></a>Jensen <i>et al</i>.<sup><a href="#ref-60">60</a></sup></td></tr><tr><a name=d17740e2861 class=n-a></a><td colspan=1 rowspan=1><a name=d17740e2863 class=n-a></a>Perindopril</td><td colspan=1 rowspan=1><a name=d17740e2866 class=n-a></a>Pituskin <i>et al</i>.<sup><a href="#ref-57">57</a></sup></td></tr><tr><a name=d17740e2875 class=n-a></a><td align=center colspan=1 rowspan=2 valign=middle><a name=d17740e2877 class=n-a></a>ARBs</td><td colspan=1 rowspan=1><a name=d17740e2880 class=n-a></a>Valsartan</td><td colspan=1 rowspan=1><a name=d17740e2883 class=n-a></a>Nakamae <i>et al</i>.<sup><a href="#ref-61">61</a></sup></td></tr><tr><a name=d17740e2892 class=n-a></a><td colspan=1 rowspan=1><a name=d17740e2894 class=n-a></a>Candesartan</td><td colspan=1 rowspan=1><a name=d17740e2897 class=n-a></a>Gulati <i>et al</i>.<sup><a href="#ref-62">62</a></sup></td></tr><tr><a name=d17740e2907 class=n-a></a><td align=center colspan=1 rowspan=1 valign=middle><a name=d17740e2909 class=n-a></a>MRAs</td><td colspan=1 rowspan=1><a name=d17740e2912 class=n-a></a>Spironolactone</td><td colspan=1 rowspan=1><a name=d17740e2915 class=n-a></a>Akpek <i>et al</i>.<sup><a href="#ref-63">63</a></sup></td></tr><tr><a name=d17740e2924 class=n-a></a><td align=center colspan=1 rowspan=1 valign=middle><a name=d17740e2926 class=n-a></a>Statins</td><td colspan=1 rowspan=1><a name=d17740e2929 class=n-a></a>Atorvastatin</td><td colspan=1 rowspan=1><a name=d17740e2932 class=n-a></a>Acar <i>et al</i>.<sup><a href="#ref-64">64</a></sup></td></tr><tr><a name=d17740e2941 class=n-a></a><td align=center colspan=1 rowspan=4 valign=middle><a name=d17740e2943 class=n-a></a>Natural supplements</td><td colspan=1 rowspan=1><a name=d17740e2946 class=n-a></a>Melatonin</td><td colspan=1 rowspan=1><a name=d17740e2949 class=n-a></a>Lissoni <i>et al</i>.<sup><a href="#ref-65">65</a></sup></td></tr><tr><a name=d17740e2958 class=n-a></a><td colspan=1 rowspan=1><a name=d17740e2960 class=n-a></a>Ubiquinone</td><td colspan=1 rowspan=1><a name=d17740e2963 class=n-a></a>Iarussi <i>et al</i>.<sup><a href="#ref-66">66</a></sup></td></tr><tr><a name=d17740e2972 class=n-a></a><td colspan=1 rowspan=1><a name=d17740e2974 class=n-a></a>Vitamins C and E</td><td colspan=1 rowspan=1><a name=d17740e2977 class=n-a></a>Wagdi <i>et al</i>.<sup><a href="#ref-67">67</a></sup></td></tr><tr><a name=d17740e2986 class=n-a></a><td colspan=1 rowspan=1><a name=d17740e2988 class=n-a></a>Levocarnitine</td><td colspan=1 rowspan=1><a name=d17740e2991 class=n-a></a>Waldner <i>et al</i>.<sup><a href="#ref-68">68</a></sup></td></tr><tr><a name=d17740e3001 class=n-a></a><td align=center colspan=1 rowspan=27 valign=middle><a name=d17740e3002 class=n-a></a>Preclinical</td><td align=center colspan=1 rowspan=3 valign=middle><a name=d17740e3005 class=n-a></a>ACEIs</td><td colspan=1 rowspan=1><a name=d17740e3008 class=n-a></a>Temocapril</td><td colspan=1 rowspan=1><a name=d17740e3011 class=n-a></a>Tokudome <i>et al</i>.<sup><a href="#ref-69">69</a></sup></td></tr><tr><a name=d17740e3020 class=n-a></a><td colspan=1 rowspan=1><a name=d17740e3022 class=n-a></a>Delapril</td><td colspan=1 rowspan=1><a name=d17740e3025 class=n-a></a>Maeda <i>et al</i>.<sup><a href="#ref-70">70</a></sup></td></tr><tr><a name=d17740e3034 class=n-a></a><td colspan=1 rowspan=1><a name=d17740e3036 class=n-a></a>Zofenopril</td><td colspan=1 rowspan=1><a name=d17740e3039 class=n-a></a>Sacco <i>et al</i>.<sup><a href="#ref-71">71</a></sup></td></tr><tr><a name=d17740e3048 class=n-a></a><td align=center colspan=1 rowspan=1 valign=middle><a name=d17740e3050 class=n-a></a>ARBs</td><td colspan=1 rowspan=1><a name=d17740e3053 class=n-a></a>Losartan</td><td colspan=1 rowspan=1><a name=d17740e3056 class=n-a></a>Matouk <i>et al</i>.<sup><a href="#ref-72">72</a></sup></td></tr><tr><a name=d17740e3065 class=n-a></a><td align=center colspan=1 rowspan=1 valign=middle><a name=d17740e3067 class=n-a></a>Statins</td><td colspan=1 rowspan=1><a name=d17740e3070 class=n-a></a>Fluvastatin</td><td colspan=1 rowspan=1><a name=d17740e3073 class=n-a></a>Riad <i>et al</i>.<sup><a href="#ref-73">73</a></sup></td></tr><tr><a name=d17740e3082 class=n-a></a><td align=center colspan=1 rowspan=1 valign=middle><a name=d17740e3084 class=n-a></a>Biguanides</td><td colspan=1 rowspan=1><a name=d17740e3087 class=n-a></a>Metformin</td><td colspan=1 rowspan=1><a name=d17740e3090 class=n-a></a>Kobashigawa <i>et al</i>.<sup><a href="#ref-74">74</a></sup></td></tr><tr><a name=d17740e3100 class=n-a></a><td align=center colspan=1 rowspan=1 valign=middle><a name=d17740e3102 class=n-a></a>Prostacyclins</td><td colspan=1 rowspan=1><a name=d17740e3105 class=n-a></a>Iloprost</td><td colspan=1 rowspan=1><a name=d17740e3108 class=n-a></a>Neilan <i>et al</i>.<sup><a href="#ref-75">75</a></sup></td></tr><tr><a name=d17740e3117 class=n-a></a><td align=center colspan=1 rowspan=1 valign=middle><a name=d17740e3119 class=n-a></a>NSAIDs</td><td colspan=1 rowspan=1><a name=d17740e3122 class=n-a></a>Meloxicam</td><td colspan=1 rowspan=1><a name=d17740e3125 class=n-a></a>Hassan <i>et al</i>.<sup><a href="#ref-76">76</a></sup></td></tr><tr><a name=d17740e3134 class=n-a></a><td align=center colspan=1 rowspan=3 valign=middle><a name=d17740e3136 class=n-a></a>Vasodilators</td><td colspan=1 rowspan=1><a name=d17740e3139 class=n-a></a>Diazoxide</td><td colspan=1 rowspan=1><a name=d17740e3142 class=n-a></a>Hole <i>et al</i>.<sup><a href="#ref-77">77</a></sup></td></tr><tr><a name=d17740e3151 class=n-a></a><td colspan=1 rowspan=1><a name=d17740e3153 class=n-a></a>Molsidomine</td><td colspan=1 rowspan=1><a name=d17740e3156 class=n-a></a>Disli <i>et al</i>.<sup><a href="#ref-78">78</a></sup></td></tr><tr><a name=d17740e3165 class=n-a></a><td colspan=1 rowspan=1><a name=d17740e3167 class=n-a></a>Nicorandil</td><td colspan=1 rowspan=1><a name=d17740e3170 class=n-a></a>Ahmed <i>et al</i>.<sup><a href="#ref-79">79</a></sup></td></tr><tr><a name=d17740e3179 class=n-a></a><td align=center colspan=1 rowspan=1 valign=middle><a name=d17740e3181 class=n-a></a>Iron salts</td><td colspan=1 rowspan=1><a name=d17740e3184 class=n-a></a>Ferric carboxymaltose</td><td colspan=1 rowspan=1><a name=d17740e3187 class=n-a></a>Toblli <i>et al</i>.<sup><a href="#ref-80">80</a></sup></td></tr><tr><a name=d17740e3197 class=n-a></a><td align=center colspan=1 rowspan=1 valign=middle><a name=d17740e3199 class=n-a></a>Neuropeptides</td><td colspan=1 rowspan=1><a name=d17740e3202 class=n-a></a>Ghrelin</td><td colspan=1 rowspan=1><a name=d17740e3205 class=n-a></a>Wang <i>et al</i>.<sup><a href="#ref-81">81</a></sup></td></tr><tr><a name=d17740e3214 class=n-a></a><td align=center colspan=1 rowspan=12 valign=middle><a name=d17740e3216 class=n-a></a>Natural antioxidants</td><td colspan=1 rowspan=1><a name=d17740e3219 class=n-a></a>Dihydromyricetin</td><td colspan=1 rowspan=1><a name=d17740e3222 class=n-a></a>Zhu <i>et al</i>.<sup><a href="#ref-82">82</a></sup></td></tr><tr><a name=d17740e3231 class=n-a></a><td colspan=1 rowspan=1><a name=d17740e3233 class=n-a></a>Hydroxytyrosol</td><td colspan=1 rowspan=1><a name=d17740e3236 class=n-a></a>Granados-Principal <i>et al</i>.<sup><a href="#ref-83">83</a></sup></td></tr><tr><a name=d17740e3245 class=n-a></a><td colspan=1 rowspan=1><a name=d17740e3247 class=n-a></a>Sesame oil</td><td colspan=1 rowspan=1><a name=d17740e3250 class=n-a></a>Saleem <i>et al</i>.<sup><a href="#ref-84">84</a></sup></td></tr><tr><a name=d17740e3259 class=n-a></a><td colspan=1 rowspan=1><a name=d17740e3261 class=n-a></a>Sesamin</td><td colspan=1 rowspan=1><a name=d17740e3264 class=n-a></a>Su <i>et al</i>.<sup><a href="#ref-85">85</a></sup></td></tr><tr><a name=d17740e3273 class=n-a></a><td colspan=1 rowspan=1><a name=d17740e3275 class=n-a></a>Salidroside</td><td colspan=1 rowspan=1><a name=d17740e3278 class=n-a></a>Wang <i>et al</i>.<sup><a href="#ref-86">86</a></sup></td></tr><tr><a name=d17740e3288 class=n-a></a><td colspan=1 rowspan=1><a name=d17740e3290 class=n-a></a>Glutathione</td><td colspan=1 rowspan=1><a name=d17740e3293 class=n-a></a>Mohamed <i>et al</i>.<sup><a href="#ref-87">87</a></sup></td></tr><tr><a name=d17740e3302 class=n-a></a><td colspan=1 rowspan=1><a name=d17740e3304 class=n-a></a>Quercetin</td><td colspan=1 rowspan=1><a name=d17740e3307 class=n-a></a>Matouk <i>et al</i>.<sup><a href="#ref-72">72</a></sup></td></tr><tr><a name=d17740e3316 class=n-a></a><td colspan=1 rowspan=1><a name=d17740e3318 class=n-a></a>Isorhamnetin</td><td colspan=1 rowspan=1><a name=d17740e3321 class=n-a></a>Sun <i>et al</i>.<sup><a href="#ref-88">88</a></sup></td></tr><tr><a name=d17740e3330 class=n-a></a><td colspan=1 rowspan=1><a name=d17740e3332 class=n-a></a>Cannabidiol</td><td colspan=1 rowspan=1><a name=d17740e3335 class=n-a></a>Fouad <i>et al</i>.<sup><a href="#ref-89">89</a></sup></td></tr><tr><a name=d17740e3344 class=n-a></a><td colspan=1 rowspan=1><a name=d17740e3346 class=n-a></a>Resveratrol</td><td colspan=1 rowspan=1><a name=d17740e3349 class=n-a></a>Dolinsky <i>et al</i>.<sup><a href="#ref-90">90</a></sup></td></tr><tr><a name=d17740e3358 class=n-a></a><td colspan=1 rowspan=1><a name=d17740e3360 class=n-a></a>indole-3-carbinol</td><td colspan=1 rowspan=1><a name=d17740e3363 class=n-a></a>Hajra e<i>t al</i>.<sup><a href="#ref-91">91</a></sup></td></tr><tr><a name=d17740e3373 class=n-a></a><td colspan=1 rowspan=1><a name=d17740e3375 class=n-a></a>α-Linolenic acid</td><td colspan=1 rowspan=1><a name=d17740e3378 class=n-a></a>Yu <i>et al</i>.<sup><a href="#ref-92">92</a></sup></td></tr><tr><a name=d17740e3387 class=n-a></a><td align=center colspan=1 rowspan=1 valign=middle><a name=d17740e3389 class=n-a></a>Synthetic antioxidants</td><td colspan=1 rowspan=1><a name=d17740e3392 class=n-a></a>Didox</td><td colspan=1 rowspan=1><a name=d17740e3395 class=n-a></a>Al-Abd <i>et al</i>.<sup><a href="#ref-93">93</a></sup></td></tr><tr><a name=d17740e3404 class=n-a></a><td align=center colspan=1 rowspan=1 valign=middle><a name=d17740e3406 class=n-a></a>Other</td><td colspan=1 rowspan=1><a name=d17740e3409 class=n-a></a>Mdivi-1</td><td colspan=1 rowspan=1><a name=d17740e3412 class=n-a></a>Gharanei <i>et al</i>.<sup><a href="#ref-94">94</a></sup></td></tr></tbody></table></div><div class=section><a name=d17740e3424 class=n-a></a><h3 class=section-title>Dexrazoxane</h3><p class="" id=d17740e3429>In the US, dexrazoxane is the only approved cardioprotective agent consistently shown to reduce the incidence or severity of AIC<sup><a href="#ref-44">44</a></sup>. It is recommended to be given intravenously, in a 10:1 ratio of dexrazoxane:doxorubicin (e.g. dexrazoxane 500 mg/m<sup>2</sup>:doxorubicin 50 mg/m<sup>2</sup>) in the context of normal renal function; cardiac monitoring should be continued during dexrazoxane therapy<sup><a href="#ref-17">17</a></sup>. Its use has been associated with statistically significant risk reductions for most doxorubicin-related cardiotoxic outcomes (other than survival)<sup><a href="#ref-45">45</a></sup>, without compromising its therapeutic efficacy, in both pediatric and adult populations<sup><a href="#ref-46">46</a>–<a href="#ref-49">49</a></sup>. Although currently dexrazoxane use is strictly restricted to women with metastatic breast cancer who have received a cumulative doxorubicin dose of 300 mg/m<sup>2</sup> and need continued treatment to maintain tumor control<sup><a href="#ref-44">44</a>,<a href="#ref-50">50</a></sup>, its use in the treatment of other malignancies has been endorsed by expert guidelines<sup><a href="#ref-51">51</a></sup>. Having said that, dexrazoxane is not currently recommended for routine use with the initiation of doxorubicin therapy for either primary or metastatic disease<sup><a href="#ref-51">51</a>–<a href="#ref-53">53</a></sup>. It needs to be noted that dexrazoxane was associated with a potential increased risk of acute myeloid leukemia, myelodysplastic syndrome, and second malignant neoplasms in a pediatric population with Hodgkin lymphoma in a single study a decade ago<sup><a href="#ref-95">95</a></sup>. Many later studies have not been able to reproduce these initial results<sup><a href="#ref-45">45</a>,<a href="#ref-96">96</a>–<a href="#ref-98">98</a></sup>. Furthermore, a recent large clinical trial in a pediatric population corroborated these latter findings, suggesting that dexrazoxane was indeed cardioprotective, did not interfere with antitumor efficacy, did not result in an increased occurrence of toxicities, and had no association with a significant rise in second malignancies<sup><a href="#ref-99">99</a></sup>.</p></div><div class=section><a name=d17740e3499 class=n-a></a><h3 class=section-title>Cardiovascular pharmacotherapy</h3><p class="" id=d17740e3504>Given their consistent benefit in other cardiovascular conditions (e.g. HF and CAD), beta-blockers, angiotensin converting-enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), mineralocorticoid receptor antagonists (MRAs), and HMG-CoA reductase inhibitors (statins) have been extensively studied in the clinical setting, in the context of both anthracycline and trastuzumab therapy, for the prevention of LV dysfunction.</p><p class="" id=d17740e3507>Beta-blocker agents with antioxidant properties such as carvedilol<sup><a href="#ref-100">100</a>–<a href="#ref-102">102</a></sup> and nebivolol<sup><a href="#ref-56">56</a></sup> have shown the most promising results in early small clinical trials investigating their cardioprotective effects. Regrettably, in the so far largest clinical trial of beta-blockers for the prevention of cardiotoxicity under contemporary anthracycline dosage, carvedilol monotherapy had no impact on the incidence of early onset of LV ejection fraction (LVEF) reduction when compared to placebo in a breast cancer population<sup><a href="#ref-55">55</a></sup>. Similarly, ACEI monotherapy with enalapril<sup><a href="#ref-59">59</a></sup> and ramipril<sup><a href="#ref-60">60</a></sup> has also been shown to be beneficial in early small clinical trials; however, the administration of enalapril monotherapy either before chemotherapy or during or after chemotherapy in selected patients with elevated serum troponin levels failed to have a significant impact on outcomes in the most recent multicenter clinical trial<sup><a href="#ref-103">103</a></sup>. As for ARBs, valsartan was shown to be beneficial in small clinical trials over a decade ago<sup><a href="#ref-61">61</a></sup>; however, the use of candesartan as a cardioprotectant has recently provided conflicting results in well-conducted randomized placebo-controlled clinical trials<sup><a href="#ref-104">104</a>,<a href="#ref-62">62</a></sup>. The cardioprotective effects of spironolactone monotherapy have also been promising in early small clinical settings<sup><a href="#ref-63">63</a></sup>, but data from larger randomized clinical trials are still lacking.</p><p class="" id=d17740e3553>Several clinical trials have investigated the cardioprotective effects of combined neurohormonal inhibition, i.e. beta-blockers plus ACEIs/ARBs, as is recommended in the general population with HF<sup><a href="#ref-34">34</a></sup>. Over a decade ago, early initiation of combined beta-blockers and ACEIs was shown to provide benefit in a small population of established AIC, albeit the effect was thought to be mediated mainly by beta-blockers<sup><a href="#ref-105">105</a></sup>. Since then, the role of combined neurohormonal inhibition in cardioprotection has been repeatedly evaluated up to this day in the settings of anthracycline, trastuzumab, or sequential chemotherapy. In the only positive trial to date, the combination of enalapril and carvedilol was shown to prevent deterioration of LV function in adult patients with hematological malignancies undergoing anthracycline therapy<sup><a href="#ref-106">106</a></sup>. However, there are significant concerns regarding this trial, including lack of blinding and differing results based on the methods used to quantify LVEF, making it difficult to conclusively interpret<sup><a href="#ref-107">107</a></sup>. In other clinical settings, metoprolol has been tested in combination with enalapril<sup><a href="#ref-58">58</a></sup> and with candesartan<sup><a href="#ref-62">62</a></sup>, with disappointing results. Similarly, the combination of bisoprolol and perindopril failed to prevent trastuzumab-induced LV remodeling in a modern cohort of ERBB-positive breast cancer patients<sup><a href="#ref-57">57</a></sup>. Finally, in the as-yet-unpublished work by Guglin <i>et al</i>. presented at the 2018 American College of Cardiology annual meeting, both lisinopril and carvedilol failed to prevent cardiotoxicity in breast cancer patients treated with trastuzumab monotherapy, whereas both drugs prevented cardiotoxicity in patients who received both anthracycline and trastuzumab sequential therapy<sup><a href="#ref-108">108</a></sup>.</p><p class="" id=d17740e3592>The cardioprotective role of statins has also been evaluated in small retrospective and prospective analyses, both with non-specific statins<sup><a href="#ref-109">109</a>,<a href="#ref-110">110</a></sup> and atorvastatin monotherapy<sup><a href="#ref-64">64</a></sup>, and was found to be beneficial. These findings are very promising but are yet to be corroborated in larger randomized placebo-controlled trials (simvastatin NCT02096588; atorvastatin NCT02674204).</p></div><div class=section><a name=d17740e3608 class=n-a></a><h3 class=section-title>Natural supplements</h3><p class="" id=d17740e3613>Clinical cardioprotective data involving natural supplements are scarce but growing. Ubiquinone (coenzyme Q10) administration in children receiving anthracyclines was associated with a lesser degree of LV dysfunction and remodeling<sup><a href="#ref-66">66</a></sup>. N-acetylcysteine, administered either alone or with vitamins E and C, averted LV dysfunction from developing in patients receiving high-dose doxorubicin and/or radiotherapy, respectively<sup><a href="#ref-67">67</a>,<a href="#ref-54">54</a></sup>. Melatonin<sup><a href="#ref-65">65</a></sup> and levocarnitine<sup><a href="#ref-68">68</a></sup> have also been tested in the clinical setting with positive results. Larger randomized placebo-controlled trials are lacking as to draw firm conclusions relevant to the clinical practice.</p></div><div class=section><a name=d17740e3636 class=n-a></a><h3 class=section-title>Preclinical agents</h3><p class="" id=d17740e3641>Many other agents have been shown to ameliorate anthracycline cardiotoxicity in small animal models of CTIC. Clinically available agents such as losartan<sup><a href="#ref-72">72</a></sup>, fluvastatin<sup><a href="#ref-73">73</a></sup>, metformin<sup><a href="#ref-74">74</a></sup>, iloprost<sup><a href="#ref-75">75</a></sup>, and meloxicam<sup><a href="#ref-76">76</a></sup> as well as other clinically unavailable ACEIs<sup><a href="#ref-69">69</a>–<a href="#ref-71">71</a></sup> have been shown to have cardioprotective results <i>in vivo</i>. Vasodilators<sup><a href="#ref-77">77</a>–<a href="#ref-79">79</a></sup>, neuropeptides<sup><a href="#ref-81">81</a></sup>, and iron salts<sup><a href="#ref-80">80</a></sup> have also been found to be useful. Finally, given that the pathogenesis of anthracyclines is in part related to increased oxidative stress<sup><a href="#ref-100">100</a></sup>, several natural antioxidants (e.g. sesamin<sup><a href="#ref-85">85</a></sup> and sesame oil<sup><a href="#ref-84">84</a></sup> and hydroxytyrosol<sup><a href="#ref-83">83</a></sup>, among others<sup><a href="#ref-82">82</a>,<a href="#ref-86">86</a>–<a href="#ref-92">92</a></sup>) have been tested and shown various degrees of cardioprotective effects. Didox, a synthetic antioxidant, was also shown to significantly potentiate the cytotoxicity of doxorubicin in liver cancer cells while at the same time protecting the murine model from cardiotoxicity<sup><a href="#ref-93">93</a></sup>. Mdivi-1, a mitochondrial division/mitophagy inhibitor, was also shown to lessen AIC<sup><a href="#ref-94">94</a></sup>.</p></div><div class=section><a name=d17740e3726 class=n-a></a><h3 class=section-title>Other cardioprotective strategies</h3><p class="" id=d17740e3731>Within a family of cardiotoxic agents, there are variations in terms of cardiac safety. For example, the use of pegylated liposomal doxorubicin has been associated with a lower incidence of CTIC and HF<sup><a href="#ref-111">111</a>,<a href="#ref-112">112</a></sup>. Similarly, epirubicin or mitoxantrone are also believed to cause less cardiotoxicity compared with doxorubicin<sup><a href="#ref-113">113</a></sup>. When considering the large family of multitargeted tyrosine kinase inhibitors, vandetanib, nilotinib, and ponatinib seem to possess the highest cardiotoxicity risk<sup><a href="#ref-17">17</a></sup>. The role of exercise therapy in the prevention of CTIC remains controversial because of conflicting results<sup><a href="#ref-114">114</a>,<a href="#ref-115">115</a></sup>.</p><p class="" id=d17740e3756>In summary, with the exception of dexrazoxane, no conclusive recommendations can be made on the clinical use of cardioprotectants for either stage B or stage C CTIC<sup><a href="#ref-5">5</a></sup>.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d17740e3767>Blood biomarkers</h2><p class="" id=d17740e3770>Blood biomarkers, in particular myocardial natriuretic peptides (i.e. NTproBNP and BNP) and sarcomeric proteins (i.e. troponin I and T), have been an integral part of the diagnostic and prognostic armamentarium in common cardiovascular conditions, such as HF and CAD. As it would seem natural, they have been progressively adopted in clinical practice to assist in the diagnosis or surveillance of patients with incipient and established CTIC, in particular LV dysfunction and HF (see <a href="#T5">Table 5</a> for a list of various clinical and preclinical biomarkers shown to predict CTIC)<sup><a href="#ref-5">5</a></sup>.</p><a name=T5 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 5. Blood biomarkers in cancer therapeutics-induced cardiotoxicity.</h3><p id=d17740e3790>ANP, atrial natriuretic peptide; BNP, B-type natriuretic peptide; cMLC1, cardiac myosin light chain-1; cTnAAbs, cardiac troponin specific autoantibodies; cTnI, cardiac troponin I; cTnT, cardiac troponin T; GWAS, genome-wide association study; hs-CRP, high-sensitive C-reactive protein; hs-TnI, high-sensitive troponin I; GDF15, growth differentiation factor-15; GPBB, glycogen phosphorylase BB; IMA, ischemia modified albumin; MPO, myeloperoxidase; NTproBNP, amino-terminal pro B-type natriuretic peptide; PlGF, placental-derived growth factor; ROS, reactive oxygen species.</p></div><table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d17740e3794 class=n-a></a><thead><a name=d17740e3796 class=n-a></a><tr><a name=d17740e3798 class=n-a></a><th align=center colspan=4 rowspan=1><a name=d17740e3800 class=n-a></a>Blood biomarkers in cancer therapeutics-induced cardiotoxicity</th></tr></thead><tbody><a name=d17740e3805 class=n-a></a><tr><a name=d17740e3807 class=n-a></a><td align=center colspan=1 rowspan=21 valign=middle><a name=d17740e3808 class=n-a></a>Clinical</td><td align=center colspan=1 rowspan=3 valign=middle><a name=d17740e3811 class=n-a></a>Myocardial natriuretic peptides</td><td colspan=1 rowspan=1><a name=d17740e3814 class=n-a></a>NTproBNP</td><td colspan=1 rowspan=1><a name=d17740e3817 class=n-a></a>De Iuliis <i>et al</i>.<sup><a href="#ref-119">119</a></sup></td></tr><tr><a name=d17740e3826 class=n-a></a><td colspan=1 rowspan=1><a name=d17740e3828 class=n-a></a>BNP</td><td colspan=1 rowspan=1><a name=d17740e3831 class=n-a></a>Lenihan <i>et al</i>.<sup><a href="#ref-37">37</a></sup></td></tr><tr><a name=d17740e3840 class=n-a></a><td colspan=1 rowspan=1><a name=d17740e3842 class=n-a></a>ANP</td><td colspan=1 rowspan=1><a name=d17740e3845 class=n-a></a>Nousiainen <i>et al</i>.<sup><a href="#ref-120">120</a></sup></td></tr><tr><a name=d17740e3854 class=n-a></a><td align=center colspan=1 rowspan=5 valign=middle><a name=d17740e3856 class=n-a></a>Myocardial sarcomere proteins</td><td colspan=1 rowspan=1><a name=d17740e3859 class=n-a></a>cTnI</td><td colspan=1 rowspan=1><a name=d17740e3862 class=n-a></a>Cardinale <i>et al</i>.<sup><a href="#ref-117">117</a></sup></td></tr><tr><a name=d17740e3871 class=n-a></a><td colspan=1 rowspan=1><a name=d17740e3873 class=n-a></a>cTnT</td><td colspan=1 rowspan=1><a name=d17740e3876 class=n-a></a>Kilickap <i>et al</i>.<sup><a href="#ref-118">118</a></sup></td></tr><tr><a name=d17740e3886 class=n-a></a><td colspan=1 rowspan=1><a name=d17740e3888 class=n-a></a>hs-cTnI</td><td colspan=1 rowspan=1><a name=d17740e3891 class=n-a></a>Sawaya <i>et al</i>.<sup><a href="#ref-121">121</a></sup></td></tr><tr><a name=d17740e3900 class=n-a></a><td colspan=1 rowspan=1><a name=d17740e3902 class=n-a></a>hs-cTnT</td><td colspan=1 rowspan=1><a name=d17740e3905 class=n-a></a>Katsurada <i>et al</i>.<sup><a href="#ref-122">122</a></sup></td></tr><tr><a name=d17740e3914 class=n-a></a><td colspan=1 rowspan=1><a name=d17740e3916 class=n-a></a>us-cTnI</td><td colspan=1 rowspan=1><a name=d17740e3919 class=n-a></a>Ky <i>et al</i>.<sup><a href="#ref-123">123</a></sup></td></tr><tr><a name=d17740e3928 class=n-a></a><td align=center colspan=1 rowspan=10 valign=middle><a name=d17740e3930 class=n-a></a>Other biomarkers</td><td colspan=1 rowspan=1><a name=d17740e3933 class=n-a></a>cTnAAbs</td><td colspan=1 rowspan=1><a name=d17740e3936 class=n-a></a>Ylänen <i>et al</i>.<sup><a href="#ref-124">124</a></sup></td></tr><tr><a name=d17740e3945 class=n-a></a><td colspan=1 rowspan=1><a name=d17740e3947 class=n-a></a>Hb</td><td colspan=1 rowspan=1><a name=d17740e3950 class=n-a></a>Garrone <i>et al</i>.<sup><a href="#ref-125">125</a></sup></td></tr><tr><a name=d17740e3959 class=n-a></a><td colspan=1 rowspan=1><a name=d17740e3961 class=n-a></a>hsCRP</td><td colspan=1 rowspan=1><a name=d17740e3964 class=n-a></a>Onitilo <i>et al</i>.<sup><a href="#ref-126">126</a></sup></td></tr><tr><a name=d17740e3974 class=n-a></a><td colspan=1 rowspan=1><a name=d17740e3976 class=n-a></a>MPO</td><td colspan=1 rowspan=1><a name=d17740e3979 class=n-a></a>Ky <i>et al</i>.<sup><a href="#ref-123">123</a></sup></td></tr><tr><a name=d17740e3988 class=n-a></a><td colspan=1 rowspan=1><a name=d17740e3990 class=n-a></a>PIGF</td><td colspan=1 rowspan=1><a name=d17740e3993 class=n-a></a>Putt <i>et al</i>.<sup><a href="#ref-127">127</a></sup></td></tr><tr><a name=d17740e4002 class=n-a></a><td colspan=1 rowspan=1><a name=d17740e4004 class=n-a></a>GDF15</td><td colspan=1 rowspan=1><a name=d17740e4007 class=n-a></a>Arslan <i>et al</i>.<sup><a href="#ref-128">128</a></sup></td></tr><tr><a name=d17740e4016 class=n-a></a><td colspan=1 rowspan=1><a name=d17740e4018 class=n-a></a>Arginine-NO metabolites</td><td colspan=1 rowspan=1><a name=d17740e4021 class=n-a></a>Finkelman <i>et al</i>.<sup><a href="#ref-129">129</a></sup></td></tr><tr><a name=d17740e4030 class=n-a></a><td colspan=1 rowspan=1><a name=d17740e4032 class=n-a></a>GPBB</td><td colspan=1 rowspan=1><a name=d17740e4035 class=n-a></a>Horacek <i>et al</i>.<sup><a href="#ref-130">130</a></sup></td></tr><tr><a name=d17740e4044 class=n-a></a><td colspan=1 rowspan=1><a name=d17740e4046 class=n-a></a>ROS</td><td colspan=1 rowspan=1><a name=d17740e4049 class=n-a></a>Mercuro <i>et al</i>.<sup><a href="#ref-131">131</a></sup></td></tr><tr><a name=d17740e4059 class=n-a></a><td colspan=1 rowspan=1><a name=d17740e4061 class=n-a></a>IMA</td><td colspan=1 rowspan=1><a name=d17740e4064 class=n-a></a>Ma <i>et al</i>.<sup><a href="#ref-132">132</a></sup></td></tr><tr><a name=d17740e4073 class=n-a></a><td align=center colspan=1 rowspan=3 valign=middle><a name=d17740e4075 class=n-a></a>Single nucleotide polymorphims (GWAS)</td><td colspan=1 rowspan=1><a name=d17740e4078 class=n-a></a>rs2229774</td><td colspan=1 rowspan=1><a name=d17740e4081 class=n-a></a>Aminkeng <i>et al</i>.<sup><a href="#ref-133">133</a></sup></td></tr><tr><a name=d17740e4090 class=n-a></a><td colspan=1 rowspan=1><a name=d17740e4092 class=n-a></a>rs1786814</td><td colspan=1 rowspan=1><a name=d17740e4095 class=n-a></a>Wang <i>et al</i>.<sup><a href="#ref-134">134</a></sup></td></tr><tr><a name=d17740e4104 class=n-a></a><td colspan=1 rowspan=1><a name=d17740e4106 class=n-a></a>rs28714259</td><td colspan=1 rowspan=1><a name=d17740e4109 class=n-a></a>Schneider <i>et al</i>.<sup><a href="#ref-135">135</a></sup></td></tr><tr><a name=d17740e4118 class=n-a></a><td align=center colspan=1 rowspan=11 valign=middle><a name=d17740e4119 class=n-a></a>Preclinical</td><td align=center colspan=1 rowspan=2 valign=middle><a name=d17740e4122 class=n-a></a>DNA</td><td colspan=1 rowspan=1><a name=d17740e4125 class=n-a></a>Doxorubcin DNA adducts</td><td colspan=1 rowspan=1><a name=d17740e4128 class=n-a></a>Hahm <i>et al</i>.<sup><a href="#ref-136">136</a></sup></td></tr><tr><a name=d17740e4137 class=n-a></a><td colspan=1 rowspan=1><a name=d17740e4139 class=n-a></a>Spp1, Fhl1, Timp1, Ccl7 and Reg3b</td><td colspan=1 rowspan=1><a name=d17740e4142 class=n-a></a>Mori <i>et al</i>.<sup><a href="#ref-137">137</a></sup></td></tr><tr><a name=d17740e4152 class=n-a></a><td align=center colspan=1 rowspan=3 valign=middle><a name=d17740e4154 class=n-a></a>MicroRNA</td><td colspan=1 rowspan=1><a name=d17740e4157 class=n-a></a>miR-34a</td><td colspan=1 rowspan=1><a name=d17740e4160 class=n-a></a>Desai <i>et al</i>.<sup><a href="#ref-138">138</a></sup></td></tr><tr><a name=d17740e4169 class=n-a></a><td colspan=1 rowspan=1><a name=d17740e4171 class=n-a></a>miR-34c</td><td colspan=1 rowspan=1><a name=d17740e4174 class=n-a></a>Vacchi-Suzzi <i>et al</i>.<sup><a href="#ref-139">139</a></sup></td></tr><tr><a name=d17740e4183 class=n-a></a><td colspan=1 rowspan=1><a name=d17740e4185 class=n-a></a>miR-146a</td><td colspan=1 rowspan=1><a name=d17740e4188 class=n-a></a>Horie <i>et al</i>.<sup><a href="#ref-140">140</a></sup></td></tr><tr><a name=d17740e4197 class=n-a></a><td align=center colspan=1 rowspan=3 valign=middle><a name=d17740e4199 class=n-a></a>Proteins</td><td colspan=1 rowspan=1><a name=d17740e4202 class=n-a></a>S100A1</td><td colspan=1 rowspan=1><a name=d17740e4205 class=n-a></a>Eryilmaz <i>et al</i>.<sup><a href="#ref-141">141</a></sup></td></tr><tr><a name=d17740e4214 class=n-a></a><td colspan=1 rowspan=1><a name=d17740e4216 class=n-a></a>cMLC1</td><td colspan=1 rowspan=1><a name=d17740e4219 class=n-a></a>ElZarrad <i>et al</i>.<sup><a href="#ref-142">142</a></sup></td></tr><tr><a name=d17740e4228 class=n-a></a><td colspan=1 rowspan=1><a name=d17740e4230 class=n-a></a>Cathepsin B</td><td colspan=1 rowspan=1><a name=d17740e4233 class=n-a></a>Bao <i>et al</i>.<sup><a href="#ref-143">143</a></sup></td></tr><tr><a name=d17740e4243 class=n-a></a><td align=center colspan=1 rowspan=1 valign=middle><a name=d17740e4245 class=n-a></a>Proteomics pattern diagnostics</td><td colspan=1 rowspan=1><a name=d17740e4248 class=n-a></a></td><td colspan=1 rowspan=1><a name=d17740e4250 class=n-a></a>Petricoin <i>et al</i>.<sup><a href="#ref-144">144</a></sup></td></tr><tr><a name=d17740e4259 class=n-a></a><td align=center colspan=1 rowspan=1 valign=middle><a name=d17740e4261 class=n-a></a>Metabolomics pattern diagnostics</td><td colspan=1 rowspan=1><a name=d17740e4264 class=n-a></a></td><td colspan=1 rowspan=1><a name=d17740e4266 class=n-a></a>Li <i>et al</i>.<sup><a href="#ref-145">145</a></sup></td></tr><tr><a name=d17740e4275 class=n-a></a><td align=center colspan=1 rowspan=1 valign=middle><a name=d17740e4277 class=n-a></a>Transcriptome profiling</td><td colspan=1 rowspan=1><a name=d17740e4280 class=n-a></a></td><td colspan=1 rowspan=1><a name=d17740e4282 class=n-a></a>Todorova <i>et al</i>.<sup><a href="#ref-146">146</a></sup></td></tr></tbody></table></div><p class="" id=d17740e4294>Troponin I<sup><a href="#ref-59">59</a>,<a href="#ref-116">116</a>,<a href="#ref-117">117</a></sup> and troponin T<sup><a href="#ref-118">118</a></sup> have been shown to be clinically useful in several clinical trials of cardiotoxicity prediction. Modern, more-sensitive assays of troponin I and T (high-sensitivity and ultra-sensitivity) have also been shown to be clinically predictive of CTIC<sup><a href="#ref-121">121</a>–<a href="#ref-123">123</a></sup>. Early studies have suggested that troponin I elevation predicted severity of CTIC<sup><a href="#ref-116">116</a>,<a href="#ref-117">117</a></sup>, and refractoriness to HF therapy in the case of trastuzumab-induced cardiomyopathy<sup><a href="#ref-117">117</a></sup>, but response to enalapril monotherapy in the case of AIC<sup><a href="#ref-59">59</a></sup>. However, in a recent large multicenter randomized clinical trial, these findings could not be corroborated<sup><a href="#ref-103">103</a></sup>. Interestingly, the presence of troponin-specific autoantibodies also predicted cardiac dysfunction by cardiac magnetic resonance (CMR) imaging in the absence of elevated traditional troponin levels<sup><a href="#ref-124">124</a></sup>. Myocardial natriuretic peptides, such as NTproBNP<sup><a href="#ref-119">119</a></sup>, BNP<sup><a href="#ref-147">147</a></sup>, and ANP<sup><a href="#ref-120">120</a></sup>, have also been shown to be clinically useful predictors of CTIC, albeit to a lesser extent.</p><p class="" id=d17740e4354>Although the use of these blood biomarkers is currently recommended in the evaluation and surveillance of patients with CTIC<sup><a href="#ref-5">5</a>,<a href="#ref-8">8</a></sup>, their helpfulness remains disputed owing to inconsistent results in terms of sensitivity, accuracy, and reliability<sup><a href="#ref-148">148</a></sup>. Hence, various other alternative blood biomarkers have been studied in recent years, either alone or in combination, and shown also to be clinically predictive of CTIC, e.g. hsCRP<sup><a href="#ref-126">126</a></sup>, MPO<sup><a href="#ref-123">123</a></sup>, and arginine-NO metabolites (arginine, citrulline, ornithine, asymmetric dimethylarginine, symmetric dimethylarginine, and N-monomethylarginine)<sup><a href="#ref-129">129</a></sup>, among others<sup><a href="#ref-125">125</a>,<a href="#ref-127">127</a>,<a href="#ref-128">128</a>,<a href="#ref-130">130</a>–<a href="#ref-132">132</a></sup>. Likewise, many other predictive biomarker strategies are currently being developed in the preclinical arena. Proteomics<sup><a href="#ref-144">144</a></sup> and metabolomics<sup><a href="#ref-145">145</a></sup> pattern diagnostics, as well as transcriptome profiling<sup><a href="#ref-146">146</a></sup>, have been shown to be useful in animal models of AIC as well as the detection of doxorubicin DNA adducts (HM-dUMP, 8-OH-dGMP, HM-dCMP, and Me-dCMP)<sup><a href="#ref-136">136</a></sup> and other particular genes that are overexpressed during incipient cardiotoxicity<sup><a href="#ref-137">137</a></sup>. Cellular proteins such as S100A1<sup><a href="#ref-141">141</a></sup>, cMLC1<sup><a href="#ref-142">142</a></sup>, and cathepsin B<sup><a href="#ref-143">143</a></sup> have also been shown to have predictive value. Some microRNAs (e.g. miR-34a<sup><a href="#ref-138">138</a></sup>, miR-34c<sup><a href="#ref-139">139</a></sup>, and miR-146a<sup><a href="#ref-140">140</a></sup>) have been shown to be useful in predicting CTIC in small animal models; however, a recent clinical trial involving miR-208a measurement in breast cancer patients failed to have a predictive impact<sup><a href="#ref-149">149</a></sup>.</p><p class="" id=d17740e4448>Finally, research efforts to identify the genetic susceptibility of AIC have been increasing in the last decade, with the purpose of risk stratifying patients before they receive anthracycline chemotherapy. To date, three main single-nucleotide polymorphisms (SNPs: rs28714259<sup><a href="#ref-135">135</a></sup>, rs1786814<sup><a href="#ref-134">134</a></sup>, and rs2229774<sup><a href="#ref-133">133</a></sup>) have been identified as being strongly associated with AIC by means of genome-wide association studies (GWAS) from pediatric and adult case-controlled clinical trial populations.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d17740e4466>Diagnostic modalities</h2><p class="" id=d17740e4469>Non-blood diagnostic modalities are also an integral part of the evaluation of CVDs. For the purpose of early diagnosis and surveillance of CTIC, several imaging modalities have been studied since the late 1970s and shown to be of value (see <a href="#T6">Table 6</a>). Historically, electrocardiography<sup><a href="#ref-150">150</a></sup> was used to diagnose arrhythmias during anthracycline infusion, and radionuclide cineangiography (MUGA)<sup><a href="#ref-151">151</a>,<a href="#ref-152">152</a></sup> was the first technique used to detect falls in LV systolic function in patients receiving anthracyclines<sup><a href="#ref-153">153</a></sup>. Although MUGA is still considered widely available and highly reproducible, it carries the main disadvantage of submitting cancer patients to small, but potentially significant, radiation exposure (5–10 mSv)<sup><a href="#ref-30">30</a>,<a href="#ref-43">43</a></sup>. Additionally, 2D-echocardiogram<sup><a href="#ref-154">154</a></sup> and stress 2D-echocardiogram<sup><a href="#ref-155">155</a></sup> have been shown to be beneficial in the serial evaluation of cancer patients undergoing cardiotoxic chemotherapies. Newer echocardiographic modalities, such as 3D-echocardiography<sup><a href="#ref-156">156</a></sup> and LV global longitudinal strain (LVGLS) measurement by speckle-tracking echocardiography (STE)<sup><a href="#ref-157">157</a></sup>, have demonstrated superiority over 2D-echocardiography in terms of reproducibility and predictability, respectively. CMR is currently considered the gold standard modality in the assessment of LV and right ventricular volumes and function<sup><a href="#ref-158">158</a></sup>. Secondary modalities such as CMR strain imaging<sup><a href="#ref-159">159</a></sup>, T1 mapping<sup><a href="#ref-160">160</a></sup>, and extracellular volume fraction (ECV)<sup><a href="#ref-161">161</a></sup> have also been clinically studied in recent years and found to be of great value in the assessment of subclinical cardiotoxicity. Among various non-imaging techniques, cardiopulmonary exercise testing was shown to detect abnormalities in peak oxygen consumption in cancer patients with apparently normal LV function<sup><a href="#ref-162">162</a></sup>, suggesting subclinical impairments of contractile reserve and chronotropic incompetence<sup><a href="#ref-28">28</a></sup>. Finally, many other imaging modalities are currently being studied in the preclinical arena to help detect incipient cardiotoxicity with high specificity and sensitivity. For example, 18F-labeled tetrapeptide caspase positron emission tomography (PET) is able to specifically diagnose doxorubicin-induced myocardial apoptosis in a murine model by detection of overexpressed myocardial caspase 3 resulting from anthracycline chemotherapy<sup><a href="#ref-163">163</a></sup>.</p><a name=T6 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 6. Diagnostic modalities in cancer therapeutics-induced cardiotoxicity.</h3><p id=d17740e4553>2D, two-dimensional; 3D, three-dimensional; 99m Tc, technetium-99; CMR, cardiac magnetic resonance; CPET, cardiopulmonary exercise testing; ECG, electrocardiogram; ECV, extracellular volume fraction; LVEF, left ventricular ejection fraction; LVGLS, left ventricular global longitudinal strain; MUGA, multigated acquisition; PET, positron emission tomography; RBC, red blood cells.</p></div><table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d17740e4557 class=n-a></a><thead><a name=d17740e4559 class=n-a></a><tr><a name=d17740e4561 class=n-a></a><th align=center colspan=3 rowspan=1><a name=d17740e4563 class=n-a></a>Diagnostic modalities in cancer therapeutics-induced cardiotoxicity</th></tr></thead><tbody><a name=d17740e4568 class=n-a></a><tr><a name=d17740e4570 class=n-a></a><td align=center colspan=1 rowspan=6 valign=middle><a name=d17740e4571 class=n-a></a>Established clinical</td><td colspan=1 rowspan=1><a name=d17740e4574 class=n-a></a>ECG</td><td colspan=1 rowspan=1><a name=d17740e4577 class=n-a></a>Steinberg <i>et al</i>.<sup><a href="#ref-150">150</a></sup></td></tr><tr><a name=d17740e4586 class=n-a></a><td colspan=1 rowspan=1><a name=d17740e4588 class=n-a></a>MUGA (99m Tc-labeled RBC)</td><td colspan=1 rowspan=1><a name=d17740e4591 class=n-a></a>Schwartz <i>et al</i>.<sup><a href="#ref-151">151</a></sup></td></tr><tr><a name=d17740e4600 class=n-a></a><td colspan=1 rowspan=1><a name=d17740e4602 class=n-a></a>Stress MUGA</td><td colspan=1 rowspan=1><a name=d17740e4605 class=n-a></a>McKillop <i>et al</i>.<sup><a href="#ref-152">152</a></sup></td></tr><tr><a name=d17740e4614 class=n-a></a><td colspan=1 rowspan=1><a name=d17740e4616 class=n-a></a>2D-echocardiography</td><td colspan=1 rowspan=1><a name=d17740e4619 class=n-a></a>Thavendiranathan <i>et al</i>.<sup><a href="#ref-154">154</a></sup></td></tr><tr><a name=d17740e4628 class=n-a></a><td colspan=1 rowspan=1><a name=d17740e4630 class=n-a></a>Stress 2D-echocardiography</td><td colspan=1 rowspan=1><a name=d17740e4633 class=n-a></a>Khouri <i>et al</i>.<sup><a href="#ref-155">155</a></sup></td></tr><tr><a name=d17740e4643 class=n-a></a><td colspan=1 rowspan=1><a name=d17740e4645 class=n-a></a>CPET</td><td colspan=1 rowspan=1><a name=d17740e4648 class=n-a></a>Jones <i>et al</i>.<sup><a href="#ref-162">162</a></sup></td></tr><tr><a name=d17740e4657 class=n-a></a><td align=center colspan=1 rowspan=6 valign=middle><a name=d17740e4658 class=n-a></a>Novel clinical</td><td colspan=1 rowspan=1><a name=d17740e4661 class=n-a></a>3D-echocardiography</td><td colspan=1 rowspan=1><a name=d17740e4664 class=n-a></a>Walker <i>et al</i>.<sup><a href="#ref-156">156</a></sup></td></tr><tr><a name=d17740e4673 class=n-a></a><td colspan=1 rowspan=1><a name=d17740e4675 class=n-a></a>Speckle-tracking echocardiography (LVGLS)</td><td colspan=1 rowspan=1><a name=d17740e4678 class=n-a></a>Negishi <i>et al</i>.<sup><a href="#ref-157">157</a></sup></td></tr><tr><a name=d17740e4687 class=n-a></a><td colspan=1 rowspan=1><a name=d17740e4689 class=n-a></a>CMR</td><td colspan=1 rowspan=1><a name=d17740e4692 class=n-a></a>Armstrong <i>et al</i>.<sup><a href="#ref-158">158</a></sup></td></tr><tr><a name=d17740e4701 class=n-a></a><td colspan=1 rowspan=1><a name=d17740e4703 class=n-a></a>CMR strain imaging</td><td colspan=1 rowspan=1><a name=d17740e4706 class=n-a></a>Drafts <i>et al</i>.<sup><a href="#ref-159">159</a></sup></td></tr><tr><a name=d17740e4715 class=n-a></a><td colspan=1 rowspan=1><a name=d17740e4717 class=n-a></a>CMR T1 mapping</td><td colspan=1 rowspan=1><a name=d17740e4720 class=n-a></a>Lightfoot <i>et al</i>.<sup><a href="#ref-160">160</a></sup></td></tr><tr><a name=d17740e4730 class=n-a></a><td colspan=1 rowspan=1><a name=d17740e4732 class=n-a></a>CMR ECV</td><td colspan=1 rowspan=1><a name=d17740e4735 class=n-a></a>Jordan <i>et al</i>.<sup><a href="#ref-161">161</a></sup></td></tr><tr><a name=d17740e4744 class=n-a></a><td align=center colspan=1 rowspan=1 valign=middle><a name=d17740e4746 class=n-a></a>Preclinical</td><td colspan=1 rowspan=1><a name=d17740e4749 class=n-a></a>PET (18F-labeled tetrapeptidic caspase)</td><td colspan=1 rowspan=1><a name=d17740e4752 class=n-a></a>Su <i>et al</i>.<sup><a href="#ref-163">163</a></sup></td></tr></tbody></table></div><p class="" id=d17740e4764>According to current guidelines, echocardiography (ideally 3D-echocardiography) is the method of choice for the evaluation of patients before, during, and after cancer therapies<sup><a href="#ref-43">43</a></sup>. CMR and MUGA scan (in that order) should be utilized as alternative modalities whenever the echocardiographic image quality is deficient<sup><a href="#ref-5">5</a></sup>. When available, measurement of LVGLS by STE is also recommended as a complementary modality<sup><a href="#ref-5">5</a></sup>. CMR should also be considered for the evaluation of chronic “constrictive” pericarditis, when the diagnosis remains uncertain after a careful echocardiographic evaluation<sup><a href="#ref-43">43</a></sup>.</p><p class="" id=d17740e4783>To date, there is little evidence to guide the indication, timing, and frequency of use of imaging modalities in patients undergoing cancer therapies. The ASCO expert consensus recommends an echocardiographic evaluation prior to the initiation of potentially cardiotoxic cancer therapies<sup><a href="#ref-5">5</a></sup>. Routine imaging surveillance in asymptomatic patients should be offered to patients based on the healthcare provider’s perceived risk of CTIC, and the frequency of it needs to be individualized based on clinical judgment and patient circumstances<sup><a href="#ref-5">5</a></sup>. Subsequent to cardiotoxic cancer therapies, it is recommended that high-risk patients undergo a follow up LVEF evaluation between 6 and 12 months after completion of therapy<sup><a href="#ref-5">5</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d17740e4801>Conclusions</h2><p class="" id=d17740e4804>In this work, we have attempted to comprehensively and concisely survey the most relevant available literature pertaining to cardioprotection during cancer therapy. We have briefly summarized the pathophysiology of CTIC, describing the mechanisms of cardiotoxicity of various agents, and risk factors that promote this phenomenon. For didactic purposes, we have classified CTIC into four progressive stages, in which four levels of prevention are applied, each having a specific goal, focus, and means of prevention. We have subsequently reviewed the available data on cardioprotective agents, blood biomarkers, and imaging diagnostic modalities, which are the core of primary and secondary prevention strategies. Finally, we have provided general evidence-based preventive recommendations for CTIC following the most current expert consensus guidelines. The promotion of the cardiovascular health of cancer patients and cancer survivors is paramount, requiring the diligent and knowledgeable effort of a multidisciplinary team of healthcare providers; as in all medical disorders, prevention is better than cure.</p></div><div id=article1-back class=generated-article-footer><div class=back-section><a name=d17740e1 class=n-a></a><h2 class=main-title id=d18273>Grant information</h2><p>W. H. Wilson Tang is supported by grants from the National Institutes of Health (R01HL103866, P20HL113452, R01DK106000, and R01HL126827).</p><p> <i>The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</i> </p></div><div class=back-section><a name=d17740e4811 class=n-a></a><span class="research-layout prime-recommended-wrapper reference-heading"><span class="f1r-icon icon-79_faculty_recommended_badge red vmiddle default-cursor"></span><span class="prime-red big">F1000 recommended</span></span><h2 class=main-title id=d18798>References</h2><div class="section ref-list"><a name=d17740e4811 class=n-a></a><ul><li><a name=ref-1 class=n-a></a><span class=label>1. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726399799"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d17740e4818 class=n-a></a>Miller KD, Siegel RL, Lin CC, <i> et al.</i>: Cancer treatment and survivorship statistics, 2016. <i>CA Cancer J Clin.</i> 2016; <b>66</b>(4): 271–89. <a target=xrefwindow id=d17740e4829 href="http://www.ncbi.nlm.nih.gov/pubmed/27253694">PubMed Abstract </a> | <a target=xrefwindow id=d17740e4832 href="http://dx.doi.org/10.3322/caac.21349">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726399799">F1000 Recommendation</a></span></li><li><a name=ref-2 class=n-a></a><span class=label>2. </span>&nbsp;<span class=citation><a name=d17740e4845 class=n-a></a>Patnaik JL, Byers T, DiGuiseppi C, <i> et al.</i>: Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: a retrospective cohort study. <i>Breast Cancer Res.</i> 2011; <b>13</b>(3): R64. <a target=xrefwindow id=d17740e4856 href="http://www.ncbi.nlm.nih.gov/pubmed/21689398">PubMed Abstract </a> | <a target=xrefwindow id=d17740e4859 href="http://dx.doi.org/10.1186/bcr2901">Publisher Full Text </a> | <a target=xrefwindow id=d17740e4863 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3218953">Free Full Text </a></span></li><li><a name=ref-3 class=n-a></a><span class=label>3. </span>&nbsp;<span class=citation><a name=d17740e4872 class=n-a></a>Tashakkor AY, Moghaddamjou A, Chen L, <i> et al.</i>: Predicting the risk of cardiovascular comorbidities in adult cancer survivors. <i>Curr Oncol.</i> 2013; <b>20</b>(5): e360–70. <a target=xrefwindow id=d17740e4883 href="http://www.ncbi.nlm.nih.gov/pubmed/24155634">PubMed Abstract </a> | <a target=xrefwindow id=d17740e4886 href="http://dx.doi.org/10.3747/co.20.1470">Publisher Full Text </a> | <a target=xrefwindow id=d17740e4890 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3805406">Free Full Text </a></span></li><li><a name=ref-4 class=n-a></a><span class=label>4. </span>&nbsp;<span class=citation><a name=d17740e4899 class=n-a></a>Oeffinger KC, Mertens AC, Sklar CA, <i> et al.</i>: Chronic health conditions in adult survivors of childhood cancer. <i>N Engl J Med.</i> 2006; <b>355</b>(15): 1572–82. <a target=xrefwindow id=d17740e4910 href="http://www.ncbi.nlm.nih.gov/pubmed/17035650">PubMed Abstract </a> | <a target=xrefwindow id=d17740e4913 href="http://dx.doi.org/10.1056/NEJMsa060185">Publisher Full Text </a></span></li><li><a name=ref-5 class=n-a></a><span class=label>5. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727072393"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d17740e4922 class=n-a></a>Armenian SH, Lacchetti C, Barac A, <i> et al.</i>: Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline. <i>J Clin Oncol.</i> 2017; <b>35</b>(8): 893–911. <a target=xrefwindow id=d17740e4933 href="http://www.ncbi.nlm.nih.gov/pubmed/27918725">PubMed Abstract </a> | <a target=xrefwindow id=d17740e4936 href="http://dx.doi.org/10.1200/JCO.2016.70.5400">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727072393">F1000 Recommendation</a></span></li><li><a name=ref-6 class=n-a></a><span class=label>6. </span>&nbsp;<span class=citation><a name=d17740e4950 class=n-a></a>Jaworski C, Mariani JA, Wheeler G, <i> et al.</i>: Cardiac complications of thoracic irradiation. <i>J Am Coll Cardiol.</i> 2013; <b>61</b>(23): 2319–28. <a target=xrefwindow id=d17740e4961 href="http://www.ncbi.nlm.nih.gov/pubmed/23583253">PubMed Abstract </a> | <a target=xrefwindow id=d17740e4964 href="http://dx.doi.org/10.1016/j.jacc.2013.01.090">Publisher Full Text </a></span></li><li><a name=ref-7 class=n-a></a><span class=label>7. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726500396"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d17740e4973 class=n-a></a>Page RL 2nd, O'Bryant CL, Cheng D, <i> et al.</i>: Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association. <i>Circulation.</i> 2016; <b>134</b>(6): e32–69. <a target=xrefwindow id=d17740e4984 href="http://www.ncbi.nlm.nih.gov/pubmed/27400984">PubMed Abstract </a> | <a target=xrefwindow id=d17740e4987 href="http://dx.doi.org/10.1161/CIR.0000000000000426">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726500396">F1000 Recommendation</a></span></li><li><a name=ref-8 class=n-a></a><span class=label>8. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726697846"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d17740e5000 class=n-a></a>Zamorano JL, Lancellotti P, Rodriguez Muñoz D, <i> et al.</i>: 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). <i>Eur Heart J.</i> 2016; <b>37</b>(36): 2768–801. <a target=xrefwindow id=d17740e5011 href="http://www.ncbi.nlm.nih.gov/pubmed/27567406">PubMed Abstract </a> | <a target=xrefwindow id=d17740e5014 href="http://dx.doi.org/10.1093/eurheartj/ehw211">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726697846">F1000 Recommendation</a></span></li><li><a name=ref-9 class=n-a></a><span class=label>9. </span>&nbsp;<span class=citation><a name=d17740e5027 class=n-a></a>Finet JE: Management of Heart Failure in Cancer Patients and Cancer Survivors. <i>Heart Fail Clin.</i> 2017; <b>13</b>(2): 253–88. <a target=xrefwindow id=d17740e5035 href="http://www.ncbi.nlm.nih.gov/pubmed/28279414">PubMed Abstract </a> | <a target=xrefwindow id=d17740e5038 href="http://dx.doi.org/10.1016/j.hfc.2016.12.004">Publisher Full Text </a></span></li><li><a name=ref-10 class=n-a></a><span class=label>10. </span>&nbsp;<span class=citation><a name=d17740e5047 class=n-a></a>Jones LW, Haykowsky MJ, Swartz JJ, <i> et al.</i>: Early breast cancer therapy and cardiovascular injury. <i>J Am Coll Cardiol.</i> 2007; <b>50</b>(15): 1435–41. <a target=xrefwindow id=d17740e5058 href="http://www.ncbi.nlm.nih.gov/pubmed/17919562">PubMed Abstract </a> | <a target=xrefwindow id=d17740e5061 href="http://dx.doi.org/10.1016/j.jacc.2007.06.037">Publisher Full Text </a></span></li><li><a name=ref-11 class=n-a></a><span class=label>11. </span>&nbsp;<span class=citation><a name=d17740e5070 class=n-a></a>Von Hoff DD, Layard MW, Basa P, <i> et al.</i>: Risk factors for doxorubicin-induced congestive heart failure. <i>Ann Intern Med.</i> 1979; <b>91</b>(5): 710–7. <a target=xrefwindow id=d17740e5081 href="http://www.ncbi.nlm.nih.gov/pubmed/496103">PubMed Abstract </a> | <a target=xrefwindow id=d17740e5084 href="http://dx.doi.org/10.7326/0003-4819-91-5-710">Publisher Full Text </a></span></li><li><a name=ref-12 class=n-a></a><span class=label>12. </span>&nbsp;<span class=citation><a name=d17740e5094 class=n-a></a>Dindogru A, Barcos M, Henderson ES, <i> et al.</i>: Electrocardiographic changes following adriamycin treatment. <i>Med Pediatr Oncol.</i> 1978; <b>5</b>(1): 65–71. <a target=xrefwindow id=d17740e5105 href="http://www.ncbi.nlm.nih.gov/pubmed/745592">PubMed Abstract </a> | <a target=xrefwindow id=d17740e5108 href="http://dx.doi.org/10.1002/mpo.2950050110">Publisher Full Text </a></span></li><li><a name=ref-13 class=n-a></a><span class=label>13. </span>&nbsp;<span class=citation><a name=d17740e5117 class=n-a></a>Steinherz LJ, Steinherz PG, Tan CT, <i> et al.</i>: Cardiac toxicity 4 to 20 years after completing anthracycline therapy. <i>JAMA.</i> 1991; <b>266</b>(12): 1672–7. <a target=xrefwindow id=d17740e5128 href="http://www.ncbi.nlm.nih.gov/pubmed/1886191">PubMed Abstract </a> | <a target=xrefwindow id=d17740e5131 href="http://dx.doi.org/10.1001/jama.1991.03470120074036">Publisher Full Text </a></span></li><li><a name=ref-14 class=n-a></a><span class=label>14. </span>&nbsp;<span class=citation><a name=d17740e5140 class=n-a></a>Temming P, Qureshi A, Hardt J, <i> et al.</i>: Prevalence and predictors of anthracycline cardiotoxicity in children treated for acute myeloid leukaemia: retrospective cohort study in a single centre in the United Kingdom. <i>Pediatr Blood Cancer.</i> 2011; <b>56</b>(4): 625–30. <a target=xrefwindow id=d17740e5151 href="http://www.ncbi.nlm.nih.gov/pubmed/21298750">PubMed Abstract </a> | <a target=xrefwindow id=d17740e5154 href="http://dx.doi.org/10.1002/pbc.22908">Publisher Full Text </a></span></li><li><a name=ref-15 class=n-a></a><span class=label>15. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732084389"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d17740e5163 class=n-a></a>Armenian SH, Mertens L, Slorach C, <i> et al.</i>: Prevalence of anthracycline-related cardiac dysfunction in long-term survivors of adult-onset lymphoma. <i>Cancer.</i> 2018; <b>124</b>(4): 850–7. <a target=xrefwindow id=d17740e5174 href="http://www.ncbi.nlm.nih.gov/pubmed/29112235">PubMed Abstract </a> | <a target=xrefwindow id=d17740e5177 href="http://dx.doi.org/10.1002/cncr.31110">Publisher Full Text </a> | <a target=xrefwindow id=d17740e5181 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5801059">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732084389">F1000 Recommendation</a></span></li><li><a name=ref-16 class=n-a></a><span class=label>16. </span>&nbsp;<span class=citation><a name=d17740e5194 class=n-a></a>Oliveira GH, Hardaway BW, Kucheryavaya AY, <i> et al.</i>: Characteristics and survival of patients with chemotherapy-induced cardiomyopathy undergoing heart transplantation. <i>J Heart Lung Transplant.</i> 2012; <b>31</b>(8): 805–10. <a target=xrefwindow id=d17740e5205 href="http://www.ncbi.nlm.nih.gov/pubmed/22551930">PubMed Abstract </a> | <a target=xrefwindow id=d17740e5208 href="http://dx.doi.org/10.1016/j.healun.2012.03.018">Publisher Full Text </a></span></li><li><a name=ref-17 class=n-a></a><span class=label>17. </span>&nbsp;<span class=citation><a name=d17740e5217 class=n-a></a>Wolters Kluwer Clinical Drug Information. Inc. (Lexi-Drugs). Wolters Kluwer Drug Information, Inc. Last accessed May 27th, 2018. <a target=xrefwindow id=d17740e5219 href="https://www.wolterskluwercdi.com/clinical-drug-information/">Reference Source</a></span></li><li><a name=ref-18 class=n-a></a><span class=label>18. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1033567"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d17740e5229 class=n-a></a>Kerkelä R, Grazette L, Yacobi R, <i> et al.</i>: Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. <i>Nat Med.</i> 2006; <b>12</b>(8): 908–16. <a target=xrefwindow id=d17740e5240 href="http://www.ncbi.nlm.nih.gov/pubmed/16862153">PubMed Abstract </a> | <a target=xrefwindow id=d17740e5243 href="http://dx.doi.org/10.1038/nm1446">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1033567">F1000 Recommendation</a></span></li><li><a name=ref-19 class=n-a></a><span class=label>19. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1119094"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d17740e5256 class=n-a></a>Chu TF, Rupnick MA, Kerkela R, <i> et al.</i>: Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. <i>Lancet.</i> 2007; <b>370</b>(9604): 2011–9. <a target=xrefwindow id=d17740e5267 href="http://www.ncbi.nlm.nih.gov/pubmed/18083403">PubMed Abstract </a> | <a target=xrefwindow id=d17740e5270 href="http://dx.doi.org/10.1016/S0140-6736(07)61865-0">Publisher Full Text </a> | <a target=xrefwindow id=d17740e5274 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2643085">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1119094">F1000 Recommendation</a></span></li><li><a name=ref-20 class=n-a></a><span class=label>20. </span>&nbsp;<span class=citation><a name=d17740e5287 class=n-a></a>Ewer MS, Vooletich MT, Durand JB, <i> et al.</i>: Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. <i>J Clin Oncol.</i> 2005; <b>23</b>(31): 7820–6. <a target=xrefwindow id=d17740e5298 href="http://www.ncbi.nlm.nih.gov/pubmed/16258084">PubMed Abstract </a> | <a target=xrefwindow id=d17740e5301 href="http://dx.doi.org/10.1200/JCO.2005.13.300">Publisher Full Text </a></span></li><li><a name=ref-21 class=n-a></a><span class=label>21. </span>&nbsp;<span class=citation><a name=d17740e5310 class=n-a></a>Lal H, Kolaja KL, Force T: Cancer genetics and the cardiotoxicity of the therapeutics. <i>J Am Coll Cardiol.</i> 2013; <b>61</b>(3): 267–74. <a target=xrefwindow id=d17740e5318 href="http://www.ncbi.nlm.nih.gov/pubmed/23328609">PubMed Abstract </a> | <a target=xrefwindow id=d17740e5321 href="http://dx.doi.org/10.1016/j.jacc.2012.05.066">Publisher Full Text </a></span></li><li><a name=ref-22 class=n-a></a><span class=label>22. </span>&nbsp;<span class=citation><a name=d17740e5330 class=n-a></a>Galper SL, Yu JB, Mauch PM, <i> et al.</i>: Clinically significant cardiac disease in patients with Hodgkin lymphoma treated with mediastinal irradiation. <i>Blood.</i> 2011; <b>117</b>(2): 412–8. <a target=xrefwindow id=d17740e5341 href="http://www.ncbi.nlm.nih.gov/pubmed/20858859">PubMed Abstract </a> | <a target=xrefwindow id=d17740e5344 href="http://dx.doi.org/10.1182/blood-2010-06-291328">Publisher Full Text </a></span></li><li><a name=ref-23 class=n-a></a><span class=label>23. </span>&nbsp;<span class=citation><a name=d17740e5353 class=n-a></a>Aleman BM, van den Belt-Dusebout AW, De Bruin ML, <i> et al.</i>: Late cardiotoxicity after treatment for Hodgkin lymphoma. <i>Blood.</i> 2007; <b>109</b>(5): 1878–86. <a target=xrefwindow id=d17740e5364 href="http://www.ncbi.nlm.nih.gov/pubmed/17119114">PubMed Abstract </a> | <a target=xrefwindow id=d17740e5367 href="http://dx.doi.org/10.1182/blood-2006-07-034405">Publisher Full Text </a></span></li><li><a name=ref-24 class=n-a></a><span class=label>24. </span>&nbsp;<span class=citation><a name=d17740e5377 class=n-a></a>Hooning MJ, Botma A, Aleman BM, <i> et al.</i>: Long-term risk of cardiovascular disease in 10-year survivors of breast cancer. <i>J Natl Cancer Inst.</i> 2007; <b>99</b>(5): 365–75. <a target=xrefwindow id=d17740e5388 href="http://www.ncbi.nlm.nih.gov/pubmed/17341728">PubMed Abstract </a> | <a target=xrefwindow id=d17740e5391 href="http://dx.doi.org/10.1093/jnci/djk064">Publisher Full Text </a></span></li><li><a name=ref-25 class=n-a></a><span class=label>25. </span>&nbsp;<span class=citation><a name=d17740e5400 class=n-a></a>Nilsson G, Holmberg L, Garmo H, <i> et al.</i>: Distribution of coronary artery stenosis after radiation for breast cancer. <i>J Clin Oncol.</i> 2012; <b>30</b>(4): 380–6. <a target=xrefwindow id=d17740e5411 href="http://www.ncbi.nlm.nih.gov/pubmed/22203772">PubMed Abstract </a> | <a target=xrefwindow id=d17740e5414 href="http://dx.doi.org/10.1200/JCO.2011.34.5900">Publisher Full Text </a></span></li><li><a name=ref-26 class=n-a></a><span class=label>26. </span>&nbsp;<span class=citation><a name=d17740e5423 class=n-a></a>Heidenreich PA, Hancock SL, Vagelos RH, <i> et al.</i>: Diastolic dysfunction after mediastinal irradiation. <i>Am Heart J.</i> 2005; <b>150</b>(5): 977–82. <a target=xrefwindow id=d17740e5434 href="http://www.ncbi.nlm.nih.gov/pubmed/16290974">PubMed Abstract </a> | <a target=xrefwindow id=d17740e5437 href="http://dx.doi.org/10.1016/j.ahj.2004.12.026">Publisher Full Text </a></span></li><li><a name=ref-27 class=n-a></a><span class=label>27. </span>&nbsp;<span class=citation><a name=d17740e5446 class=n-a></a>Armstrong GT, Joshi VM, Ness KK, <i> et al.</i>: Comprehensive Echocardiographic Detection of Treatment-Related Cardiac Dysfunction in Adult Survivors of Childhood Cancer: Results From the St. Jude Lifetime Cohort Study. <i>J Am Coll Cardiol.</i> 2015; <b>65</b>(23): 2511–22. <a target=xrefwindow id=d17740e5457 href="http://www.ncbi.nlm.nih.gov/pubmed/26065990">PubMed Abstract </a> | <a target=xrefwindow id=d17740e5460 href="http://dx.doi.org/10.1016/j.jacc.2015.04.013">Publisher Full Text </a> | <a target=xrefwindow id=d17740e5464 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4539123">Free Full Text </a></span></li><li><a name=ref-28 class=n-a></a><span class=label>28. </span>&nbsp;<span class=citation><a name=d17740e5473 class=n-a></a>Groarke JD, Tanguturi VK, Hainer J, <i> et al.</i>: Abnormal exercise response in long-term survivors of hodgkin lymphoma treated with thoracic irradiation: evidence of cardiac autonomic dysfunction and impact on outcomes. <i>J Am Coll Cardiol.</i> 2015; <b>65</b>(6): 573–83. <a target=xrefwindow id=d17740e5484 href="http://www.ncbi.nlm.nih.gov/pubmed/25677317">PubMed Abstract </a> | <a target=xrefwindow id=d17740e5487 href="http://dx.doi.org/10.1016/j.jacc.2014.11.035">Publisher Full Text </a></span></li><li><a name=ref-29 class=n-a></a><span class=label>29. </span>&nbsp;<span class=citation><a name=d17740e5496 class=n-a></a>Heidenreich PA, Hancock SL, Lee BK, <i> et al.</i>: Asymptomatic cardiac disease following mediastinal irradiation. <i>J Am Coll Cardiol.</i> 2003; <b>42</b>(4): 743–9. <a target=xrefwindow id=d17740e5507 href="http://www.ncbi.nlm.nih.gov/pubmed/12932613">PubMed Abstract </a> | <a target=xrefwindow id=d17740e5510 href="http://dx.doi.org/10.1016/S0735-1097(03)00759-9">Publisher Full Text </a></span></li><li><a name=ref-30 class=n-a></a><span class=label>30. </span>&nbsp;<span class=citation><a name=d17740e5520 class=n-a></a>Lancellotti P, Nkomo VT, Badano LP, <i> et al.</i>: Expert consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults: a report from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. <i>Eur Heart J Cardiovasc Imaging.</i> 2013; <b>14</b>(8): 721–40. <a target=xrefwindow id=d17740e5531 href="http://www.ncbi.nlm.nih.gov/pubmed/23847385">PubMed Abstract </a> | <a target=xrefwindow id=d17740e5534 href="http://dx.doi.org/10.1093/ehjci/jet123">Publisher Full Text </a></span></li><li><a name=ref-31 class=n-a></a><span class=label>31. </span>&nbsp;<span class=citation><a name=d17740e5543 class=n-a></a>WRITING COMMITTEE MEMBERS, Yancy CW, Jessup M, <i> et al.</i>: 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. <i>Circulation.</i> 2013; <b>128</b>(16): e240–327. <a target=xrefwindow id=d17740e5554 href="http://www.ncbi.nlm.nih.gov/pubmed/23741058">PubMed Abstract </a> | <a target=xrefwindow id=d17740e5557 href="http://dx.doi.org/10.1161/CIR.0b013e31829e8776">Publisher Full Text </a></span></li><li><a name=ref-32 class=n-a></a><span class=label>32. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732656071"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d17740e5566 class=n-a></a>Mehta LS, Watson KE, Barac A, <i> et al.</i>: Cardiovascular Disease and Breast Cancer: Where These Entities Intersect: A Scientific Statement From the American Heart Association. <i>Circulation.</i> 2018; <b>137</b>(8): e30–e66. <a target=xrefwindow id=d17740e5577 href="http://www.ncbi.nlm.nih.gov/pubmed/29437116">PubMed Abstract </a> | <a target=xrefwindow id=d17740e5580 href="http://dx.doi.org/10.1161/CIR.0000000000000556">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732656071">F1000 Recommendation</a></span></li><li><a name=ref-33 class=n-a></a><span class=label>33. </span>&nbsp;<span class=citation><a name=d17740e5593 class=n-a></a>Benjamin EJ, Virani SS, Callaway CW, <i> et al.</i>: Heart Disease and Stroke Statistics-2018 Update: A Report From the American Heart Association. <i>Circulation.</i> 2018; <b>137</b>(12): e67–e492. <a target=xrefwindow id=d17740e5604 href="http://www.ncbi.nlm.nih.gov/pubmed/29386200">PubMed Abstract </a> | <a target=xrefwindow id=d17740e5607 href="http://dx.doi.org/10.1161/CIR.0000000000000558">Publisher Full Text </a></span></li><li><a name=ref-34 class=n-a></a><span class=label>34. </span>&nbsp;<span class=citation><a name=d17740e5616 class=n-a></a>Yancy CW, Jessup M, Bozkurt B, <i> et al.</i>: 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. <i>J Am Coll Cardiol.</i> 2017; <b>70</b>(6): 776–803. <a target=xrefwindow id=d17740e5627 href="http://www.ncbi.nlm.nih.gov/pubmed/28461007">PubMed Abstract </a> | <a target=xrefwindow id=d17740e5630 href="http://dx.doi.org/10.1016/j.jacc.2017.04.025">Publisher Full Text </a></span></li><li><a name=ref-35 class=n-a></a><span class=label>35. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726145773"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d17740e5639 class=n-a></a>Nishimura RA, Otto CM, Bonow RO, <i> et al.</i>: 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>J Am Coll Cardiol.</i> 2014; <b>63</b>(22): e57–185. <a target=xrefwindow id=d17740e5650 href="http://www.ncbi.nlm.nih.gov/pubmed/24603191">PubMed Abstract </a> | <a target=xrefwindow id=d17740e5653 href="http://dx.doi.org/10.1016/j.jacc.2014.02.536">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726145773">F1000 Recommendation</a></span></li><li><a name=ref-36 class=n-a></a><span class=label>36. </span>&nbsp;<span class=citation><a name=d17740e5667 class=n-a></a>Zipes DP, Camm AJ, Borggrefe M, <i> et al.</i>: ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (writing committee to develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. <i>Circulation.</i> 2006; <b>114</b>(10): e385–484. <a target=xrefwindow id=d17740e5678 href="http://www.ncbi.nlm.nih.gov/pubmed/16935995">PubMed Abstract </a> | <a target=xrefwindow id=d17740e5681 href="http://dx.doi.org/10.1161/CIRCULATIONAHA.106.178233">Publisher Full Text </a></span></li><li><a name=ref-37 class=n-a></a><span class=label>37. </span>&nbsp;<span class=citation><a name=d17740e5690 class=n-a></a>Lenihan DJ, Hartlage G, DeCara J, <i> et al.</i>: Cardio-Oncology Training: A Proposal From the International Cardioncology Society and Canadian Cardiac Oncology Network for a New Multidisciplinary Specialty. <i>J Card Fail.</i> 2016; <b>22</b>(6): 465–71. <a target=xrefwindow id=d17740e5701 href="http://www.ncbi.nlm.nih.gov/pubmed/27038642">PubMed Abstract </a> | <a target=xrefwindow id=d17740e5704 href="http://dx.doi.org/10.1016/j.cardfail.2016.03.012">Publisher Full Text </a></span></li><li><a name=ref-38 class=n-a></a><span class=label>38. </span>&nbsp;<span class=citation><a name=d17740e5713 class=n-a></a>Cardinale D, Colombo A, Bacchiani G, <i> et al.</i>: Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. <i>Circulation.</i> 2015; <b>131</b>(22): 1981–8. <a target=xrefwindow id=d17740e5724 href="http://www.ncbi.nlm.nih.gov/pubmed/25948538">PubMed Abstract </a> | <a target=xrefwindow id=d17740e5727 href="http://dx.doi.org/10.1161/CIRCULATIONAHA.114.013777">Publisher Full Text </a></span></li><li><a name=ref-39 class=n-a></a><span class=label>39. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726473736"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d17740e5736 class=n-a></a>Virani SA, Dent S, Brezden-Masley C, <i> et al.</i>: Canadian Cardiovascular Society Guidelines for Evaluation and Management of Cardiovascular Complications of Cancer Therapy. <i>Can J Cardiol.</i> 2016; <b>32</b>(7): 831–41. <a target=xrefwindow id=d17740e5747 href="http://www.ncbi.nlm.nih.gov/pubmed/27343741">PubMed Abstract </a> | <a target=xrefwindow id=d17740e5750 href="http://dx.doi.org/10.1016/j.cjca.2016.02.078">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726473736">F1000 Recommendation</a></span></li><li><a name=ref-40 class=n-a></a><span class=label>40. </span>&nbsp;<span class=citation><a name=d17740e5763 class=n-a></a>Curigliano G, Cardinale D, Suter T, <i> et al.</i>: Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. <i>Ann Oncol.</i> 2012; <b>23 Suppl 7</b>: vii155–66. <a target=xrefwindow id=d17740e5774 href="http://www.ncbi.nlm.nih.gov/pubmed/22997448">PubMed Abstract </a> | <a target=xrefwindow id=d17740e5777 href="http://dx.doi.org/10.1093/annonc/mds293">Publisher Full Text </a></span></li><li><a name=ref-41 class=n-a></a><span class=label>41. </span>&nbsp;<span class=citation><a name=d17740e5786 class=n-a></a>Fuster V, Rydén LE, Cannom DS, <i> et al.</i>: 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. <i>Circulation.</i> 2011; <b>123</b>(10): e269–367. <a target=xrefwindow id=d17740e5797 href="http://www.ncbi.nlm.nih.gov/pubmed/21382897">PubMed Abstract </a> | <a target=xrefwindow id=d17740e5800 href="http://dx.doi.org/10.1161/CIR.0b013e318214876d">Publisher Full Text </a></span></li><li><a name=ref-42 class=n-a></a><span class=label>42. </span>&nbsp;<span class=citation><a name=d17740e5810 class=n-a></a>Adler Y, Charron P, Imazio M, <i> et al.</i>: 2015 ESC Guidelines for the diagnosis and management of pericardial diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC)Endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS). <i>Eur Heart J.</i> 2015; <b>36</b>(42): 2921–64. <a target=xrefwindow id=d17740e5821 href="http://www.ncbi.nlm.nih.gov/pubmed/26320112">PubMed Abstract </a> | <a target=xrefwindow id=d17740e5824 href="http://dx.doi.org/10.1093/eurheartj/ehv318">Publisher Full Text </a></span></li><li><a name=ref-43 class=n-a></a><span class=label>43. </span>&nbsp;<span class=citation><a name=d17740e5833 class=n-a></a>Plana JC, Galderisi M, Barac A, <i> et al.</i>: Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. <i>J Am Soc Echocardiogr.</i> 2014; <b>27</b>(9): 911–39. <a target=xrefwindow id=d17740e5844 href="http://www.ncbi.nlm.nih.gov/pubmed/25172399">PubMed Abstract </a> | <a target=xrefwindow id=d17740e5847 href="http://dx.doi.org/10.1016/j.echo.2014.07.012">Publisher Full Text </a></span></li><li><a name=ref-44 class=n-a></a><span class=label>44. </span>&nbsp;<span class=citation><a name=d17740e5856 class=n-a></a>FDA Statement on Dexrazoxane (07-09-2011). <a target=xrefwindow id=d17740e5858 href="http://www.fda.gov/drugs/drugsafety/ucm263729.htm">Reference Source</a></span></li><li><a name=ref-45 class=n-a></a><span class=label>45. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725957560"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d17740e5867 class=n-a></a>Shaikh F, Dupuis LL, Alexander S, <i> et al.</i>: Cardioprotection and Second Malignant Neoplasms Associated With Dexrazoxane in Children Receiving Anthracycline Chemotherapy: A Systematic Review and Meta-Analysis. <i>J Natl Cancer Inst.</i> 2015; <b>108</b>(4): pii: djv357. <a target=xrefwindow id=d17740e5878 href="http://www.ncbi.nlm.nih.gov/pubmed/26598513">PubMed Abstract </a> | <a target=xrefwindow id=d17740e5881 href="http://dx.doi.org/10.1093/jnci/djv357">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725957560">F1000 Recommendation</a></span></li><li><a name=ref-46 class=n-a></a><span class=label>46. </span>&nbsp;<span class=citation><a name=d17740e5894 class=n-a></a>Venturini M, Michelotti A, Del Mastro L, <i> et al.</i>: Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer. <i>J Clin Oncol.</i> 1996; <b>14</b>(12): 3112–20. <a target=xrefwindow id=d17740e5905 href="http://www.ncbi.nlm.nih.gov/pubmed/8955656">PubMed Abstract </a> | <a target=xrefwindow id=d17740e5908 href="http://dx.doi.org/10.1200/JCO.1996.14.12.3112">Publisher Full Text </a></span></li><li><a name=ref-47 class=n-a></a><span class=label>47. </span>&nbsp;<span class=citation><a name=d17740e5917 class=n-a></a>Marty M, Espié M, Llombart A, <i> et al.</i>: Multicenter randomized phase III study of the cardioprotective effect of dexrazoxane (Cardioxane) in advanced/metastatic breast cancer patients treated with anthracycline-based chemotherapy. <i>Ann Oncol.</i> 2006; <b>17</b>(4): 614–22. <a target=xrefwindow id=d17740e5928 href="http://www.ncbi.nlm.nih.gov/pubmed/16423847">PubMed Abstract </a> | <a target=xrefwindow id=d17740e5931 href="http://dx.doi.org/10.1093/annonc/mdj134">Publisher Full Text </a></span></li><li><a name=ref-48 class=n-a></a><span class=label>48. </span>&nbsp;<span class=citation><a name=d17740e5941 class=n-a></a>Choi HS, Park ES, Kang HJ, <i> et al.</i>: Dexrazoxane for preventing anthracycline cardiotoxicity in children with solid tumors. <i>J Korean Med Sci.</i> 2010; <b>25</b>(9): 1336–42. <a target=xrefwindow id=d17740e5952 href="http://www.ncbi.nlm.nih.gov/pubmed/20808678">PubMed Abstract </a> | <a target=xrefwindow id=d17740e5955 href="http://dx.doi.org/10.3346/jkms.2010.25.9.1336">Publisher Full Text </a> | <a target=xrefwindow id=d17740e5959 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2923785">Free Full Text </a></span></li><li><a name=ref-49 class=n-a></a><span class=label>49. </span>&nbsp;<span class=citation><a name=d17740e5968 class=n-a></a>Lipshultz SE, Rifai N, Dalton VM, <i> et al.</i>: The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. <i>N Engl J Med.</i> 2004; <b>351</b>(2): 145–53. <a target=xrefwindow id=d17740e5979 href="http://www.ncbi.nlm.nih.gov/pubmed/15247354">PubMed Abstract </a> | <a target=xrefwindow id=d17740e5982 href="http://dx.doi.org/10.1056/NEJMoa035153">Publisher Full Text </a></span></li><li><a name=ref-50 class=n-a></a><span class=label>50. </span>&nbsp;<span class=citation><a name=d17740e5991 class=n-a></a>Swain SM, Whaley FS, Gerber MC, <i> et al.</i>: Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy. <i>J Clin Oncol.</i> 1997; <b>15</b>(4): 1333–40. <a target=xrefwindow id=d17740e6002 href="http://www.ncbi.nlm.nih.gov/pubmed/9193324">PubMed Abstract </a> | <a target=xrefwindow id=d17740e6005 href="http://dx.doi.org/10.1200/JCO.1997.15.4.1333">Publisher Full Text </a></span></li><li><a name=ref-51 class=n-a></a><span class=label>51. </span>&nbsp;<span class=citation><a name=d17740e6014 class=n-a></a>Hensley ML, Hagerty KL, Kewalramani T, <i> et al.</i>: American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. <i>J Clin Oncol.</i> 2009; <b>27</b>(1): 127–45. <a target=xrefwindow id=d17740e6025 href="http://www.ncbi.nlm.nih.gov/pubmed/19018081">PubMed Abstract </a> | <a target=xrefwindow id=d17740e6028 href="http://dx.doi.org/10.1200/JCO.2008.17.2627">Publisher Full Text </a></span></li><li><a name=ref-52 class=n-a></a><span class=label>52. </span>&nbsp;<span class=citation><a name=d17740e6037 class=n-a></a>FDA Drug Safety: Zinecard. 2012. <a target=xrefwindow id=d17740e6039 href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020212s013lbl.pdf">Reference Source</a></span></li><li><a name=ref-53 class=n-a></a><span class=label>53. </span>&nbsp;<span class=citation><a name=d17740e6048 class=n-a></a>Swain SM, Whaley FS, Gerber MC, <i> et al.</i>: Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. <i>J Clin Oncol.</i> 1997; <b>15</b>(4): 1318–32. <a target=xrefwindow id=d17740e6059 href="http://www.ncbi.nlm.nih.gov/pubmed/9193323">PubMed Abstract </a> | <a target=xrefwindow id=d17740e6062 href="http://dx.doi.org/10.1200/JCO.1997.15.4.1318">Publisher Full Text </a></span></li><li><a name=ref-54 class=n-a></a><span class=label>54. </span>&nbsp;<span class=citation><a name=d17740e6072 class=n-a></a>Myers C, Bonow R, Palmeri S, <i> et al.</i>: A randomized controlled trial assessing the prevention of doxorubicin cardiomyopathy by N-acetylcysteine. <i>Semin Oncol.</i> 1983; <b>10</b>(1 Suppl 1): 53–5. <a target=xrefwindow id=d17740e6083 href="http://www.ncbi.nlm.nih.gov/pubmed/6340204">PubMed Abstract </a></span></li><li><a name=ref-55 class=n-a></a><span class=label>55. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732850386"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d17740e6092 class=n-a></a>Avila MS, Ayub-Ferreira SM, de Barros Wanderley MR Jr, <i> et al.</i>: Carvedilol for Prevention of Chemotherapy-Related Cardiotoxicity: The CECCY Trial. <i>J Am Coll Cardiol.</i> 2018; <b>71</b>(20): 2281–90. <a target=xrefwindow id=d17740e6103 href="http://www.ncbi.nlm.nih.gov/pubmed/29540327">PubMed Abstract </a> | <a target=xrefwindow id=d17740e6106 href="http://dx.doi.org/10.1016/j.jacc.2018.02.049">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732850386">F1000 Recommendation</a></span></li><li><a name=ref-56 class=n-a></a><span class=label>56. </span>&nbsp;<span class=citation><a name=d17740e6119 class=n-a></a>Kaya MG, Ozkan M, Gunebakmaz O, <i> et al.</i>: Protective effects of nebivolol against anthracycline-induced cardiomyopathy: a randomized control study. <i>Int J Cardiol.</i> 2013; <b>167</b>(5): 2306–10. <a target=xrefwindow id=d17740e6130 href="http://www.ncbi.nlm.nih.gov/pubmed/22727976">PubMed Abstract </a> | <a target=xrefwindow id=d17740e6133 href="http://dx.doi.org/10.1016/j.ijcard.2012.06.023">Publisher Full Text </a></span></li><li><a name=ref-57 class=n-a></a><span class=label>57. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727038048"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d17740e6142 class=n-a></a>Pituskin E, Mackey JR, Koshman S, <i> et al.</i>: Multidisciplinary Approach to Novel Therapies in Cardio-Oncology Research (MANTICORE 101-Breast): A Randomized Trial for the Prevention of Trastuzumab-Associated Cardiotoxicity. <i>J Clin Oncol.</i> 2017; <b>35</b>(8): 870–7. <a target=xrefwindow id=d17740e6153 href="http://www.ncbi.nlm.nih.gov/pubmed/27893331">PubMed Abstract </a> | <a target=xrefwindow id=d17740e6156 href="http://dx.doi.org/10.1200/JCO.2016.68.7830">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727038048">F1000 Recommendation</a></span></li><li><a name=ref-58 class=n-a></a><span class=label>58. </span>&nbsp;<span class=citation><a name=d17740e6169 class=n-a></a>Georgakopoulos P, Roussou P, Matsakas E, <i> et al.</i>: Cardioprotective effect of metoprolol and enalapril in doxorubicin-treated lymphoma patients: a prospective, parallel-group, randomized, controlled study with 36-month follow-up. <i>Am J Hematol.</i> 2010; <b>85</b>(11): 894–6. <a target=xrefwindow id=d17740e6180 href="http://www.ncbi.nlm.nih.gov/pubmed/20872550">PubMed Abstract </a> | <a target=xrefwindow id=d17740e6183 href="http://dx.doi.org/10.1002/ajh.21840">Publisher Full Text </a></span></li><li><a name=ref-59 class=n-a></a><span class=label>59. </span>&nbsp;<span class=citation><a name=d17740e6192 class=n-a></a>Cardinale D, Colombo A, Sandri MT, <i> et al.</i>: Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. <i>Circulation.</i> 2006; <b>114</b>(23): 2474–81. <a target=xrefwindow id=d17740e6203 href="http://www.ncbi.nlm.nih.gov/pubmed/17101852">PubMed Abstract </a></span></li><li><a name=ref-60 class=n-a></a><span class=label>60. </span>&nbsp;<span class=citation><a name=d17740e6213 class=n-a></a>Jensen BV, Nielsen SL, Skovsgaard T: Treatment with angiotensin-converting-enzyme inhibitor for epirubicin-induced dilated cardiomyopathy. <i>Lancet.</i> 1996; <b>347</b>(8997): 297–9. <a target=xrefwindow id=d17740e6221 href="http://www.ncbi.nlm.nih.gov/pubmed/8569365">PubMed Abstract </a> | <a target=xrefwindow id=d17740e6224 href="http://dx.doi.org/10.1016/S0140-6736(96)90469-9">Publisher Full Text </a></span></li><li><a name=ref-61 class=n-a></a><span class=label>61. </span>&nbsp;<span class=citation><a name=d17740e6233 class=n-a></a>Nakamae H, Tsumura K, Terada Y, <i> et al.</i>: Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone. <i>Cancer.</i> 2005; <b>104</b>(11): 2492–8. <a target=xrefwindow id=d17740e6244 href="http://www.ncbi.nlm.nih.gov/pubmed/16247790">PubMed Abstract </a> | <a target=xrefwindow id=d17740e6247 href="http://dx.doi.org/10.1002/cncr.21478">Publisher Full Text </a></span></li><li><a name=ref-62 class=n-a></a><span class=label>62. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726165826"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d17740e6256 class=n-a></a>Gulati G, Heck SL, Ree AH, <i> et al.</i>: Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. <i>Eur Heart J.</i> 2016; <b>37</b>(21): 1671–80. <a target=xrefwindow id=d17740e6267 href="http://www.ncbi.nlm.nih.gov/pubmed/26903532">PubMed Abstract </a> | <a target=xrefwindow id=d17740e6270 href="http://dx.doi.org/10.1093/eurheartj/ehw022">Publisher Full Text </a> | <a target=xrefwindow id=d17740e6274 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4887703">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726165826">F1000 Recommendation</a></span></li><li><a name=ref-63 class=n-a></a><span class=label>63. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725242991"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d17740e6287 class=n-a></a>Akpek M, Ozdogru I, Sahin O, <i> et al.</i>: Protective effects of spironolactone against anthracycline-induced cardiomyopathy. <i>Eur J Heart Fail.</i> 2015; <b>17</b>(1): 81–9. <a target=xrefwindow id=d17740e6298 href="http://www.ncbi.nlm.nih.gov/pubmed/25410653">PubMed Abstract </a> | <a target=xrefwindow id=d17740e6301 href="http://dx.doi.org/10.1002/ejhf.196">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725242991">F1000 Recommendation</a></span></li><li><a name=ref-64 class=n-a></a><span class=label>64. </span>&nbsp;<span class=citation><a name=d17740e6314 class=n-a></a>Acar Z, Kale A, Turgut M, <i> et al.</i>: Efficiency of atorvastatin in the protection of anthracycline-induced cardiomyopathy. <i>J Am Coll Cardiol.</i> 2011; <b>58</b>(9): 988–9. <a target=xrefwindow id=d17740e6325 href="http://www.ncbi.nlm.nih.gov/pubmed/21851890">PubMed Abstract </a> | <a target=xrefwindow id=d17740e6328 href="http://dx.doi.org/10.1016/j.jacc.2011.05.025">Publisher Full Text </a></span></li><li><a name=ref-65 class=n-a></a><span class=label>65. </span>&nbsp;<span class=citation><a name=d17740e6337 class=n-a></a>Lissoni P, Barni S, Mandalà M, <i> et al.</i>: Decreased toxicity and increased efficacy of cancer chemotherapy using the pineal hormone melatonin in metastatic solid tumour patients with poor clinical status. <i>Eur J Cancer.</i> 1999; <b>35</b>(12): 1688–92. <a target=xrefwindow id=d17740e6348 href="http://www.ncbi.nlm.nih.gov/pubmed/10674014">PubMed Abstract </a> | <a target=xrefwindow id=d17740e6351 href="http://dx.doi.org/10.1016/S0959-8049(99)00159-8">Publisher Full Text </a></span></li><li><a name=ref-66 class=n-a></a><span class=label>66. </span>&nbsp;<span class=citation><a name=d17740e6361 class=n-a></a>Iarussi D, Auricchio U, Agretto A, <i> et al.</i>: Protective effect of coenzyme Q<sub>10</sub> on anthracyclines cardiotoxicity: Control study in children with acute lymphoblastic leukemia and non-Hodgkin lymphoma. <i>Mol Aspects Med.</i> 1994; <b>15 Suppl</b>: s207–12. <a target=xrefwindow id=d17740e6375 href="http://www.ncbi.nlm.nih.gov/pubmed/7752832">PubMed Abstract </a> | <a target=xrefwindow id=d17740e6379 href="http://dx.doi.org/10.1016/0098-2997(94)90030-2">Publisher Full Text </a></span></li><li><a name=ref-67 class=n-a></a><span class=label>67. </span>&nbsp;<span class=citation><a name=d17740e6388 class=n-a></a>Wagdi P, Rouvinez G, Fluri M, <i> et al.</i>: Kardioprotektion bei Chemo- und Radiotherapie für maligne Erkrankungen--eine echokardiographische Pilotstudie. <i>Praxis (Bern 1994).</i> 1995; <b>84</b>: 1220–3.</span></li><li><a name=ref-68 class=n-a></a><span class=label>68. </span>&nbsp;<span class=citation><a name=d17740e6406 class=n-a></a>Waldner R, Laschan C, Lohninger A, <i> et al.</i>: Effects of doxorubicin-containing chemotherapy and a combination with L-carnitine on oxidative metabolism in patients with non-Hodgkin lymphoma. <i>J Cancer Res Clin Oncol.</i> 2006; <b>132</b>(2): 121–8. <a target=xrefwindow id=d17740e6417 href="http://www.ncbi.nlm.nih.gov/pubmed/16283381">PubMed Abstract </a> | <a target=xrefwindow id=d17740e6420 href="http://dx.doi.org/10.1007/s00432-005-0054-8">Publisher Full Text </a></span></li><li><a name=ref-69 class=n-a></a><span class=label>69. </span>&nbsp;<span class=citation><a name=d17740e6429 class=n-a></a>Tokudome T, Mizushige K, Noma T, <i> et al.</i>: Prevention of doxorubicin (adriamycin)-induced cardiomyopathy by simultaneous administration of angiotensin-converting enzyme inhibitor assessed by acoustic densitometry. <i>J Cardiovasc Pharmacol.</i> 2000; <b>36</b>(3): 361–8. <a target=xrefwindow id=d17740e6440 href="http://www.ncbi.nlm.nih.gov/pubmed/10975594">PubMed Abstract </a> | <a target=xrefwindow id=d17740e6443 href="http://dx.doi.org/10.1097/00005344-200009000-00012">Publisher Full Text </a></span></li><li><a name=ref-70 class=n-a></a><span class=label>70. </span>&nbsp;<span class=citation><a name=d17740e6452 class=n-a></a>Maeda A, Honda M, Kuramochi T, <i> et al.</i>: An angiotensin-converting enzyme inhibitor protects against doxorubicin-induced impairment of calcium handling in neonatal rat cardiac myocytes. <i>Clin Exp Pharmacol Physiol.</i> 1997; <b>24</b>(9–10): 720–6. <a target=xrefwindow id=d17740e6463 href="http://www.ncbi.nlm.nih.gov/pubmed/9315376">PubMed Abstract </a> | <a target=xrefwindow id=d17740e6466 href="http://dx.doi.org/10.1111/j.1440-1681.1997.tb02119.x">Publisher Full Text </a></span></li><li><a name=ref-71 class=n-a></a><span class=label>71. </span>&nbsp;<span class=citation><a name=d17740e6475 class=n-a></a>Sacco G, Bigioni M, Evangelista S, <i> et al.</i>: Cardioprotective effects of zofenopril, a new angiotensin-converting enzyme inhibitor, on doxorubicin-induced cardiotoxicity in the rat. <i>Eur J Pharmacol.</i> 2001; <b>414</b>(1): 71–8. <a target=xrefwindow id=d17740e6486 href="http://www.ncbi.nlm.nih.gov/pubmed/11230997">PubMed Abstract </a> | <a target=xrefwindow id=d17740e6489 href="http://dx.doi.org/10.1016/S0014-2999(01)00782-8">Publisher Full Text </a></span></li><li><a name=ref-72 class=n-a></a><span class=label>72. </span>&nbsp;<span class=citation><a name=d17740e6499 class=n-a></a>Matouk AI, Taye A, Heeba GH, <i> et al.</i>: Quercetin augments the protective effect of losartan against chronic doxorubicin cardiotoxicity in rats. <i>Environ Toxicol Pharmacol.</i> 2013; <b>36</b>(2): 443–50. <a target=xrefwindow id=d17740e6510 href="http://www.ncbi.nlm.nih.gov/pubmed/23770454">PubMed Abstract </a> | <a target=xrefwindow id=d17740e6513 href="http://dx.doi.org/10.1016/j.etap.2013.05.006">Publisher Full Text </a></span></li><li><a name=ref-73 class=n-a></a><span class=label>73. </span>&nbsp;<span class=citation><a name=d17740e6522 class=n-a></a>Riad A, Bien S, Westermann D, <i> et al.</i>: Pretreatment with statin attenuates the cardiotoxicity of Doxorubicin in mice. <i>Cancer Res.</i> 2009; <b>69</b>(2): 695–9. <a target=xrefwindow id=d17740e6533 href="http://www.ncbi.nlm.nih.gov/pubmed/19147586">PubMed Abstract </a> | <a target=xrefwindow id=d17740e6536 href="http://dx.doi.org/10.1158/0008-5472.CAN-08-3076">Publisher Full Text </a></span></li><li><a name=ref-74 class=n-a></a><span class=label>74. </span>&nbsp;<span class=citation><a name=d17740e6545 class=n-a></a>Kobashigawa LC, Xu YC, Padbury JF, <i> et al.</i>: Metformin protects cardiomyocyte from doxorubicin induced cytotoxicity through an AMP-activated protein kinase dependent signaling pathway: an <i>in vitro</i> study. <i>PLoS One.</i> 2014; <b>9</b>(8): e104888. <a target=xrefwindow id=d17740e6559 href="http://www.ncbi.nlm.nih.gov/pubmed/25127116">PubMed Abstract </a> | <a target=xrefwindow id=d17740e6563 href="http://dx.doi.org/10.1371/journal.pone.0104888">Publisher Full Text </a> | <a target=xrefwindow id=d17740e6566 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4134245">Free Full Text </a></span></li><li><a name=ref-75 class=n-a></a><span class=label>75. </span>&nbsp;<span class=citation><a name=d17740e6575 class=n-a></a>Neilan TG, Jassal DS, Scully MF, <i> et al.</i>: Iloprost attenuates doxorubicin-induced cardiac injury in a murine model without compromising tumour suppression. <i>Eur Heart J.</i> 2006; <b>27</b>(10): 1251–6. <a target=xrefwindow id=d17740e6586 href="http://www.ncbi.nlm.nih.gov/pubmed/16624831">PubMed Abstract </a> | <a target=xrefwindow id=d17740e6589 href="http://dx.doi.org/10.1093/eurheartj/ehl003">Publisher Full Text </a></span></li><li><a name=ref-76 class=n-a></a><span class=label>76. </span>&nbsp;<span class=citation><a name=d17740e6598 class=n-a></a>Hassan MH, El-Beshbishy HA, Aly H, <i> et al.</i>: Modulatory effects of meloxicam on cardiotoxicity and antitumor activity of doxorubicin in mice. <i>Cancer Chemother Pharmacol.</i> 2014; <b>74</b>(3): 559–69. <a target=xrefwindow id=d17740e6609 href="http://www.ncbi.nlm.nih.gov/pubmed/25053391">PubMed Abstract </a> | <a target=xrefwindow id=d17740e6612 href="http://dx.doi.org/10.1007/s00280-014-2544-3">Publisher Full Text </a></span></li><li><a name=ref-77 class=n-a></a><span class=label>77. </span>&nbsp;<span class=citation><a name=d17740e6621 class=n-a></a>Hole LD, Larsen TH, Fossan KO, <i> et al.</i>: Diazoxide protects against doxorubicin-induced cardiotoxicity in the rat. <i>BMC Pharmacol Toxicol.</i> 2014; <b>15</b>: 28. <a target=xrefwindow id=d17740e6632 href="http://www.ncbi.nlm.nih.gov/pubmed/24887454">PubMed Abstract </a> | <a target=xrefwindow id=d17740e6635 href="http://dx.doi.org/10.1186/2050-6511-15-28">Publisher Full Text </a> | <a target=xrefwindow id=d17740e6639 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4045949">Free Full Text </a></span></li><li><a name=ref-78 class=n-a></a><span class=label>78. </span>&nbsp;<span class=citation><a name=d17740e6649 class=n-a></a>Disli OM, Sarihan E, Colak MC, <i> et al.</i>: Effects of molsidomine against doxorubicin-induced cardiotoxicity in rats. <i>Eur Surg Res.</i> 2013; <b>51</b>(1–2): 79–90. <a target=xrefwindow id=d17740e6660 href="http://www.ncbi.nlm.nih.gov/pubmed/24157421">PubMed Abstract </a> | <a target=xrefwindow id=d17740e6663 href="http://dx.doi.org/10.1159/000354807">Publisher Full Text </a></span></li><li><a name=ref-79 class=n-a></a><span class=label>79. </span>&nbsp;<span class=citation><a name=d17740e6672 class=n-a></a>Ahmed LA, El-Maraghy SA: Nicorandil ameliorates mitochondrial dysfunction in doxorubicin-induced heart failure in rats: possible mechanism of cardioprotection. <i>Biochem Pharmacol.</i> 2013; <b>86</b>(9): 1301–10. <a target=xrefwindow id=d17740e6680 href="http://www.ncbi.nlm.nih.gov/pubmed/23872193">PubMed Abstract </a> | <a target=xrefwindow id=d17740e6683 href="http://dx.doi.org/10.1016/j.bcp.2013.07.005">Publisher Full Text </a></span></li><li><a name=ref-80 class=n-a></a><span class=label>80. </span>&nbsp;<span class=citation><a name=d17740e6692 class=n-a></a>Toblli JE, Rivas C, Cao G, <i> et al.</i>: Ferric carboxymaltose-mediated attenuation of Doxorubicin-induced cardiotoxicity in an iron deficiency rat model. <i>Chemother Res Pract.</i> 2014; <b>2014</b>: 570241. <a target=xrefwindow id=d17740e6703 href="http://www.ncbi.nlm.nih.gov/pubmed/24876963">PubMed Abstract </a> | <a target=xrefwindow id=d17740e6706 href="http://dx.doi.org/10.1155/2014/570241">Publisher Full Text </a> | <a target=xrefwindow id=d17740e6710 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4022115">Free Full Text </a></span></li><li><a name=ref-81 class=n-a></a><span class=label>81. </span>&nbsp;<span class=citation><a name=d17740e6719 class=n-a></a>Wang X, Wang XL, Chen HL, <i> et al.</i>: Ghrelin inhibits doxorubicin cardiotoxicity by inhibiting excessive autophagy through AMPK and p38-MAPK. <i>Biochem Pharmacol.</i> 2014; <b>88</b>(3): 334–50. <a target=xrefwindow id=d17740e6730 href="http://www.ncbi.nlm.nih.gov/pubmed/24522112">PubMed Abstract </a> | <a target=xrefwindow id=d17740e6733 href="http://dx.doi.org/10.1016/j.bcp.2014.01.040">Publisher Full Text </a></span></li><li><a name=ref-82 class=n-a></a><span class=label>82. </span>&nbsp;<span class=citation><a name=d17740e6742 class=n-a></a>Zhu H, Luo P, Fu Y, <i> et al.</i>: Dihydromyricetin prevents cardiotoxicity and enhances anticancer activity induced by adriamycin. <i>Oncotarget.</i> 2015; <b>6</b>(5): 3254–6. <a target=xrefwindow id=d17740e6753 href="http://www.ncbi.nlm.nih.gov/pubmed/25226612">PubMed Abstract </a> | <a target=xrefwindow id=d17740e6756 href="http://dx.doi.org/10.18632/oncotarget.2410">Publisher Full Text </a> | <a target=xrefwindow id=d17740e6760 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4413651">Free Full Text </a></span></li><li><a name=ref-83 class=n-a></a><span class=label>83. </span>&nbsp;<span class=citation><a name=d17740e6769 class=n-a></a>Granados-Principal S, El-Azem N, Pamplona R, <i> et al.</i>: Hydroxytyrosol ameliorates oxidative stress and mitochondrial dysfunction in doxorubicin-induced cardiotoxicity in rats with breast cancer. <i>Biochem Pharmacol.</i> 2014; <b>90</b>(1): 25–33. <a target=xrefwindow id=d17740e6780 href="http://www.ncbi.nlm.nih.gov/pubmed/24727461">PubMed Abstract </a> | <a target=xrefwindow id=d17740e6783 href="http://dx.doi.org/10.1016/j.bcp.2014.04.001">Publisher Full Text </a></span></li><li><a name=ref-84 class=n-a></a><span class=label>84. </span>&nbsp;<span class=citation><a name=d17740e6793 class=n-a></a>Saleem MT, Chetty MC, Kavimani S: Antioxidants and tumor necrosis factor alpha-inhibiting activity of sesame oil against doxorubicin-induced cardiotoxicity. <i>Ther Adv Cardiovasc Dis.</i> 2014; <b>8</b>(1): 4–11. <a target=xrefwindow id=d17740e6801 href="http://www.ncbi.nlm.nih.gov/pubmed/24441175">PubMed Abstract </a> | <a target=xrefwindow id=d17740e6804 href="http://dx.doi.org/10.1177/1753944713516532">Publisher Full Text </a></span></li><li><a name=ref-85 class=n-a></a><span class=label>85. </span>&nbsp;<span class=citation><a name=d17740e6813 class=n-a></a>Su S, Li Q, Liu Y, <i> et al.</i>: Sesamin ameliorates doxorubicin-induced cardiotoxicity: involvement of Sirt1 and Mn-SOD pathway. <i>Toxicol Lett.</i> 2014; <b>224</b>(2): 257–63. <a target=xrefwindow id=d17740e6824 href="http://www.ncbi.nlm.nih.gov/pubmed/24211423">PubMed Abstract </a> | <a target=xrefwindow id=d17740e6827 href="http://dx.doi.org/10.1016/j.toxlet.2013.10.034">Publisher Full Text </a></span></li><li><a name=ref-86 class=n-a></a><span class=label>86. </span>&nbsp;<span class=citation><a name=d17740e6836 class=n-a></a>Wang XL, Wang X, Xiong LL, <i> et al.</i>: Salidroside improves doxorubicin-induced cardiac dysfunction by suppression of excessive oxidative stress and cardiomyocyte apoptosis. <i>J Cardiovasc Pharmacol.</i> 2013; <b>62</b>(6): 512–23. <a target=xrefwindow id=d17740e6847 href="http://www.ncbi.nlm.nih.gov/pubmed/24072175">PubMed Abstract </a> | <a target=xrefwindow id=d17740e6850 href="http://dx.doi.org/10.1097/FJC.0000000000000009">Publisher Full Text </a></span></li><li><a name=ref-87 class=n-a></a><span class=label>87. </span>&nbsp;<span class=citation><a name=d17740e6859 class=n-a></a>Mohamed HE, El-Swefy SE, Hagar HH: The protective effect of glutathione administration on adriamycin-induced acute cardiac toxicity in rats. <i>Pharmacol Res.</i> 2000; <b>42</b>(2): 115–21. <a target=xrefwindow id=d17740e6867 href="http://www.ncbi.nlm.nih.gov/pubmed/10887039">PubMed Abstract </a> | <a target=xrefwindow id=d17740e6870 href="http://dx.doi.org/10.1006/phrs.1999.0630">Publisher Full Text </a></span></li><li><a name=ref-88 class=n-a></a><span class=label>88. </span>&nbsp;<span class=citation><a name=d17740e6879 class=n-a></a>Sun J, Sun G, Meng X, <i> et al.</i>: Isorhamnetin protects against doxorubicin-induced cardiotoxicity <i>in vivo</i> and <i>in vitro</i>. <i>PLoS One.</i> 2013; <b>8</b>(5): e64526. <a target=xrefwindow id=d17740e6897 href="http://www.ncbi.nlm.nih.gov/pubmed/23724057">PubMed Abstract </a> | <a target=xrefwindow id=d17740e6900 href="http://dx.doi.org/10.1371/journal.pone.0064526">Publisher Full Text </a> | <a target=xrefwindow id=d17740e6903 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3665796">Free Full Text </a></span></li><li><a name=ref-89 class=n-a></a><span class=label>89. </span>&nbsp;<span class=citation><a name=d17740e6912 class=n-a></a>Fouad AA, Albuali WH, Al-Mulhim AS, <i> et al.</i>: Cardioprotective effect of cannabidiol in rats exposed to doxorubicin toxicity. <i>Environ Toxicol Pharmacol.</i> 2013; <b>36</b>(2): 347–5. <a target=xrefwindow id=d17740e6923 href="http://www.ncbi.nlm.nih.gov/pubmed/23721741">PubMed Abstract </a> | <a target=xrefwindow id=d17740e6926 href="http://dx.doi.org/10.1016/j.etap.2013.04.018">Publisher Full Text </a></span></li><li><a name=ref-90 class=n-a></a><span class=label>90. </span>&nbsp;<span class=citation><a name=d17740e6936 class=n-a></a>Dolinsky VW, Rogan KJ, Sung MM, <i> et al.</i>: Both aerobic exercise and resveratrol supplementation attenuate doxorubicin-induced cardiac injury in mice. <i>Am J Physiol Endocrinol Metab.</i> 2013; <b>305</b>(2): E243–53. <a target=xrefwindow id=d17740e6947 href="http://www.ncbi.nlm.nih.gov/pubmed/23695218">PubMed Abstract </a> | <a target=xrefwindow id=d17740e6950 href="http://dx.doi.org/10.1152/ajpendo.00044.2013">Publisher Full Text </a> | <a target=xrefwindow id=d17740e6954 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4116416">Free Full Text </a></span></li><li><a name=ref-91 class=n-a></a><span class=label>91. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732819183"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d17740e6963 class=n-a></a>Hajra S, Patra AR, Basu A, <i> et al.</i>: Prevention of doxorubicin (DOX)-induced genotoxicity and cardiotoxicity: Effect of plant derived small molecule indole-3-carbinol (I3C) on oxidative stress and inflammation. <i>Biomed Pharmacother.</i> 2018; <b>101</b>: 228–43. <a target=xrefwindow id=d17740e6974 href="http://www.ncbi.nlm.nih.gov/pubmed/29494960">PubMed Abstract </a> | <a target=xrefwindow id=d17740e6977 href="http://dx.doi.org/10.1016/j.biopha.2018.02.088">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732819183">F1000 Recommendation</a></span></li><li><a name=ref-92 class=n-a></a><span class=label>92. </span>&nbsp;<span class=citation><a name=d17740e6990 class=n-a></a>Yu X, Cui L, Zhang Z, <i> et al.</i>: α-Linolenic acid attenuates doxorubicin-induced cardiotoxicity in rats through suppression of oxidative stress and apoptosis. <i>Acta Biochim Biophys Sin (Shanghai).</i> 2013; <b>45</b>(10): 817–26. <a target=xrefwindow id=d17740e7001 href="http://www.ncbi.nlm.nih.gov/pubmed/23896563">PubMed Abstract </a> | <a target=xrefwindow id=d17740e7004 href="http://dx.doi.org/10.1093/abbs/gmt082">Publisher Full Text </a></span></li><li><a name=ref-93 class=n-a></a><span class=label>93. </span>&nbsp;<span class=citation><a name=d17740e7013 class=n-a></a>Al-Abd AM, Al-Abbasi FA, Asaad GF, <i> et al.</i>: Didox potentiates the cytotoxic profile of doxorubicin and protects from its cardiotoxicity. <i>Eur J Pharmacol.</i> 2013; <b>718</b>(1–3): 361–9. <a target=xrefwindow id=d17740e7024 href="http://www.ncbi.nlm.nih.gov/pubmed/24021537">PubMed Abstract </a> | <a target=xrefwindow id=d17740e7027 href="http://dx.doi.org/10.1016/j.ejphar.2013.08.009">Publisher Full Text </a></span></li><li><a name=ref-94 class=n-a></a><span class=label>94. </span>&nbsp;<span class=citation><a name=d17740e7036 class=n-a></a>Gharanei M, Hussain A, Janneh O, <i> et al.</i>: Attenuation of doxorubicin-induced cardiotoxicity by mdivi-1: a mitochondrial division/mitophagy inhibitor. <i>PLoS One.</i> 2013; <b>8</b>(10): e77713. <a target=xrefwindow id=d17740e7047 href="http://www.ncbi.nlm.nih.gov/pubmed/24147064">PubMed Abstract </a> | <a target=xrefwindow id=d17740e7050 href="http://dx.doi.org/10.1371/journal.pone.0077713">Publisher Full Text </a> | <a target=xrefwindow id=d17740e7054 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3798380">Free Full Text </a></span></li><li><a name=ref-95 class=n-a></a><span class=label>95. </span>&nbsp;<span class=citation><a name=d17740e7063 class=n-a></a>Tebbi CK, London WB, Friedman D, <i> et al.</i>: Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease. <i>J Clin Oncol.</i> 2007; <b>25</b>(5): 493–500. <a target=xrefwindow id=d17740e7074 href="http://www.ncbi.nlm.nih.gov/pubmed/17290056">PubMed Abstract </a> | <a target=xrefwindow id=d17740e7077 href="http://dx.doi.org/10.1200/JCO.2005.02.3879">Publisher Full Text </a></span></li><li><a name=ref-96 class=n-a></a><span class=label>96. </span>&nbsp;<span class=citation><a name=d17740e7087 class=n-a></a>van Dalen EC, Caron HN, Dickinson HO, <i> et al.</i>: Cardioprotective interventions for cancer patients receiving anthracyclines. <i>Cochrane Database Syst Rev.</i> 2011; (6): CD003917. <a target=xrefwindow id=d17740e7095 href="http://www.ncbi.nlm.nih.gov/pubmed/21678342">PubMed Abstract </a> | <a target=xrefwindow id=d17740e7098 href="http://dx.doi.org/10.1002/14651858.CD003917.pub4">Publisher Full Text </a></span></li><li><a name=ref-97 class=n-a></a><span class=label>97. </span>&nbsp;<span class=citation><a name=d17740e7107 class=n-a></a>Barry EV, Vrooman LM, Dahlberg SE, <i> et al.</i>: Absence of secondary malignant neoplasms in children with high-risk acute lymphoblastic leukemia treated with dexrazoxane. <i>J Clin Oncol.</i> 2008; <b>26</b>(7): 1106–11. <a target=xrefwindow id=d17740e7118 href="http://www.ncbi.nlm.nih.gov/pubmed/18309945">PubMed Abstract </a> | <a target=xrefwindow id=d17740e7121 href="http://dx.doi.org/10.1200/JCO.2007.12.2481">Publisher Full Text </a></span></li><li><a name=ref-98 class=n-a></a><span class=label>98. </span>&nbsp;<span class=citation><a name=d17740e7130 class=n-a></a>Seif AE, Walker DM, Li Y, <i> et al.</i>: Dexrazoxane exposure and risk of secondary acute myeloid leukemia in pediatric oncology patients. <i>Pediatr Blood Cancer.</i> 2015; <b>62</b>(4): 704–9. <a target=xrefwindow id=d17740e7141 href="http://www.ncbi.nlm.nih.gov/pubmed/24668949">PubMed Abstract </a> | <a target=xrefwindow id=d17740e7144 href="http://dx.doi.org/10.1002/pbc.25043">Publisher Full Text </a> | <a target=xrefwindow id=d17740e7148 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4177031">Free Full Text </a></span></li><li><a name=ref-99 class=n-a></a><span class=label>99. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726037545"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d17740e7157 class=n-a></a>Asselin BL, Devidas M, Chen L, <i> et al.</i>: Cardioprotection and Safety of Dexrazoxane in Patients Treated for Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Advanced-Stage Lymphoblastic Non-Hodgkin Lymphoma: A Report of the Children's Oncology Group Randomized Trial Pediatric Oncology Group 9404. <i>J Clin Oncol.</i> 2016; <b>34</b>(8): 854–62. <a target=xrefwindow id=d17740e7168 href="http://www.ncbi.nlm.nih.gov/pubmed/26700126">PubMed Abstract </a> | <a target=xrefwindow id=d17740e7171 href="http://dx.doi.org/10.1200/JCO.2015.60.8851">Publisher Full Text </a> | <a target=xrefwindow id=d17740e7175 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4872007">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726037545">F1000 Recommendation</a></span></li><li><a name=ref-100 class=n-a></a><span class=label>100. </span>&nbsp;<span class=citation><a name=d17740e7188 class=n-a></a>Oliveira PJ, Bjork JA, Santos MS, <i> et al.</i>: Carvedilol-mediated antioxidant protection against doxorubicin-induced cardiac mitochondrial toxicity. <i>Toxicol Appl Pharmacol.</i> 2004; <b>200</b>(2): 159–68. <a target=xrefwindow id=d17740e7199 href="http://www.ncbi.nlm.nih.gov/pubmed/15476868">PubMed Abstract </a> | <a target=xrefwindow id=d17740e7202 href="http://dx.doi.org/10.1016/j.taap.2004.04.005">Publisher Full Text </a></span></li><li><a name=ref-101 class=n-a></a><span class=label>101. </span>&nbsp;<span class=citation><a name=d17740e7211 class=n-a></a>Kalay N, Basar E, Ozdogru I, <i> et al.</i>: Protective effects of carvedilol against anthracycline-induced cardiomyopathy. <i>J Am Coll Cardiol.</i> 2006; <b>48</b>(11): 2258–62. <a target=xrefwindow id=d17740e7222 href="http://www.ncbi.nlm.nih.gov/pubmed/17161256">PubMed Abstract </a> | <a target=xrefwindow id=d17740e7225 href="http://dx.doi.org/10.1016/j.jacc.2006.07.052">Publisher Full Text </a></span></li><li><a name=ref-102 class=n-a></a><span class=label>102. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727256297"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d17740e7235 class=n-a></a>Nabati M, Janbabai G, Baghyari S, <i> et al.</i>: Cardioprotective Effects of Carvedilol in Inhibiting Doxorubicin-induced Cardiotoxicity. <i>J Cardiovasc Pharmacol.</i> 2017; <b>69</b>(5): 279–85. <a target=xrefwindow id=d17740e7246 href="http://www.ncbi.nlm.nih.gov/pubmed/28141699">PubMed Abstract </a> | <a target=xrefwindow id=d17740e7249 href="http://dx.doi.org/10.1097/FJC.0000000000000470">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727256297">F1000 Recommendation</a></span></li><li><a name=ref-103 class=n-a></a><span class=label>103. </span>&nbsp;<span class=citation><a name=d17740e7262 class=n-a></a>Cardinale D, Ciceri F, Latini R, <i> et al.</i>: Anthracycline-induced cardiotoxicity: A multicenter randomised trial comparing two strategies for guiding prevention with enalapril: The International CardioOncology Society-one trial. <i>Eur J Cancer.</i> 2018; <b>94</b>: 126–37. <a target=xrefwindow id=d17740e7273 href="http://www.ncbi.nlm.nih.gov/pubmed/29567630">PubMed Abstract </a> | <a target=xrefwindow id=d17740e7276 href="http://dx.doi.org/10.1016/j.ejca.2018.02.005">Publisher Full Text </a></span></li><li><a name=ref-104 class=n-a></a><span class=label>104. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726478654"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d17740e7285 class=n-a></a>Boekhout AH, Gietema JA, Milojkovic Kerklaan B, <i> et al.</i>: Angiotensin II-Receptor Inhibition With Candesartan to Prevent Trastuzumab-Related Cardiotoxic Effects in Patients With Early Breast Cancer: A Randomized Clinical Trial. <i>JAMA Oncol.</i> 2016; <b>2</b>(8): 1030–7. <a target=xrefwindow id=d17740e7296 href="http://www.ncbi.nlm.nih.gov/pubmed/27348762">PubMed Abstract </a> | <a target=xrefwindow id=d17740e7299 href="http://dx.doi.org/10.1001/jamaoncol.2016.1726">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726478654">F1000 Recommendation</a></span></li><li><a name=ref-105 class=n-a></a><span class=label>105. </span>&nbsp;<span class=citation><a name=d17740e7312 class=n-a></a>Tallaj JA, Franco V, Rayburn BK, <i> et al.</i>: Response of doxorubicin-induced cardiomyopathy to the current management strategy of heart failure. <i>J Heart Lung Transplant.</i> 2005; <b>24</b>(12): 2196–201. <a target=xrefwindow id=d17740e7323 href="http://www.ncbi.nlm.nih.gov/pubmed/16364871">PubMed Abstract </a> | <a target=xrefwindow id=d17740e7326 href="http://dx.doi.org/10.1016/j.healun.2004.12.108">Publisher Full Text </a></span></li><li><a name=ref-106 class=n-a></a><span class=label>106. </span>&nbsp;<span class=citation><a name=d17740e7335 class=n-a></a>Bosch X, Rovira M, Sitges M, <i> et al.</i>: Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies). <i>J Am Coll Cardiol.</i> 2013; <b>61</b>(23): 2355–62. <a target=xrefwindow id=d17740e7346 href="http://www.ncbi.nlm.nih.gov/pubmed/23583763">PubMed Abstract </a> | <a target=xrefwindow id=d17740e7349 href="http://dx.doi.org/10.1016/j.jacc.2013.02.072">Publisher Full Text </a></span></li><li><a name=ref-107 class=n-a></a><span class=label>107. </span>&nbsp;<span class=citation><a name=d17740e7358 class=n-a></a>Payne DL, Nohria A: Prevention of Chemotherapy Induced Cardiomyopathy. <i>Curr Heart Fail Rep.</i> 2017; <b>14</b>(5): 398–403. <a target=xrefwindow id=d17740e7366 href="http://www.ncbi.nlm.nih.gov/pubmed/28779279">PubMed Abstract </a> | <a target=xrefwindow id=d17740e7369 href="http://dx.doi.org/10.1007/s11897-017-0353-9">Publisher Full Text </a></span></li><li><a name=ref-108 class=n-a></a><span class=label>108. </span>&nbsp;<span class=citation><a name=d17740e7379 class=n-a></a>Guglin M, Munster P, Fink A, <i> et al.</i>: Lisinopril or Coreg CR in reducing cardiotoxicity in women with breast cancer receiving trastuzumab: A rationale and design of a randomized clinical trial. <i>Am Heart J.</i> 2017; <b>188</b>: 87–92. <a target=xrefwindow id=d17740e7390 href="http://www.ncbi.nlm.nih.gov/pubmed/28577685">PubMed Abstract </a> | <a target=xrefwindow id=d17740e7393 href="http://dx.doi.org/10.1016/j.ahj.2017.03.010">Publisher Full Text </a> | <a target=xrefwindow id=d17740e7397 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5458618">Free Full Text </a></span></li><li><a name=ref-109 class=n-a></a><span class=label>109. </span>&nbsp;<span class=citation><a name=d17740e7406 class=n-a></a>Seicean S, Seicean A, Plana JC, <i> et al.</i>: Effect of statin therapy on the risk for incident heart failure in patients with breast cancer receiving anthracycline chemotherapy: An observational clinical cohort study. <i>J Am Coll Cardiol.</i> 2012; <b>60</b>(23): 2384–90. <a target=xrefwindow id=d17740e7417 href="http://www.ncbi.nlm.nih.gov/pubmed/23141499">PubMed Abstract </a> | <a target=xrefwindow id=d17740e7420 href="http://dx.doi.org/10.1016/j.jacc.2012.07.067">Publisher Full Text </a></span></li><li><a name=ref-110 class=n-a></a><span class=label>110. </span>&nbsp;<span class=citation><a name=d17740e7429 class=n-a></a>Chotenimitkhun R, D'Agostino R Jr, Lawrence JA, <i> et al.</i>: Chronic statin administration may attenuate early anthracycline-associated declines in left ventricular ejection function. <i>Can J Cardiol.</i> 2015; <b>31</b>(3): 302–7. <a target=xrefwindow id=d17740e7440 href="http://www.ncbi.nlm.nih.gov/pubmed/25662284">PubMed Abstract </a> | <a target=xrefwindow id=d17740e7443 href="http://dx.doi.org/10.1016/j.cjca.2014.11.020">Publisher Full Text </a> | <a target=xrefwindow id=d17740e7447 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4410009">Free Full Text </a></span></li><li><a name=ref-111 class=n-a></a><span class=label>111. </span>&nbsp;<span class=citation><a name=d17740e7456 class=n-a></a>Gabizon AA, Lyass O, Berry GJ, <i> et al.</i>: Cardiac safety of pegylated liposomal doxorubicin (Doxil/Caelyx) demonstrated by endomyocardial biopsy in patients with advanced malignancies. <i>Cancer Invest.</i> 2004; <b>22</b>(5): 663–9. <a target=xrefwindow id=d17740e7467 href="http://www.ncbi.nlm.nih.gov/pubmed/15581046">PubMed Abstract </a> | <a target=xrefwindow id=d17740e7470 href="http://dx.doi.org/10.1081/CNV-200032899">Publisher Full Text </a></span></li><li><a name=ref-112 class=n-a></a><span class=label>112. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/730364601"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d17740e7479 class=n-a></a>Skubitz KM, Blaes AH, Konety SH, <i> et al.</i>: Cardiac safety profile of patients receiving high cumulative doses of pegylated-liposomal doxorubicin: use of left ventricular ejection fraction is of unproven value. <i>Cancer Chemother Pharmacol.</i> 2017; <b>80</b>(4): 787–98. <a target=xrefwindow id=d17740e7490 href="http://www.ncbi.nlm.nih.gov/pubmed/28856562">PubMed Abstract </a> | <a target=xrefwindow id=d17740e7493 href="http://dx.doi.org/10.1007/s00280-017-3420-8">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/730364601">F1000 Recommendation</a></span></li><li><a name=ref-113 class=n-a></a><span class=label>113. </span>&nbsp;<span class=citation><a name=d17740e7506 class=n-a></a>Smith LA, Cornelius VR, Plummer CJ, <i> et al.</i>: Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials. <i>BMC Cancer.</i> 2010; <b>10</b>: 337. <a target=xrefwindow id=d17740e7517 href="http://www.ncbi.nlm.nih.gov/pubmed/20587042">PubMed Abstract </a> | <a target=xrefwindow id=d17740e7520 href="http://dx.doi.org/10.1186/1471-2407-10-337">Publisher Full Text </a> | <a target=xrefwindow id=d17740e7524 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2907344">Free Full Text </a></span></li><li><a name=ref-114 class=n-a></a><span class=label>114. </span>&nbsp;<span class=citation><a name=d17740e7534 class=n-a></a>Jones LW, Habel LA, Weltzien E, <i> et al.</i>: Exercise and Risk of Cardiovascular Events in Women With Nonmetastatic Breast Cancer. <i>J Clin Oncol.</i> 2016; <b>34</b>(23): 2743–9. <a target=xrefwindow id=d17740e7545 href="http://www.ncbi.nlm.nih.gov/pubmed/27217451">PubMed Abstract </a> | <a target=xrefwindow id=d17740e7548 href="http://dx.doi.org/10.1200/JCO.2015.65.6603">Publisher Full Text </a> | <a target=xrefwindow id=d17740e7552 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5019746">Free Full Text </a></span></li><li><a name=ref-115 class=n-a></a><span class=label>115. </span>&nbsp;<span class=citation><a name=d17740e7561 class=n-a></a>Haykowsky MJ, Mackey JR, Thompson RB, <i> et al.</i>: Adjuvant trastuzumab induces ventricular remodeling despite aerobic exercise training. <i>Clin Cancer Res.</i> 2009; <b>15</b>(15): 4963–7. <a target=xrefwindow id=d17740e7572 href="http://www.ncbi.nlm.nih.gov/pubmed/19622583">PubMed Abstract </a> | <a target=xrefwindow id=d17740e7575 href="http://dx.doi.org/10.1158/1078-0432.CCR-09-0628">Publisher Full Text </a></span></li><li><a name=ref-116 class=n-a></a><span class=label>116. </span>&nbsp;<span class=citation><a name=d17740e7584 class=n-a></a>Cardinale D, Sandri MT, Martinoni A, <i> et al.</i>: Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. <i>J Am Coll Cardiol.</i> 2000; <b>36</b>(2): 517–22. <a target=xrefwindow id=d17740e7595 href="http://www.ncbi.nlm.nih.gov/pubmed/10933366">PubMed Abstract </a> | <a target=xrefwindow id=d17740e7598 href="http://dx.doi.org/10.1016/S0735-1097(00)00748-8">Publisher Full Text </a></span></li><li><a name=ref-117 class=n-a></a><span class=label>117. </span>&nbsp;<span class=citation><a name=d17740e7607 class=n-a></a>Cardinale D, Colombo A, Torrisi R, <i> et al.</i>: Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. <i>J Clin Oncol.</i> 2010; <b>28</b>(25): 3910–6. <a target=xrefwindow id=d17740e7618 href="http://www.ncbi.nlm.nih.gov/pubmed/20679614">PubMed Abstract </a> | <a target=xrefwindow id=d17740e7621 href="http://dx.doi.org/10.1200/JCO.2009.27.3615">Publisher Full Text </a></span></li><li><a name=ref-118 class=n-a></a><span class=label>118. </span>&nbsp;<span class=citation><a name=d17740e7630 class=n-a></a>Kilickap S, Barista I, Akgul E, <i> et al.</i>: cTnT can be a useful marker for early detection of anthracycline cardiotoxicity. <i>Ann Oncol.</i> 2005; <b>16</b>(5): 798–804. <a target=xrefwindow id=d17740e7641 href="http://www.ncbi.nlm.nih.gov/pubmed/15774486">PubMed Abstract </a> | <a target=xrefwindow id=d17740e7644 href="http://dx.doi.org/10.1093/annonc/mdi152">Publisher Full Text </a></span></li><li><a name=ref-119 class=n-a></a><span class=label>119. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/730501675"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d17740e7653 class=n-a></a>De Iuliis F, Salerno G, Taglieri L, <i> et al.</i>: Serum biomarkers evaluation to predict chemotherapy-induced cardiotoxicity in breast cancer patients. <i>Tumour Biol.</i> 2016; <b>37</b>(3): 3379–87. <a target=xrefwindow id=d17740e7664 href="http://www.ncbi.nlm.nih.gov/pubmed/26449821">PubMed Abstract </a> | <a target=xrefwindow id=d17740e7667 href="http://dx.doi.org/10.1007/s13277-015-4183-7">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/730501675">F1000 Recommendation</a></span></li><li><a name=ref-120 class=n-a></a><span class=label>120. </span>&nbsp;<span class=citation><a name=d17740e7681 class=n-a></a>Nousiainen T, Vanninen E, Jantunen E, <i> et al.</i>: Natriuretic peptides during the development of doxorubicin-induced left ventricular diastolic dysfunction. <i>J Intern Med.</i> 2002; <b>251</b>(3): 228–34. <a target=xrefwindow id=d17740e7692 href="http://www.ncbi.nlm.nih.gov/pubmed/11886482">PubMed Abstract </a> | <a target=xrefwindow id=d17740e7695 href="http://dx.doi.org/10.1046/j.1365-2796.2002.00951.x">Publisher Full Text </a></span></li><li><a name=ref-121 class=n-a></a><span class=label>121. </span>&nbsp;<span class=citation><a name=d17740e7704 class=n-a></a>Sawaya H, Sebag IA, Plana JC, <i> et al.</i>: Early detection and prediction of cardiotoxicity in chemotherapy-treated patients. <i>Am J Cardiol.</i> 2011; <b>107</b>(9): 1375–80. <a target=xrefwindow id=d17740e7715 href="http://www.ncbi.nlm.nih.gov/pubmed/21371685">PubMed Abstract </a> | <a target=xrefwindow id=d17740e7718 href="http://dx.doi.org/10.1016/j.amjcard.2011.01.006">Publisher Full Text </a> | <a target=xrefwindow id=d17740e7722 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3703314">Free Full Text </a></span></li><li><a name=ref-122 class=n-a></a><span class=label>122. </span>&nbsp;<span class=citation><a name=d17740e7731 class=n-a></a>Katsurada K, Ichida M, Sakuragi M, <i> et al.</i>: High-sensitivity troponin T as a marker to predict cardiotoxicity in breast cancer patients with adjuvant trastuzumab therapy. <i>Springerplus.</i> 2014; <b>3</b>: 620. <a target=xrefwindow id=d17740e7742 href="http://www.ncbi.nlm.nih.gov/pubmed/25392790">PubMed Abstract </a> | <a target=xrefwindow id=d17740e7745 href="http://dx.doi.org/10.1186/2193-1801-3-620">Publisher Full Text </a> | <a target=xrefwindow id=d17740e7749 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4216824">Free Full Text </a></span></li><li><a name=ref-123 class=n-a></a><span class=label>123. </span>&nbsp;<span class=citation><a name=d17740e7758 class=n-a></a>Ky B, Putt M, Sawaya H, <i> et al.</i>: Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab. <i>J Am Coll Cardiol.</i> 2014; <b>63</b>(8): 809–16. <a target=xrefwindow id=d17740e7769 href="http://www.ncbi.nlm.nih.gov/pubmed/24291281">PubMed Abstract </a> | <a target=xrefwindow id=d17740e7772 href="http://dx.doi.org/10.1016/j.jacc.2013.10.061">Publisher Full Text </a> | <a target=xrefwindow id=d17740e7776 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4286181">Free Full Text </a></span></li><li><a name=ref-124 class=n-a></a><span class=label>124. </span>&nbsp;<span class=citation><a name=d17740e7785 class=n-a></a>Ylänen K, Poutanen T, Savukoski T, <i> et al.</i>: Cardiac biomarkers indicate a need for sensitive cardiac imaging among long-term childhood cancer survivors exposed to anthracyclines. <i>Acta Paediatr.</i> 2015; <b>104</b>(3): 313–9. <a target=xrefwindow id=d17740e7796 href="http://www.ncbi.nlm.nih.gov/pubmed/25393922">PubMed Abstract </a> | <a target=xrefwindow id=d17740e7799 href="http://dx.doi.org/10.1111/apa.12862">Publisher Full Text </a></span></li><li><a name=ref-125 class=n-a></a><span class=label>125. </span>&nbsp;<span class=citation><a name=d17740e7808 class=n-a></a>Garrone O, Crosetto N, Lo Nigro C, <i> et al.</i>: Prediction of anthracycline cardiotoxicity after chemotherapy by biomarkers kinetic analysis. <i>Cardiovasc Toxicol.</i> 2012; <b>12</b>(2): 135–42. <a target=xrefwindow id=d17740e7819 href="http://www.ncbi.nlm.nih.gov/pubmed/22189487">PubMed Abstract </a> | <a target=xrefwindow id=d17740e7822 href="http://dx.doi.org/10.1007/s12012-011-9149-4">Publisher Full Text </a></span></li><li><a name=ref-126 class=n-a></a><span class=label>126. </span>&nbsp;<span class=citation><a name=d17740e7832 class=n-a></a>Onitilo AA, Engel JM, Stankowski RV, <i> et al.</i>: High-sensitivity C-reactive protein (hs-CRP) as a biomarker for trastuzumab-induced cardiotoxicity in HER2-positive early-stage breast cancer: a pilot study. <i>Breast Cancer Res Treat.</i> 2012; <b>134</b>(1): 291–8. <a target=xrefwindow id=d17740e7843 href="http://www.ncbi.nlm.nih.gov/pubmed/22476854">PubMed Abstract </a> | <a target=xrefwindow id=d17740e7846 href="http://dx.doi.org/10.1007/s10549-012-2039-z">Publisher Full Text </a></span></li><li><a name=ref-127 class=n-a></a><span class=label>127. </span>&nbsp;<span class=citation><a name=d17740e7855 class=n-a></a>Putt M, Hahn VS, Januzzi JL, <i> et al.</i>: Longitudinal Changes in Multiple Biomarkers Are Associated with Cardiotoxicity in Breast Cancer Patients Treated with Doxorubicin, Taxanes, and Trastuzumab. <i>Clin Chem.</i> 2015; <b>61</b>(9): 1164–72. <a target=xrefwindow id=d17740e7866 href="http://www.ncbi.nlm.nih.gov/pubmed/26220066">PubMed Abstract </a> | <a target=xrefwindow id=d17740e7869 href="http://dx.doi.org/10.1373/clinchem.2015.241232">Publisher Full Text </a> | <a target=xrefwindow id=d17740e7873 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4667170">Free Full Text </a></span></li><li><a name=ref-128 class=n-a></a><span class=label>128. </span>&nbsp;<span class=citation><a name=d17740e7882 class=n-a></a>Arslan D, Cihan T, Kose D, <i> et al.</i>: Growth-differentiation factor-15 and tissue doppler ımaging in detection of asymptomatic anthracycline cardiomyopathy in childhood cancer survivors. <i>Clin Biochem.</i> 2013; <b>46</b>(13–14): 1239–43. <a target=xrefwindow id=d17740e7893 href="http://www.ncbi.nlm.nih.gov/pubmed/23850849">PubMed Abstract </a> | <a target=xrefwindow id=d17740e7896 href="http://dx.doi.org/10.1016/j.clinbiochem.2013.06.029">Publisher Full Text </a></span></li><li><a name=ref-129 class=n-a></a><span class=label>129. </span>&nbsp;<span class=citation><a name=d17740e7905 class=n-a></a>Finkelman BS, Putt M, Wang T, <i> et al.</i>: Arginine-Nitric Oxide Metabolites and Cardiac Dysfunction in Patients With Breast Cancer. <i>J Am Coll Cardiol.</i> 2017; <b>70</b>(2): 152–62. <a target=xrefwindow id=d17740e7916 href="http://www.ncbi.nlm.nih.gov/pubmed/28683962">PubMed Abstract </a> | <a target=xrefwindow id=d17740e7919 href="http://dx.doi.org/10.1016/j.jacc.2017.05.019">Publisher Full Text </a> | <a target=xrefwindow id=d17740e7923 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5665653">Free Full Text </a></span></li><li><a name=ref-130 class=n-a></a><span class=label>130. </span>&nbsp;<span class=citation><a name=d17740e7932 class=n-a></a>Horacek JM, Vasatova M, Tichy M, <i> et al.</i>: The use of cardiac biomarkers in detection of cardiotoxicity associated with conventional and high-dose chemotherapy for acute leukemia. <i>Exp Oncol.</i> 2010; <b>32</b>(2): 97–9. <a target=xrefwindow id=d17740e7943 href="http://www.ncbi.nlm.nih.gov/pubmed/20693970">PubMed Abstract </a></span></li><li><a name=ref-131 class=n-a></a><span class=label>131. </span>&nbsp;<span class=citation><a name=d17740e7952 class=n-a></a>Mercuro G, Cadeddu C, Piras A, <i> et al.</i>: Early epirubicin-induced myocardial dysfunction revealed by serial tissue Doppler echocardiography: correlation with inflammatory and oxidative stress markers. <i>Oncologist.</i> 2007; <b>12</b>(9): 1124–33. <a target=xrefwindow id=d17740e7963 href="http://www.ncbi.nlm.nih.gov/pubmed/17914082">PubMed Abstract </a> | <a target=xrefwindow id=d17740e7966 href="http://dx.doi.org/10.1634/theoncologist.12-9-1124">Publisher Full Text </a></span></li><li><a name=ref-132 class=n-a></a><span class=label>132. </span>&nbsp;<span class=citation><a name=d17740e7976 class=n-a></a>Ma Y, Kang W, Bao Y, <i> et al.</i>: Clinical significance of ischemia-modified albumin in the diagnosis of doxorubicin-induced myocardial injury in breast cancer patients. <i>PLoS One.</i> 2013; <b>8</b>(11): e79426. <a target=xrefwindow id=d17740e7987 href="http://www.ncbi.nlm.nih.gov/pubmed/24223946">PubMed Abstract </a> | <a target=xrefwindow id=d17740e7990 href="http://dx.doi.org/10.1371/journal.pone.0079426">Publisher Full Text </a> | <a target=xrefwindow id=d17740e7994 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3817059">Free Full Text </a></span></li><li><a name=ref-133 class=n-a></a><span class=label>133. </span>&nbsp;<span class=citation><a name=d17740e8003 class=n-a></a>Aminkeng F, Bhavsar AP, Visscher H, <i> et al.</i>: A coding variant in <i>RARG</i> confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer. <i>Nat Genet.</i> 2015; <b>47</b>(9): 1079–84. <a target=xrefwindow id=d17740e8017 href="http://www.ncbi.nlm.nih.gov/pubmed/26237429">PubMed Abstract </a> | <a target=xrefwindow id=d17740e8021 href="http://dx.doi.org/10.1038/ng.3374">Publisher Full Text </a> | <a target=xrefwindow id=d17740e8024 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4552570">Free Full Text </a></span></li><li><a name=ref-134 class=n-a></a><span class=label>134. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726102447"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d17740e8033 class=n-a></a>Wang X, Sun CL, Quiñones-Lombraña A, <i> et al.</i>: <i>CELF4</i> Variant and Anthracycline-Related Cardiomyopathy: A Children's Oncology Group Genome-Wide Association Study. <i>J Clin Oncol.</i> 2016; <b>34</b>(8): 863–70. <a target=xrefwindow id=d17740e8047 href="http://www.ncbi.nlm.nih.gov/pubmed/26811534">PubMed Abstract </a> | <a target=xrefwindow id=d17740e8051 href="http://dx.doi.org/10.1200/JCO.2015.63.4550">Publisher Full Text </a> | <a target=xrefwindow id=d17740e8054 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5070560">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726102447">F1000 Recommendation</a></span></li><li><a name=ref-135 class=n-a></a><span class=label>135. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727127835"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d17740e8067 class=n-a></a>Schneider BP, Shen F, Gardner L, <i> et al.</i>: Genome-Wide Association Study for Anthracycline-Induced Congestive Heart Failure. <i>Clin Cancer Res.</i> 2017; <b>23</b>(1): 43–51. <a target=xrefwindow id=d17740e8078 href="http://www.ncbi.nlm.nih.gov/pubmed/27993963">PubMed Abstract </a> | <a target=xrefwindow id=d17740e8081 href="http://dx.doi.org/10.1158/1078-0432.CCR-16-0908">Publisher Full Text </a> | <a target=xrefwindow id=d17740e8085 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5215621">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727127835">F1000 Recommendation</a></span></li><li><a name=ref-136 class=n-a></a><span class=label>136. </span>&nbsp;<span class=citation><a name=d17740e8098 class=n-a></a>Hahm S, Dresner HS, Podwall D, <i> et al.</i>: DNA biomarkers antecede semiquantitative anthracycline cardiomyopathy. <i>Cancer Invest.</i> 2003; <b>21</b>(1): 53–67. <a target=xrefwindow id=d17740e8109 href="http://www.ncbi.nlm.nih.gov/pubmed/12643010">PubMed Abstract </a> | <a target=xrefwindow id=d17740e8112 href="http://dx.doi.org/10.1081/CNV-120016404">Publisher Full Text </a></span></li><li><a name=ref-137 class=n-a></a><span class=label>137. </span>&nbsp;<span class=citation><a name=d17740e8121 class=n-a></a>Mori Y, Kondo C, Tonomura Y, <i> et al.</i>: Identification of potential genomic biomarkers for early detection of chemically induced cardiotoxicity in rats. <i>Toxicology.</i> 2010; <b>271</b>(1–2): 36–44. <a target=xrefwindow id=d17740e8132 href="http://www.ncbi.nlm.nih.gov/pubmed/20211217">PubMed Abstract </a> | <a target=xrefwindow id=d17740e8135 href="http://dx.doi.org/10.1016/j.tox.2010.02.015">Publisher Full Text </a></span></li><li><a name=ref-138 class=n-a></a><span class=label>138. </span>&nbsp;<span class=citation><a name=d17740e8145 class=n-a></a>Desai VG, C Kwekel J, Vijay V, <i> et al.</i>: Early biomarkers of doxorubicin-induced heart injury in a mouse model. <i>Toxicol Appl Pharmacol.</i> 2014; <b>281</b>(2): 221–9. <a target=xrefwindow id=d17740e8156 href="http://www.ncbi.nlm.nih.gov/pubmed/25448438">PubMed Abstract </a> | <a target=xrefwindow id=d17740e8159 href="http://dx.doi.org/10.1016/j.taap.2014.10.006">Publisher Full Text </a></span></li><li><a name=ref-139 class=n-a></a><span class=label>139. </span>&nbsp;<span class=citation><a name=d17740e8168 class=n-a></a>Vacchi-Suzzi C, Bauer Y, Berridge BR, <i> et al.</i>: Perturbation of microRNAs in rat heart during chronic doxorubicin treatment. <i>PLoS One.</i> 2012; <b>7</b>(7): e40395. <a target=xrefwindow id=d17740e8179 href="http://www.ncbi.nlm.nih.gov/pubmed/22859947">PubMed Abstract </a> | <a target=xrefwindow id=d17740e8182 href="http://dx.doi.org/10.1371/journal.pone.0040395">Publisher Full Text </a> | <a target=xrefwindow id=d17740e8186 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3409211">Free Full Text </a></span></li><li><a name=ref-140 class=n-a></a><span class=label>140. </span>&nbsp;<span class=citation><a name=d17740e8195 class=n-a></a>Horie T, Ono K, Nishi H, <i> et al.</i>: Acute doxorubicin cardiotoxicity is associated with miR-146a-induced inhibition of the neuregulin-ErbB pathway. <i>Cardiovasc Res.</i> 2010; <b>87</b>(4): 656–64. <a target=xrefwindow id=d17740e8206 href="http://www.ncbi.nlm.nih.gov/pubmed/20495188">PubMed Abstract </a> | <a target=xrefwindow id=d17740e8209 href="http://dx.doi.org/10.1093/cvr/cvq148">Publisher Full Text </a> | <a target=xrefwindow id=d17740e8213 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2920811">Free Full Text </a></span></li><li><a name=ref-141 class=n-a></a><span class=label>141. </span>&nbsp;<span class=citation><a name=d17740e8222 class=n-a></a>Eryilmaz U, Demirci B, Aksun S, <i> et al.</i>: S100A1 as a Potential Diagnostic Biomarker for Assessing Cardiotoxicity and Implications for the Chemotherapy of Certain Cancers. <i>PLoS One.</i> 2015; <b>10</b>(12): e0145418. <a target=xrefwindow id=d17740e8233 href="http://www.ncbi.nlm.nih.gov/pubmed/26682543">PubMed Abstract </a> | <a target=xrefwindow id=d17740e8236 href="http://dx.doi.org/10.1371/journal.pone.0145418">Publisher Full Text </a> | <a target=xrefwindow id=d17740e8240 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4687715">Free Full Text </a></span></li><li><a name=ref-142 class=n-a></a><span class=label>142. </span>&nbsp;<span class=citation><a name=d17740e8249 class=n-a></a>ElZarrad MK, Mukhopadhyay P, Mohan N, <i> et al.</i>: Trastuzumab alters the expression of genes essential for cardiac function and induces ultrastructural changes of cardiomyocytes in mice. <i>PLoS One.</i> 2013; <b>8</b>(11): e79543. <a target=xrefwindow id=d17740e8260 href="http://www.ncbi.nlm.nih.gov/pubmed/24255707">PubMed Abstract </a> | <a target=xrefwindow id=d17740e8263 href="http://dx.doi.org/10.1371/journal.pone.0079543">Publisher Full Text </a> | <a target=xrefwindow id=d17740e8267 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3821852">Free Full Text </a></span></li><li><a name=ref-143 class=n-a></a><span class=label>143. </span>&nbsp;<span class=citation><a name=d17740e8276 class=n-a></a>Bao GY, Wang HZ, Shang YJ, <i> et al.</i>: Quantitative proteomic study identified cathepsin B associated with doxorubicin-induced damage in H9c2 cardiomyocytes. <i>Biosci Trends.</i> 2012; <b>6</b>(6): 283–7. <a target=xrefwindow id=d17740e8287 href="http://www.ncbi.nlm.nih.gov/pubmed/23337787">PubMed Abstract </a> | <a target=xrefwindow id=d17740e8290 href="http://dx.doi.org/10.5582/bst.2012.v6.6.283">Publisher Full Text </a></span></li><li><a name=ref-144 class=n-a></a><span class=label>144. </span>&nbsp;<span class=citation><a name=d17740e8300 class=n-a></a>Petricoin EF, Rajapaske V, Herman EH, <i> et al.</i>: Toxicoproteomics: serum proteomic pattern diagnostics for early detection of drug induced cardiac toxicities and cardioprotection. <i>Toxicol Pathol.</i> 2004; <b>32 Suppl 1</b>: 122–30. <a target=xrefwindow id=d17740e8311 href="http://www.ncbi.nlm.nih.gov/pubmed/15209412">PubMed Abstract </a> | <a target=xrefwindow id=d17740e8314 href="http://dx.doi.org/10.1080/01926230490426516">Publisher Full Text </a></span></li><li><a name=ref-145 class=n-a></a><span class=label>145. </span>&nbsp;<span class=citation><a name=d17740e8323 class=n-a></a>Li Y, Ju L, Hou Z, <i> et al.</i>: Screening, verification, and optimization of biomarkers for early prediction of cardiotoxicity based on metabolomics. <i>J Proteome Res.</i> 2015; <b>14</b>(6): 2437–45. <a target=xrefwindow id=d17740e8334 href="http://www.ncbi.nlm.nih.gov/pubmed/25919346">PubMed Abstract </a> | <a target=xrefwindow id=d17740e8337 href="http://dx.doi.org/10.1021/pr501116c">Publisher Full Text </a></span></li><li><a name=ref-146 class=n-a></a><span class=label>146. </span>&nbsp;<span class=citation><a name=d17740e8346 class=n-a></a>Todorova VK, Beggs ML, Delongchamp RR, <i> et al.</i>: Transcriptome profiling of peripheral blood cells identifies potential biomarkers for doxorubicin cardiotoxicity in a rat model. <i>PLoS One.</i> 2012; <b>7</b>(11): e48398. <a target=xrefwindow id=d17740e8357 href="http://www.ncbi.nlm.nih.gov/pubmed/23209553">PubMed Abstract </a> | <a target=xrefwindow id=d17740e8360 href="http://dx.doi.org/10.1371/journal.pone.0048398">Publisher Full Text </a> | <a target=xrefwindow id=d17740e8364 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3507887">Free Full Text </a></span></li><li><a name=ref-147 class=n-a></a><span class=label>147. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726288918"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d17740e8373 class=n-a></a>Lenihan DJ, Stevens PL, Massey M, <i> et al.</i>: The Utility of Point-of-Care Biomarkers to Detect Cardiotoxicity During Anthracycline Chemotherapy: A Feasibility Study. <i>J Card Fail.</i> 2016; <b>22</b>(6): 433–8. <a target=xrefwindow id=d17740e8384 href="http://www.ncbi.nlm.nih.gov/pubmed/27079675">PubMed Abstract </a> | <a target=xrefwindow id=d17740e8387 href="http://dx.doi.org/10.1016/j.cardfail.2016.04.003">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726288918">F1000 Recommendation</a></span></li><li><a name=ref-148 class=n-a></a><span class=label>148. </span>&nbsp;<span class=citation><a name=d17740e8400 class=n-a></a>Kim YH, Kirsop J, Tang WH: Alternative Biomarkers for Combined Biology. <i>Heart Fail Clin.</i> 2017; <b>13</b>(2): 381–401. <a target=xrefwindow id=d17740e8408 href="http://www.ncbi.nlm.nih.gov/pubmed/28279423">PubMed Abstract </a> | <a target=xrefwindow id=d17740e8411 href="http://dx.doi.org/10.1016/j.hfc.2016.12.009">Publisher Full Text </a> | <a target=xrefwindow id=d17740e8414 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5347470">Free Full Text </a></span></li><li><a name=ref-149 class=n-a></a><span class=label>149. </span>&nbsp;<span class=citation><a name=d17740e8423 class=n-a></a>Oliveira-Carvalho V, Ferreira LR, Bocchi EA: Circulating mir-208a fails as a biomarker of doxorubicin-induced cardiotoxicity in breast cancer patients. <i>J Appl Toxicol.</i> 2015; <b>35</b>(9): 1071–2. <a target=xrefwindow id=d17740e8431 href="http://www.ncbi.nlm.nih.gov/pubmed/26046768">PubMed Abstract </a> | <a target=xrefwindow id=d17740e8434 href="http://dx.doi.org/10.1002/jat.3185">Publisher Full Text </a></span></li><li><a name=ref-150 class=n-a></a><span class=label>150. </span>&nbsp;<span class=citation><a name=d17740e8444 class=n-a></a>Steinberg JS, Cohen AJ, Wasserman AG, <i> et al.</i>: Acute arrhythmogenicity of doxorubicin administration. <i>Cancer.</i> 1987; <b>60</b>(6): 1213–8. <a target=xrefwindow id=d17740e8455 href="http://www.ncbi.nlm.nih.gov/pubmed/3621107">PubMed Abstract </a> | <a target="xrefwindow" id="d17740e8458" href="http://dx.doi.org/10.1002/1097-0142(19870915)60:6<1213::AID-CNCR2820600609&gt;3.0.CO;2-V">Publisher Full Text </a></span></li><li><a name=ref-151 class=n-a></a><span class=label>151. </span>&nbsp;<span class=citation><a name=d17740e8467 class=n-a></a>Schwartz RG, McKenzie WB, Alexander J, <i> et al.</i>: Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography. <i>Am J Med.</i> 1987; <b>82</b>(6): 1109–18. <a target=xrefwindow id=d17740e8478 href="http://www.ncbi.nlm.nih.gov/pubmed/3605130">PubMed Abstract </a> | <a target=xrefwindow id=d17740e8481 href="http://dx.doi.org/10.1016/0002-9343(87)90212-9">Publisher Full Text </a></span></li><li><a name=ref-152 class=n-a></a><span class=label>152. </span>&nbsp;<span class=citation><a name=d17740e8490 class=n-a></a>McKillop JH, Bristow MR, Goris ML, <i> et al.</i>: Sensitivity and specificity of radionuclide ejection fractions in doxorubicin cardiotoxicity. <i>Am Heart J.</i> 1983; <b>106</b>(5 Pt 1): 1048–56. <a target=xrefwindow id=d17740e8501 href="http://www.ncbi.nlm.nih.gov/pubmed/6637763">PubMed Abstract </a> | <a target=xrefwindow id=d17740e8504 href="http://dx.doi.org/10.1016/0002-8703(83)90651-8">Publisher Full Text </a></span></li><li><a name=ref-153 class=n-a></a><span class=label>153. </span>&nbsp;<span class=citation><a name=d17740e8513 class=n-a></a>Gottdiener JS, Mathisen DJ, Borer JS, <i> et al.</i>: Doxorubicin cardiotoxicity: assessment of late left ventricular dysfunction by radionuclide cineangiography. <i>Ann Intern Med.</i> 1981; <b>94</b>(4 pt 1): 430–5. <a target=xrefwindow id=d17740e8524 href="http://www.ncbi.nlm.nih.gov/pubmed/7212498">PubMed Abstract </a></span></li><li><a name=ref-154 class=n-a></a><span class=label>154. </span>&nbsp;<span class=citation><a name=d17740e8533 class=n-a></a>Thavendiranathan P, Grant AD, Negishi T, <i> et al.</i>: Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes: application to patients undergoing cancer chemotherapy. <i>J Am Coll Cardiol.</i> 2013; <b>61</b>(1): 77–84. <a target=xrefwindow id=d17740e8544 href="http://www.ncbi.nlm.nih.gov/pubmed/23199515">PubMed Abstract </a> | <a target=xrefwindow id=d17740e8547 href="http://dx.doi.org/10.1016/j.jacc.2012.09.035">Publisher Full Text </a></span></li><li><a name=ref-155 class=n-a></a><span class=label>155. </span>&nbsp;<span class=citation><a name=d17740e8556 class=n-a></a>Khouri MG, Hornsby WE, Risum N, <i> et al.</i>: Utility of 3-dimensional echocardiography, global longitudinal strain, and exercise stress echocardiography to detect cardiac dysfunction in breast cancer patients treated with doxorubicin-containing adjuvant therapy. <i>Breast Cancer Res Treat.</i> 2014; <b>143</b>(3): 531–9. <a target=xrefwindow id=d17740e8567 href="http://www.ncbi.nlm.nih.gov/pubmed/24390149">PubMed Abstract </a> | <a target=xrefwindow id=d17740e8570 href="http://dx.doi.org/10.1007/s10549-013-2818-1">Publisher Full Text </a> | <a target=xrefwindow id=d17740e8574 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4521213">Free Full Text </a></span></li><li><a name=ref-156 class=n-a></a><span class=label>156. </span>&nbsp;<span class=citation><a name=d17740e8584 class=n-a></a>Walker J, Bhullar N, Fallah-Rad N, <i> et al.</i>: Role of three-dimensional echocardiography in breast cancer: comparison with two-dimensional echocardiography, multiple-gated acquisition scans, and cardiac magnetic resonance imaging. <i>J Clin Oncol.</i> 2010; <b>28</b>(21): 3429–36. <a target=xrefwindow id=d17740e8595 href="http://www.ncbi.nlm.nih.gov/pubmed/20530277">PubMed Abstract </a> | <a target=xrefwindow id=d17740e8598 href="http://dx.doi.org/10.1200/JCO.2009.26.7294">Publisher Full Text </a></span></li><li><a name=ref-157 class=n-a></a><span class=label>157. </span>&nbsp;<span class=citation><a name=d17740e8607 class=n-a></a>Negishi K, Negishi T, Haluska BA, <i> et al.</i>: Use of speckle strain to assess left ventricular responses to cardiotoxic chemotherapy and cardioprotection. <i>Eur Heart J Cardiovasc Imaging.</i> 2014; <b>15</b>(3): 324–31. <a target=xrefwindow id=d17740e8618 href="http://www.ncbi.nlm.nih.gov/pubmed/24057661">PubMed Abstract </a> | <a target=xrefwindow id=d17740e8621 href="http://dx.doi.org/10.1093/ehjci/jet159">Publisher Full Text </a></span></li><li><a name=ref-158 class=n-a></a><span class=label>158. </span>&nbsp;<span class=citation><a name=d17740e8630 class=n-a></a>Armstrong GT, Plana JC, Zhang N, <i> et al.</i>: Screening adult survivors of childhood cancer for cardiomyopathy: comparison of echocardiography and cardiac magnetic resonance imaging. <i>J Clin Oncol.</i> 2012; <b>30</b>(23): 2876–84. <a target=xrefwindow id=d17740e8641 href="http://www.ncbi.nlm.nih.gov/pubmed/22802310">PubMed Abstract </a> | <a target=xrefwindow id=d17740e8644 href="http://dx.doi.org/10.1200/JCO.2011.40.3584">Publisher Full Text </a> | <a target=xrefwindow id=d17740e8648 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3671529">Free Full Text </a></span></li><li><a name=ref-159 class=n-a></a><span class=label>159. </span>&nbsp;<span class=citation><a name=d17740e8657 class=n-a></a>Drafts BC, Twomley KM, D'Agostino R Jr, <i> et al.</i>: Low to moderate dose anthracycline-based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease. <i>JACC Cardiovasc Imaging.</i> 2013; <b>6</b>(8): 877–85. <a target=xrefwindow id=d17740e8668 href="http://www.ncbi.nlm.nih.gov/pubmed/23643285">PubMed Abstract </a> | <a target=xrefwindow id=d17740e8671 href="http://dx.doi.org/10.1016/j.jcmg.2012.11.017">Publisher Full Text </a> | <a target=xrefwindow id=d17740e8675 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3745801">Free Full Text </a></span></li><li><a name=ref-160 class=n-a></a><span class=label>160. </span>&nbsp;<span class=citation><a name=d17740e8684 class=n-a></a>Lightfoot JC, D'Agostino RB Jr, Hamilton CA, <i> et al.</i>: Novel approach to early detection of doxorubicin cardiotoxicity by gadolinium-enhanced cardiovascular magnetic resonance imaging in an experimental model. <i>Circ Cardiovasc Imaging.</i> 2010; <b>3</b>(5): 550–8. <a target=xrefwindow id=d17740e8695 href="http://www.ncbi.nlm.nih.gov/pubmed/20622140">PubMed Abstract </a> | <a target=xrefwindow id=d17740e8698 href="http://dx.doi.org/10.1161/CIRCIMAGING.109.918540">Publisher Full Text </a> | <a target=xrefwindow id=d17740e8702 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3068484">Free Full Text </a></span></li><li><a name=ref-161 class=n-a></a><span class=label>161. </span>&nbsp;<span class=citation><a name=d17740e8711 class=n-a></a>Jordan JH, D'Agostino RB Jr, Hamilton CA, <i> et al.</i>: Longitudinal assessment of concurrent changes in left ventricular ejection fraction and left ventricular myocardial tissue characteristics after administration of cardiotoxic chemotherapies using T1-weighted and T2-weighted cardiovascular magnetic resonance. <i>Circ Cardiovasc Imaging.</i> 2014; <b>7</b>(6): 872–9. <a target=xrefwindow id=d17740e8722 href="http://www.ncbi.nlm.nih.gov/pubmed/25273568">PubMed Abstract </a> | <a target=xrefwindow id=d17740e8725 href="http://dx.doi.org/10.1161/CIRCIMAGING.114.002217">Publisher Full Text </a> | <a target=xrefwindow id=d17740e8729 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4241241">Free Full Text </a></span></li><li><a name=ref-162 class=n-a></a><span class=label>162. </span>&nbsp;<span class=citation><a name=d17740e8739 class=n-a></a>Jones LW, Courneya KS, Mackey JR, <i> et al.</i>: Cardiopulmonary function and age-related decline across the breast cancer survivorship continuum. <i>J Clin Oncol.</i> 2012; <b>30</b>(20): 2530–7. <a target=xrefwindow id=d17740e8750 href="http://www.ncbi.nlm.nih.gov/pubmed/22614980">PubMed Abstract </a> | <a target=xrefwindow id=d17740e8753 href="http://dx.doi.org/10.1200/JCO.2011.39.9014">Publisher Full Text </a> | <a target=xrefwindow id=d17740e8757 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3397786">Free Full Text </a></span></li><li><a name=ref-163 class=n-a></a><span class=label>163. </span>&nbsp;<span class=citation><a name=d17740e8766 class=n-a></a>Su H, Gorodny N, Gomez LF, <i> et al.</i>: Noninvasive molecular imaging of apoptosis in a mouse model of anthracycline-induced cardiotoxicity. <i>Circ Cardiovasc Imaging.</i> 2015; <b>8</b>(2): e001952. <a target=xrefwindow id=d17740e8777 href="http://www.ncbi.nlm.nih.gov/pubmed/25657296">PubMed Abstract </a> | <a target=xrefwindow id=d17740e8780 href="http://dx.doi.org/10.1161/CIRCIMAGING.114.001952">Publisher Full Text </a> | <a target=xrefwindow id=d17740e8784 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4384653">Free Full Text </a></span></li></ul></div></div></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 28 Sep 2018</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/7-1566.html&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/7-1566.html&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> <div class="f1r-article-mobile margin-bottom-30"> <div class=contracted-details> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> Section of Heart Failure and Transplantation Medicine, Robert and Suzanne Tomsich Department of Cardiovascular Medicine, and Sydell and Arnold Miller Family Heart and Vascular Institute, Cleveland Clinic, Cleveland, USA<br/> <sup>2</sup> Cleveland Clinic Lerner College of Medicine at Case Western Reserve University; Center for Clinical Genomics; Cleveland Clinic, Cleveland, USA<br/> <p> <div class=margin-bottom> J. Emanuel Finet <br/> <span>Roles: </span> Conceptualization, Data Curation, Writing – Original Draft Preparation </div> <div class=margin-bottom> W. H. Wilson Tang <br/> <span>Roles: </span> Conceptualization, Funding Acquisition, Writing – Review & Editing </div> </p> </div> </div> <div class=contracted-details> <a href="#" class=section-title>Article Versions (1)</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> <div> <a href="https://f1000research.com/articles/7-1566/v1" title="Open version 1 of this article." class="" gahelper=1>version 1</a> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div> Published: 28 Sep 2018, 7:1566 </div> <div class=""><a href="https://doi.org/10.12688/f1000research.15190.1">https://doi.org/10.12688/f1000research.15190.1</a></div> </div> </div> <div class=contracted-details> <a href="#" class=section-title> <span class="f1r-icon icon-100_open_access"></span> Copyright </a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> © 2018 Finet JE and Tang WHW. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </div> </div> <div class="padding-top-30 research-layout"> <div class=article-toolbox-wrapper-mobile> <div class=article-tools-icon-mobile data-section=download> <span class="f1r-icon icon-76_download_file white"></span> </div> <div class="article-tools-icon-mobile mobile-metrics article-metrics-wrapper metrics-icon-wrapper" data-section=metrics data-version-id=16550 data-id=15190 data-downloads="" data-views="" data-scholar="10.12688/f1000research.15190.1" data-recommended="" data-f1r-ga-helper="Article Page Metrics (Mobile)"> <span class="f1r-icon icon-89_metrics white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=cite> <span class="f1r-icon icon-82_quote white"></span> </div> <div class="article-tools-icon-mobile " data-section=track> <span class="f1r-icon icon-90_track white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=share> <span class="f1r-icon icon-34_share white"></span> </div> <span class=article-toolbox-stretch></span> </div> <div class=article-toolbox-content-mobile> <div class="toolbox-section download"> <div class=toolbox-section-heading>Download</div> <div class=toolbox-section-content> <a href="https://f1000research.com/articles/7-1566/v1/pdf?article_uuid=6187c644-06df-464f-8554-a8942e79cdcc" title="Download PDF" class="no-decoration pdf-download-helper"> <span class="f1r-icon icon-102_download_pdf toolbox-section-icon"></span> </a> <div class=toolbox-section-option-divider>&nbsp;</div> <a id=mobile-download-xml class=no-decoration href="#" title="Download XML"> <span class="f1r-icon icon-103_download_xml toolbox-section-icon"></span> </a> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>Export To</div> <div class=toolbox-section-content> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=WORKSPACE>Sciwheel</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=BIBTEX>Bibtex</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=ENDNOTE>EndNote</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=PROCITE>ProCite</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=REF_MANAGER>Ref. Manager (RIS)</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=SENTE>Sente</button> </div> </div> <div class="toolbox-section metrics"> <div class="toolbox-section-heading no-top-border">metrics</div> <div class="toolbox-section-divider toolbox-section-divider--no-height"></div> <div class=article-metrics-pageinfo> <div class=c-article-metrics-table> <table class=c-article-metrics-table__table> <thead> <tr> <th></th> <th><span class=c-article-metrics-table__heading>Views</span></th> <th><span class=c-article-metrics-table__heading>Downloads</span></th> </tr> </thead> <tbody> <tr> <th class=c-article-metrics-table__row-heading><span class="c-article-metrics-table__platform u-platform--" data-test-id=metrics_platform_name_mob>F1000Research</span></th> <td class="c-article-metrics-table__value js-article-views-count" data-test-id=metrics_platform_views_mob>-</td> <td class="c-article-metrics-table__value js-article-downloads-count" data-test-id=metrics_platform_downloads_mob>-</td> </tr> <tr> <th class=c-article-metrics-table__row-heading> <span class="u-ib u-middle c-article-metrics-table__pmc" data-test-id=metrics_pmc_name_mob>PubMed Central</span> <div class="c-block-tip c-block-tip--centered c-article-metrics-table__tooltip c-block-tip--md-padding c-block-tip--small-arrow u-ib u-middle"> <button type=button class="u-black--medium u-black--high@hover u-ib u-middle c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content>Data from PMC are received and updated monthly.</div> </div> </th> <td class="c-article-metrics-table__value js-pmc-views-count" data-test-id=metrics_pmc_views_mob>-</td> <td class="c-article-metrics-table__value js-pmc-downloads-count" data-test-id=metrics_pmc_downloads_mob>-</td> </tr> </tbody> </table> </div> </div> <span class=metrics-citations-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-heading u-mb--1">Citations</div> <div> <div class=toolbox-section-colsplit> <div class=citations-scopus-logo> <a href="" target=_blank class="is-hidden metrics-citation-icon" title="View full citation details at www.scopus.com"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count scopus"> <a href='' class='scopus-citation-link is-hidden' target=_blank title='View full citation details at www.scopus.com'>0</a> </div> </div> <div class=toolbox-section-colsplit> <div class="citations-pubmed-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon f1000research" title="View full citation details"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count pubmed"> <a href='' class='pubmed-citation-link is-hidden' target=_blank title='View full citation details'>0</a> </div> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <div class="citations-scholar-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon google-scholar f1000research" title="View full citation details" data-scholar="10.12688/f1000research.15190.1"><i class="material-icons scopus-icon">open_in_new</i></a> </div> </div> </div> </span> <span class=metrics-details-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-content altmetric-section"> <div class=altmetrics-image></div> <div class=altmetrics-more-link> <a href="" target=_blank class=f1r-standard-link>SEE MORE DETAILS</a> </div> <div class=altmetric-mobile-column-counts></div> <div class=altmetric-mobile-column-readers></div> <div class=toolbox-section-divider></div> </div> </span> </div> <div class="toolbox-section cite"> <div class="toolbox-section-heading no-top-border">CITE</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>how to cite this article</div> <div id=citation-copy-mobile class="toolbox-section-content text-content heading9 small" data-test-id=mob_copy-citation_text> Finet JE and Tang WHW. Protecting the heart in cancer therapy [version 1; peer review: 2 approved] <i>F1000Research</i> 2018, <b>7</b>(F1000 Faculty Rev):1566 (<a href="https://doi.org/10.12688/f1000research.15190.1" target=_blank>https://doi.org/10.12688/f1000research.15190.1</a>) </div> <div class=toolbox-section-divider></div> <div class="toolbox-section-content text-content heading9 small"> NOTE: <em>it is important to ensure the information in <b>square brackets after the title</b> is included in all citations of this article.</em> </div> <div class=toolbox-section-content> <button class="primary orange extra-padding copy-cite-article-mobile js-clipboard" data-clipboard-target="#citation-copy-mobile" title="Copy the current citation details." data-test-id=mob_copy-citation_button-mob>COPY CITATION DETAILS</button> </div> </div> <div class="toolbox-section track"> <div class="toolbox-section-heading no-top-border">track</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>receive updates on this article</div> <div class="toolbox-section-content padding-left-20 padding-right-20 heading9 small"> Track an article to receive email alerts on any updates to this article. </div> <div class=toolbox-section-content> <a data-article-id=15190 id=mobile-track-article-signin-15190 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/15190?target=/articles/7-1566.html"> <button class="primary orange extra-padding"> TRACK THIS ARTICLE </button> </a> </div> </div> <div class="toolbox-section share"> <div class="toolbox-section-heading no-top-border">Share</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <a target=_blank class="f1r-shares-icon-square f1r-shares-email" title="Email this article"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-twitter" title="Share on Twitter"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-facebook" title="Share on Facebook"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-linkedin" title="Share on LinkedIn"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-reddit" title="Share on Reddit"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-mendelay" title="Share on Mendeley"></a> <div class="email-article-wrapper email-article-version-container"> <div class=toolbox-section-divider></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form-mobile research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=16550 /> <input name=articleId type=hidden value=15190 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> </div> </div> </div> <a name=article-reports></a> <div id=article-reports class="u-mt--3 reports-comments no-divider"> <div class="current-referee-status current-referee-status--faculty "> <h2 class=main-title id=current-referee-status> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-85_peer_review size30"></span> </span> Open Peer Review <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> <a name=current-referee-status></a> <div class=current-referee-status__content name=add-new-report-comment id=add-new-report-comment> Current Reviewer Status: <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile"> <div class=mobile-ref-status-help> Key to Reviewer Statuses <span class=referee-status-pointer></span> <span class="view-control float-right">VIEW</span> <span class="view-control float-right is-hidden">HIDE</span> <div class=mobile-ref-status-help-content> <div class="cf margin-top"> <span class="f1r-icon icon-86_approved status-green smaller float-left margin-bottom-40 margin-right" title=Approved></span> <span class=title>Approved</span>The paper is scientifically sound in its current form and only minor, if any, improvements are suggested </div> <div class="cf margin-top"> <span class="f1r-icon icon-87_approved_reservations status-green smaller float-left margin-bottom-40 margin-right" title="Approved with Reservations"></span> <span class=title>Approved with reservations</span> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </div> <div class="cf margin-top"> <span class="f1r-icon icon-88_not_approved status-red small float-left margin-bottom-30 margin-right" title="Not Approved"></span> <span class=title>Not approved</span>Fundamental flaws in the paper seriously undermine the findings and conclusions </div> </div> </div> </span> <div class=editorial-note> <h5 class=editorial-note__title>Editorial Note on the Review Process</h5> <p class=editorial-note__text><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home">Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> </div> <div class=approved-referee> <h4 class=approved-referee__title>Reviewers who approved this article</h4> <ol class=approved-referee__list> <li class="approved-referee__list-item "> <span class=approved-referee__co-referee> <strong>Edimar A Bocchi</strong>, Heart Failure Department, Heart Institute (InCor) do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, Brazil </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> <span class=approved-referee__co-referee> <strong>Monica S &Aacute;vila</strong>, Heart Failure Department, Heart Institute (InCor) do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, Brazil </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Ana Barac</strong>, Medstar Washington Hospital Center, Medstar Heart and Vascular Institute, USA </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> </ol> </div> </div> </div> </div> <div class="f1r-article-mobile research-layout"> <div class="mobile-sections-divider before-comments"></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 28 Sep 2018</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/7-1566.html&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/7-1566.html&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> </div> </div> <div id=article_main-column class="p-article__sidebar o-layout__item u-1/3 not-expanded js-article-sidebar"> <div class="o-tab p-article__column-toggle-container"> <button class="c-tab c-tab--left js-column-toggle p-article__column-toggle not-expanded " type=button data-target-main=article_main-column data-target-secondary=article_secondary-column><i class="c-tab__icon material-icons u-hide@expanded">keyboard_arrow_left</i><i class="c-tab__icon material-icons u-show@expanded">keyboard_arrow_right</i></button> </div> <div class=p-article__sidebar-content> <div class="p-article__sidebar-scroller js-article-sidebar-scroller"> <section class="p-article__sidebar-view js-article-sidebar-view js-article-sidebar-main u-pt u-pb--8" data-view=peer-review> <div class="o-layout o-layout--flush"> <div class="o-layout__item u-pl"> <h3 class="u-mt--0 u-mb--2 t-h3 u-weight--md u-pl" data-test-id=article_sidebar_heading>Open Peer Review</h3> </div> <div class=o-layout__item> <section class=""> <div class="p-article__sidebar-highlight u-mb--2 u-pr--1"> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md u-mr--1/2">Reviewer Status</h4> <div class="c-referee-status__icons u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=39294-38452></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=39295-38453></i> </div> </div> <div class="o-actions__secondary _mdl-layout"> <div class="c-block-tip p-article__sidebar-tooltip c-block-tip--below c-block-tip--small-arrow c-block-tip--sm-padding"> <button type=button class="c-button c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content> <p class="t-body u-mt--0 u-mb--0"><em class=u-weight--md>Alongside their report, reviewers assign a status to the article:</em></p> <dl class=c-definitions> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved</span></dt> <dd class="c-definitions__description t-caption">The paper is scientifically sound in its current form and only minor, if any, improvements are suggested</dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--reservations" title="Approved with Reservations" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved with reservations</span></dt> <dd class="c-definitions__description t-caption"> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--not-approved " title="Not Approved" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Not approved</span></dt> <dd class="c-definitions__description t-caption">Fundamental flaws in the paper seriously undermine the findings and conclusions</dd> </dl> </div> </div> </div> </div> </div> <div class="o-layout__item u-mb--1"><h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md">Reviewer Reports</h4></div> <table class="c-report-timeline u-mb--2"> <thead class=c-report-timeline__headings> <tr> <th></th> <th class="u-pb--1/2" colspan=2><em class="t-body u-weight--rg">Invited Reviewers</em></th> </tr> <tr class=c-report-timeline__headings-row> <th></th> <th class="c-report-timeline__headings-version p-article__color--dark">1</th> <th class="c-report-timeline__headings-version p-article__color--dark">2</th> </tr> </thead> <tbody> <tr class="c-report-timeline__row c-report-timeline__row--selected "> <th class=c-report-timeline__version> <a data-test-id=sidebar_timeline_v1_version href="https://f1000research.com/articles/7-1566/v1">Version 1</a><br/> <span class=p-article__color--dark> <span data-test-id=sidebar_timeline_v1_date class=c-report-timeline__date>28 Sep 18</span> </span> </th> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> </tr> </tbody> </table> <div class=o-layout__item> <hr class="c-hr c-hr--low u-mb--2"> </div> </section> </div> <div class=o-layout__item> <div class="u-pl u-pr"> <p class="t-body u-mt--0 u-mb--2"><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home" target=_blank class=in-text-link>Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> <ol class="p-article__faculty-referee-list t-caption"> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Edimar A Bocchi</strong>, Heart Failure Department, Heart Institute (InCor) do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, Brazil </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> <p class=" u-mt--2 u-mb--1/2"><strong>Monica S &Aacute;vila</strong>, Heart Failure Department, Heart Institute (InCor) do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, Brazil </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Ana Barac</strong>, Medstar Washington Hospital Center, Medstar Heart and Vascular Institute, USA </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> </ol> </div> </div> <section class="o-layout__item u-pl"> <div class=u-pl> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--2">Comments on this article</h4> <div class=u-mb--4> <p class="u-mt--0 u-mb--1 t-h4"><a class=p-article__color--light href="#article-comments">All Comments</a><span class=" u-ib u-ml--1/2 p-article__color--light">(0)</span></p> <a class=t-h4 href="/login?originalPath=/articles/7-1566.html&scrollTo=add-new-comment" data-test-id=add-comment>Add a comment</a> </div> <hr class="c-hr c-hr--low c-hr--md u-mb--4"> <div class="research-layout f1r-article-desk"> <div class="heading6 c-ribbon-wrapper c-ribbon-wrapper--etoc f1000research "> <div class=c-ribbon-wrapper__body>Sign up for content alerts</div> </div> </div> <div class="research-layout sidebar-sign-up-form f1r-article-desk u-mb--4 "> <form class=js-email-alert-signup action="#" method=POST data-email=tocAlertWeekly> <input type=hidden name=isUserLoggedIn class=js-email-alert-signup-logged-in value=N /> <input type=hidden name=userId class=js-email-alert-signup-user-id value=""/> <input type=hidden name=frequency class=js-email-alert-signup-frequency value=WEEKLY /> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <input type=email name=emailAddress class="form-input-field js-email-alert-signup-address u-1/1 u-bb" required=required placeholder=Email /> </div> <div class=o-actions__secondary> <div class="_mdl-layout u-ml--1/2"> <button class="mdl-button mdl-js-button mdl-button--colored mdl-button--small mdl-button--filled js-email-alert-signup-submit">Sign Up</button> </div> </div> </div> </form> <div id=sidebar-sign-up-message class="section-text js-email-alert-signup-msg is-hidden">You are now signed up to receive this alert</div> </div> <section class=js-terms-container> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--1">Browse by related subjects</h4> <div class="article-subcontainer article-subcontainer--sidebar"> <ul class=js-terms-list></ul> </div> </section> </div> </section> </div> </section> </div> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/read-more.js"></script> <script src="/js/article/article-router.js"></script> <script src="/js/article/article-sidebar.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/article/article-column-toggle.js"></script> </div> </div> </div> </main> <input type=hidden id=_articleVersionUrl value="https://f1000research.com/articles/7-1566/v1/"> <div class=research-help id=about-referee-status> <div class="research-layout research-help-content about-referee-status"> <span class="close-research-help dark-cross" title=Close></span> Alongside their report, reviewers assign a status to the article: <div class="cf research-help-row"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> <span class=research-help-text>Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested</span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-87_approved_reservations status-green smaller" title="Approved with Reservations"></span> <span class=research-help-text>Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-88_not_approved status-red small" title="Not Approved"></span> <span class=research-help-text>Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions</span> </div> </div> </div> <div id=datasets-info class=is-hidden> </div> <div class=article-interactive-content-container style="display: none;"> <a name=f-template class=n-a></a> <div class="interactive-content-wrapper padding-20"> <img src="" class=interactive-content-image title="Open the interactive image display"> <div class=interactive-content-title></div> <div class=interactive-content-text></div> <div class="f1r-article-desk interactive-content-ribbon" data-interactive-content-type=R-Script> <div class=interactive-content-label>Adjust parameters to alter display</div> <div class=interactive-content-button></div> </div> <div class="f1r-article-mobile mobile-interactive-note"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div id=article-interactive-omero-container class=article-interactive-omero-container style="display: none;"> <div class=interactive-content-wrapper> <div class="interactive-omero-button omero-content" title="Open the interactive content window." data-interactive-content-type=Omero></div> <div class=has-interactive-content-image> <span class=box-arrow></span> <span class=box-middle>Includes Interactive Elements</span> <span class=box-end></span> </div> <div class="fig panel clearfix" style="margin: 0; padding-bottom: 20px;"> <a name=templatelink class=n-a></a> <a target=_blank href="" class=link-for-omero-image> <img src="" class=interactive-omero-image title="Open the image display window."> </a> <div class=caption> <div class=interactive-content-title></div> <div class=interactive-content-text></div> </div> <div class="is-hidden omero-image-list"></div> </div> <div class="f1r-article-mobile mobile-interactive-note omero"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div class="add-comment-container shadow-box is-hidden" id=save-comment-container> <span id=save-comment-text class=intro-text>Edit comment</span> <textarea id=new-comment name=new-comment class="global-textarea comment margin-bottom margin-top"></textarea> <p><strong>Competing Interests</strong></p> <textarea id=new-competing-interests name=competing-interests class="global-textarea competing-interests margin-bottom check-xss"></textarea> <div class=clearfix></div> <button id=cancelComment type=button class="general-white-orange-button float-right no-background-button margin-left"> Cancel </button> <button id=save-comment-button commentId="" type=button class="general-white-orange-button float-right"> Save </button> <div class=clearfix></div> <div class="green-message margin-top is-hidden comment-is-saved">The comment has been saved.</div> <div class="red-message margin-top is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class="red-message margin-top is-hidden comment-enter-text ucf">Your must enter a comment.</div> <div class="red-message margin-top is-hidden comment-references-error references">References error.</div> </div> <div class="modal-window-wrapper is-hidden"> <div id=conflicts-interests class="modal-window padding-20"> <div class=modal-window__content> <h2 class=h2-title>Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div class="f1r-article-mobile research-layout"> <span class=modal-window-close-button></span> </div> </div> </div> <div class="o-modal c-email-alert-popup js-email-alert-popup is-hidden"> <div class="o-modal__body js-modal-body c-email-alert-popup__inner"> <h3 class=c-email-alert-popup__title>Stay Updated</h3> <p class=c-email-alert-popup__sub>Sign up for content alerts and receive a weekly or monthly email with all newly published articles</p> <p><a href="/register?originalPath=" class="c-email-alert-popup__lnk c-email-alert-popup__button js-email-alert-popup-action">Register with F1000Research</a></p> <p>Already registered? <a href="/login?originalPath=" class="c-email-alert-popup__lnk js-email-alert-popup-action">Sign in</a></p> <p class=c-email-alert-popup__footer><a class="c-email-alert-popup__lnk js-email-alert-popup-cancel" href="#">Not now, thanks</a></p> </div> </div> <div id=addCommentModal role=dialog aria-labelledby=addCommentModal_title aria-describedby=addCommentModal_description> <div class="c-modal js-modal is-closed p-article__add-comment-modal c-modal--xlarge js-article-comment-modal c-modal--scroll "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-bg--2 c-modal--scroll-always "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <div id=addCommentModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div class="js-add-comment-container t-caption u-black--high"> <div class=u-weight--bd>PLEASE NOTE</div> <div class=u-mt--1> <span class="red u-weight--bd">If you are an AUTHOR of this article,</span> please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a &ldquo;User Comment&rdquo;. </div> <div class=u-mt--1> <span class="red u-weight--bd">If you are a REVIEWER of this article,</span> please check that you have signed in with the account associated with this article and then go to your <a href="/my/referee">account</a> to submit your report, please do not post your review here. </div> <div class="u-mt--1 u-mb--1"> If you do not have access to your original account, please <a href="mailto:research@f1000.com">contact us</a>. </div> <p class=no-top-margin>All commenters must hold a formal affiliation as per our <a href="/about/policies#commentspolicy" target=_blank>Policies</a>. The information that you give us will be displayed next to your comment.</p> <p>User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the <a href="/about/legal/usercommenttermsandconditions" target=_blank>User Comment Terms and Conditions</a>. Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available.</p> <div class="comments-note margin-bottom" id=accept-user-comments> <input class=js-add-comment-accept-terms type=checkbox id=acceptedTermsAndConditions name=acceptedTermsAndConditions> I accept the <a href="/about/legal/usercommenttermsandconditions" target=_blank> User Comment Terms and Conditions</a> <span class=required>&nbsp;</span> </div> <div class="default-error margin-top is-hidden comment-accept-conditions utac">Please confirm that you accept the User Comment Terms and Conditions.</div> <div class="research-layout registration-form u-mb--2"> <div class="u-mb--1 u-mt--2"> <strong>Affiliation</strong> </div> <div class=form-field> <input type=text name=institution class="form-input-field check-xss js-add-comment-institution" placeholder="Organization *" autocomplete=off /> <div class="default-error margin-top is-hidden comment-enter-institution institution">Please enter your organisation.</div> </div> <div class=form-field> <input type=text name=place class="form-input-field check-xss js-add-comment-place" placeholder=Place> </div> <div class=form-field> <div class="form-input-wrapper hundred-percent-wide"> <div class="new-select-standard-wrapper half-width inline-display heading10"> <select name=countryId id=country class="form-select-menu smaller js-add-comment-country"> <option value=-1>Country*</option> <option value=840>USA</option> <option value=826>UK</option> <option value=124>Canada</option> <option value=156>China</option> <option value=250>France</option> <option value=276>Germany</option> <optgroup label=-----------------------------------------------></optgroup> <option value=4>Afghanistan</option> <option value=248>Aland Islands</option> <option value=8>Albania</option> <option value=12>Algeria</option> <option value=16>American Samoa</option> <option value=20>Andorra</option> <option value=24>Angola</option> <option value=660>Anguilla</option> <option value=10>Antarctica</option> <option value=28>Antigua and Barbuda</option> <option value=32>Argentina</option> <option value=51>Armenia</option> <option value=533>Aruba</option> <option value=36>Australia</option> <option value=40>Austria</option> <option value=31>Azerbaijan</option> <option value=44>Bahamas</option> <option value=48>Bahrain</option> <option value=50>Bangladesh</option> <option value=52>Barbados</option> <option value=112>Belarus</option> <option value=56>Belgium</option> <option value=84>Belize</option> <option value=204>Benin</option> <option value=60>Bermuda</option> <option value=64>Bhutan</option> <option value=68>Bolivia</option> <option value=70>Bosnia and Herzegovina</option> <option value=72>Botswana</option> <option value=74>Bouvet Island</option> <option value=76>Brazil</option> <option value=86>British Indian Ocean Territory</option> <option value=92>British Virgin Islands</option> <option value=96>Brunei</option> <option value=100>Bulgaria</option> <option value=854>Burkina Faso</option> <option value=108>Burundi</option> <option value=116>Cambodia</option> <option value=120>Cameroon</option> <option value=124>Canada</option> <option value=132>Cape Verde</option> <option value=136>Cayman Islands</option> <option value=140>Central African Republic</option> <option value=148>Chad</option> <option value=152>Chile</option> <option value=156>China</option> <option value=162>Christmas Island</option> <option value=166>Cocos (Keeling) Islands</option> <option value=170>Colombia</option> <option value=174>Comoros</option> <option value=178>Congo</option> <option value=184>Cook Islands</option> <option value=188>Costa Rica</option> <option value=384>Cote d'Ivoire</option> <option value=191>Croatia</option> <option value=192>Cuba</option> <option value=196>Cyprus</option> <option value=203>Czech Republic</option> <option value=180>Democratic Republic of the Congo</option> <option value=208>Denmark</option> <option value=262>Djibouti</option> <option value=212>Dominica</option> <option value=214>Dominican Republic</option> <option value=218>Ecuador</option> <option value=818>Egypt</option> <option value=222>El Salvador</option> <option value=226>Equatorial Guinea</option> <option value=232>Eritrea</option> <option value=233>Estonia</option> <option value=231>Ethiopia</option> <option value=238>Falkland Islands</option> <option value=234>Faroe Islands</option> <option value=583>Federated States of Micronesia</option> <option value=242>Fiji</option> <option value=246>Finland</option> <option value=250>France</option> <option value=254>French Guiana</option> <option value=258>French Polynesia</option> <option value=260>French Southern Territories</option> <option value=266>Gabon</option> <option value=268>Georgia</option> <option value=276>Germany</option> <option value=288>Ghana</option> <option value=292>Gibraltar</option> <option value=300>Greece</option> <option value=304>Greenland</option> <option value=308>Grenada</option> <option value=312>Guadeloupe</option> <option value=316>Guam</option> <option value=320>Guatemala</option> <option value=831>Guernsey</option> <option value=324>Guinea</option> <option value=624>Guinea-Bissau</option> <option value=328>Guyana</option> <option value=332>Haiti</option> <option value=334>Heard Island and Mcdonald Islands</option> <option value=336>Holy See (Vatican City State)</option> <option value=340>Honduras</option> <option value=344>Hong Kong</option> <option value=348>Hungary</option> <option value=352>Iceland</option> <option value=356>India</option> <option value=360>Indonesia</option> <option value=364>Iran</option> <option value=368>Iraq</option> <option value=372>Ireland</option> <option value=376>Israel</option> <option value=380>Italy</option> <option value=388>Jamaica</option> <option value=392>Japan</option> <option value=832>Jersey</option> <option value=400>Jordan</option> <option value=398>Kazakhstan</option> <option value=404>Kenya</option> <option value=296>Kiribati</option> <option value=901>Kosovo (Serbia and Montenegro)</option> <option value=414>Kuwait</option> <option value=417>Kyrgyzstan</option> <option value=418>Lao People's Democratic Republic</option> <option value=428>Latvia</option> <option value=422>Lebanon</option> <option value=426>Lesotho</option> <option value=430>Liberia</option> <option value=434>Libya</option> <option value=438>Liechtenstein</option> <option value=440>Lithuania</option> <option value=442>Luxembourg</option> <option value=446>Macao</option> <option value=807>Macedonia</option> <option value=450>Madagascar</option> <option value=454>Malawi</option> <option value=458>Malaysia</option> <option value=462>Maldives</option> <option value=466>Mali</option> <option value=470>Malta</option> <option value=584>Marshall Islands</option> <option value=474>Martinique</option> <option value=478>Mauritania</option> <option value=480>Mauritius</option> <option value=175>Mayotte</option> <option value=484>Mexico</option> <option value=581>Minor Outlying Islands of the United States</option> <option value=498>Moldova</option> <option value=492>Monaco</option> <option value=496>Mongolia</option> <option value=499>Montenegro</option> <option value=500>Montserrat</option> <option value=504>Morocco</option> <option value=508>Mozambique</option> <option value=104>Myanmar</option> <option value=516>Namibia</option> <option value=520>Nauru</option> <option value=524>Nepal</option> <option value=530>Netherlands Antilles</option> <option value=540>New Caledonia</option> <option value=554>New Zealand</option> <option value=558>Nicaragua</option> <option value=562>Niger</option> <option value=566>Nigeria</option> <option value=570>Niue</option> <option value=574>Norfolk Island</option> <option value=580>Northern Mariana Islands</option> <option value=408>North Korea</option> <option value=578>Norway</option> <option value=512>Oman</option> <option value=586>Pakistan</option> <option value=585>Palau</option> <option value=275>Palestinian Territory</option> <option value=591>Panama</option> <option value=598>Papua New Guinea</option> <option value=600>Paraguay</option> <option value=604>Peru</option> <option value=608>Philippines</option> <option value=612>Pitcairn</option> <option value=616>Poland</option> <option value=620>Portugal</option> <option value=630>Puerto Rico</option> <option value=634>Qatar</option> <option value=638>Reunion</option> <option value=642>Romania</option> <option value=643>Russian Federation</option> <option value=646>Rwanda</option> <option value=654>Saint Helena</option> <option value=659>Saint Kitts and Nevis</option> <option value=662>Saint Lucia</option> <option value=666>Saint Pierre and Miquelon</option> <option value=670>Saint Vincent and the Grenadines</option> <option value=882>Samoa</option> <option value=674>San Marino</option> <option value=678>Sao Tome and Principe</option> <option value=682>Saudi Arabia</option> <option value=686>Senegal</option> <option value=688>Serbia</option> <option value=690>Seychelles</option> <option value=694>Sierra Leone</option> <option value=702>Singapore</option> <option value=703>Slovakia</option> <option value=705>Slovenia</option> <option value=90>Solomon Islands</option> <option value=706>Somalia</option> <option value=710>South Africa</option> <option value=239>South Georgia and the South Sandwich Is</option> <option value=410>South Korea</option> <option value=724>Spain</option> <option value=144>Sri Lanka</option> <option value=736>Sudan</option> <option value=740>Suriname</option> <option value=744>Svalbard and Jan Mayen</option> <option value=748>Swaziland</option> <option value=752>Sweden</option> <option value=756>Switzerland</option> <option value=760>Syria</option> <option value=158>Taiwan</option> <option value=762>Tajikistan</option> <option value=834>Tanzania</option> <option value=764>Thailand</option> <option value=270>The Gambia</option> <option value=528>The Netherlands</option> <option value=626>Timor-Leste</option> <option value=768>Togo</option> <option value=772>Tokelau</option> <option value=776>Tonga</option> <option value=780>Trinidad and Tobago</option> <option value=788>Tunisia</option> <option value=792>Turkey</option> <option value=795>Turkmenistan</option> <option value=796>Turks and Caicos Islands</option> <option value=798>Tuvalu</option> <option value=800>Uganda</option> <option value=826>UK</option> <option value=804>Ukraine</option> <option value=784>United Arab Emirates</option> <option value=850>United States Virgin Islands</option> <option value=858>Uruguay</option> <option value=840>USA</option> <option value=860>Uzbekistan</option> <option value=548>Vanuatu</option> <option value=862>Venezuela</option> <option value=704>Vietnam</option> <option value=876>Wallis and Futuna</option> <option value=905>West Bank and Gaza Strip</option> <option value=732>Western Sahara</option> <option value=887>Yemen</option> <option value=894>Zambia</option> <option value=716>Zimbabwe</option> </select> </div> </div> <div class="default-error margin-top is-hidden comment-enter-country country">Please select your country.</div> </div> </div> <textarea data-test-id=article_add-comment_comment name=new-comment class="js-add-comment-comment comment margin-bottom margin-top"></textarea> <div class="default-error margin-top comment-enter-text comment-error is-hidden ">You must enter a comment.</div> <label class="comments-note u-mt--2 u-mb--2" for=competingInterests_1> <div class="u-mb--1 u-mt--2"><strong data-test-id=article_report-add-comment_competing-interests-title>Competing Interests</strong></div> <p class="u-mb--2 u-mt--0" data-test-id=article_report-add-comment_competing-interests-description>Please disclose any <a href="#article-competing-intersts-policy" class=js-modal-competing-intersts-toggle>competing interests</a> that might be construed to influence your judgment of the article's or peer review report's validity or importance.</p> </label> <div id=article-competing-intersts-policy class=js-article-competing-interests-policy style="display: none;"> <h2 class="h2-title u-mt--0 u-pt--0">Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div id=competingInterests_1 class="c-inline-editor js-inline-editor js-form_input u-bb--all u-mb--2 js-comment-competing-interests" data-name=competing-interests data-rows=3> <textarea id=competingInterests_1_input name=competing-interests placeholder="&nbsp;" required=false class="u-hide-visually js-inline-editor_input" tabindex=-1></textarea> <div class="c-inline-editor__editor js-inline-editor_editor o-box c-box o-box--tiny u-bg--11" data-target=competingInterests_1_input role=textbox required=false data-placeholder="&nbsp;" contenteditable=true></div> <span class="c-inline-editor__error js-inline-editor-message">Please state your competing interests</span> </div> <div data-test-id=article_add-comment_saved class="green-message comments is-hidden comment-is-saved">The comment has been saved.</div> <div data-test-id=article_add-comment_error class="default-error comments is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class=clearfix></div> <div class=js-hook></div> </div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" data-test-id=article_add-comment_cancel class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" data-test-id=article_add-comment_post class="c-button c-button--full js-modal__confirm c-button--primary">Post</a> </div> </aside> </div> </div> <style>
                .at-icon-wrapper {
        background-size: 100% !important;
    }
</style> <script src="/js/namespace.js"></script> <script src="/js/constants.js"></script> <script src="/js/utilities.js"></script> <script src="/js/article/alert-signup.js"></script> <script type='text/javascript'>
    var lTitle = "Protecting the heart in cancer therapy".replace("'", '');
    var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/7-1566/v1" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by ');

    var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/7-1566/v1&title=" + encodeURIComponent(lTitle);

    var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/7-1566/v1" + "&title=" + encodeURIComponent(lTitle);

            linkedInUrl += encodeURIComponent('Finet JE and Tang WHW');
    
    var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; 
    var addthis_config = {
            ui_offset_top: offsetTop,
                                    services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_custom : [
                {
                    name: "LinkedIn",
                    url:  linkedInUrl,
                    icon:"/img/icon/at_linkedin.svg"
                },
                {
                    name: "Mendeley",
                    url:  "http://www.mendeley.com/import/?url=https://f1000research.com/articles/7-1566/v1/mendeley",
                    icon:"/img/icon/at_mendeley.svg"
                },
                {
                    name: "Reddit",
                    url:  redditUrl,
                    icon:"/img/icon/at_reddit.svg"
                },
            ]
        };


    var addthis_share = {
            url: "https://f1000research.com/articles/7-1566",
            templates : {
                twitter : "Protecting the heart in cancer therapy. Finet JE and Tang WHW, published by " + 
               "@F1000Research"
       + ", https://f1000research.com/articles/7-1566/v1"
            }
        };

    if (typeof(addthis) != "undefined"){
        addthis.addEventListener('addthis.ready', checkCount);
        addthis.addEventListener('addthis.menu.share', checkCount);
    }

        $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter);
    $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url);
    $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url);
    $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url);
    $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url);

    function checkCount(){
        setTimeout(function(){
            $(".addthis_button_expanded").each(function(){
                var count = $(this).text();
                if (count !== "" && count != "0")
                    $(this).removeClass("is-hidden");
                else
                    $(this).addClass("is-hidden");
            });
        }, 1000);
    }
</script> <div id=citeReportModal role=dialog aria-labelledby=citeReportModal_title aria-describedby=citeReportModal_description> <div class="c-modal js-modal is-closed c-modal--large js-cite-report-modal "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-black--high "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <h1 id=citeReportModal_title class="c-modal__title t-h3 u-mt--0 u-mb--2 u-weight--md">How to cite this report</h1> <div id=citeReportModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div id="" class=js-report-citation-container>{{reportCitation}}</div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" title="Copy the current citation details to the clipboard." data-clipboard-target="#referee-report-citation" data-test-id=report_copy-citation_button class="c-button c-button--full js-modal__confirm c-button--primary js-clipboard c-mini-tooltip--above">Copy Citation Details</a> </div> </aside> </div> </div> <script src="/js/referee/new/referee_validators.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/referee/new/referee_checkbox-input.js"></script> <script src="/js/referee/new/referee_inline-editor.js"></script> <script type="text/javascript">
    $(function(){
        var gaCat = "F1000Research";
        if (gaCat === "") {
            gaCat = $("body").hasClass("wellcome-brand") ? "Wellcome Open Research" : "F1000Research";
        }
        GAHelper.track({category: gaCat, action: "Article Page: Protecting the heart in cancer therapy", label: "pageviews"});
        GAHelper.track({category: gaCat, action: "Article Type: Review", label: "Article Page"});
        $(".f1r-article-desk .collection-image").each(function (idx, el) {
            var whatChannel = $(el).find("a").attr("href"),
                channelName = $.trim($(el).parent().find(".collection-detail a").text()),
                gaRef = "(ID: " + whatChannel.replace("/collections/", "") + ") " + channelName;
            GAHelper.track({category: 'ChannelStats', action: "Article Page: Protecting the heart in cancer therapy", label: gaRef});
        });
    });
</script> <script>
    $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');});
    $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');});
</script> <script src="/js/article/track_article.js" type="text/javascript"></script> <script type="text/javascript">
    $.get("/articles/acj/15190/16550")
</script> <script type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js"></script> <script type="text/javascript" src="/js/app/messenger.js"></script> <script type="text/javascript" src="/js/article/article_mobiles.js"></script> <script src="/js/vendor/clipboard.min.js"></script> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/clipboard.js"></script> <script src="/js/article/thesaurus-terms-display.js"></script> <script>
    new F1000.Clipboard();
    new F1000.ThesaurusTermsDisplay("faculty-reviews", "article", "16550");
</script> <script>
    $(document).ready(function() {
        $( "#frame1" ).on('load', function() {
            var mydiv = $(this).contents().find("div");
            var h     = mydiv.height();
            console.log(h)
        });

        
        var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"),
            titleLivingFigure = tooltipLivingFigure.attr("title");
        tooltipLivingFigure.simpletip({
            fixed: true,
            position: ["-115", "30"],
            baseClass: 'small-tooltip',
            content:titleLivingFigure + "<div class='tooltip-arrow'></div>"
        });
        tooltipLivingFigure.removeAttr("title");

        $("body").on("click", ".cite-living-figure", function(e) {
            e.preventDefault();
            var ref = $(this).attr("data-ref");
            $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200);
        });
        $("body").on("click", ".close-cite-living-figure", function(e) {
            e.preventDefault();
            $(this).closest(".popup-window-wrapper").fadeOut(200);
        });

                $(document).on("mouseup", function(e) {
            var metricsContainer = $(".article-metrics-popover-wrapper");
            if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) {
                $(".article-metrics-close-button").click();
            }
        });

        var articleId = $('#articleId').val();

        if($("#main-article-count-box").attachArticleMetrics) {
            $("#main-article-count-box").attachArticleMetrics(articleId, {
                articleMetricsView: true
            });
        }
    });

    var figshareWidget = $(".new_figshare_widget");
    if (figshareWidget.length > 0) {
        window.figshare.load("f1000", function(Widget) {
            // Select a tag/tags defined in your page. In this tag we will place the widget.
            _.map(figshareWidget, function(el){
                var widget = new Widget({
                    articleId: $(el).attr("figshare_articleId")
                    //height:300 // this is the height of the viewer part. [Default: 550]
                });
                widget.initialize(); // initialize the widget
                widget.mount(el); // mount it in a tag that's on your page
                // this will save the widget on the global scope for later use from
                // your JS scripts. This line is optional.
                //window.widget = widget;
            });
        });
    }
</script>

<script>
    $(document).ready(function () {

        
        var reportIds = {
                           "38452": 0,
                           "38453": 0,
                    };

        $(".referee-response-container,.js-referee-report").each(function(index, el) {
            var reportId = $(el).attr("data-reportid"),
                reportCount = reportIds[reportId] || 0;
            $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount);
        });

        var uuidInput = $("#article_uuid"),
            oldUUId = uuidInput.val(),
            newUUId = "e39d877b-0470-4eae-bc51-0b9586021c24";
        uuidInput.val(newUUId);

        $("a[href*='article_uuid=']").each(function(index, el) {
            var newHref = $(el).attr("href").replace(oldUUId, newUUId);
            $(el).attr("href", newHref);
        });

    });
</script>              </div>
        </div>

        
            
            <div class="o-page__footer sticky-email-wrapper">
                
                

                


<footer class="c-footer t-inverted">

    <div class="o-wrapper">
        <div class="o-layout">


                        
            <div class="o-layout__item u-mb--3">
                <div class="c-branding c-branding--research">
                    <img src="/img/research/F1000Research_white.svg" alt="F1000Research">
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <p class="t-h3 u-mt--0 u-mb--0">An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing.</p>

            </div>


                        
            <div class="o-layout__item u-2/3@md">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <div class="o-layout">
                    <nav class="c-footer__nav">

                            <div class="o-layout__item u-3/5@sm u-mb--3">


                                <div class="o-columns o-columns--2">

                                                                            <a href="/browse/articles" class="t-body c-footer__nav-item "      >Browse</a>
                                                                            <a href="/gateways" class="t-body c-footer__nav-item "      >Gateways</a>
                                                                            <a href="/collections" class="t-body c-footer__nav-item "      >Collections</a>
                                                                            <a href="/about" class="t-body c-footer__nav-item "      >How it Works</a>
                                                                            <a href="https://blog.f1000.com/blogs/f1000research/" class="t-body c-footer__nav-item "      >Blog</a>
                                                                            <a href="/contact" class="t-body c-footer__nav-item "      >Contact</a>
                                                                            <a href="/developers" class="t-body c-footer__nav-item u-hide u-show@navbar"      >For Developers</a>
                                                                            <a href="/published/rss" class="t-body c-footer__nav-item "   title="RSS feed of published articles"     >RSS</a>
                                    
                                </div>

                            </div>

                            <div class="o-layout__item u-2/5@sm u-center u-right@sm u-mb--3">

                                <div class="u-hide u-show@lg">
                                    <div class="_mdl-layout">
                                        <a class="mdl-button mdl-js-button mdl-button--inverted mdl-button--no-shadow mdl-js-ripple-effect mdl-button--outline" href="/for-authors/publish-your-research"   data-test-id="footer_submit_research"  >Submit Your Research</a>
                                    </div>
                                </div>

                            </div>

                    </nav>
                </div>

            </div>

            <div class="o-layout__item u-mb--2">
                <div class="c-footer__share">
                        <div class="c-footer__share">
        <span class="c-footer__share-icon" title="Open Access">
            <span class="f1r-icon icon-100_open_access license-icon"></span>
        </span>

        <a class="c-footer__share-icon" href="//creativecommons.org/licenses" target="_blank" title="Creative Commons License CC-BY">
            <span class="f1r-icon icon-116_cc license-icon license-icon-cc"></span>
            <span class="f1r-icon icon-117_ccby license-icon license-icon-cc"></span>
        </a>

        <a class="c-footer__share-icon" href="//creativecommons.org/about/cc0" target="_blank" title="Creative Commons License CC0">
            <span class="f1r-icon icon-118_cco license-icon"></span>
        </a>

    </div>
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="c-footer__social u-mt--0 u-mb--0 u-white--low-med">Follow us
                    <a href="https://www.facebook.com/F1000" target="_blank" class="c-footer__social-icon f1r-icon icon-55_footer_facebook"></a>
                    <a href="https://twitter.com/#!/F1000Research" target="_blank" class="c-footer__social-icon f1r-icon icon-56_footer_twitter"></a>
                    <a href="http://www.youtube.com/user/F1000research" target="_blank" class="c-footer__social-icon f1r-icon icon-57_footer_youtube"></a></p>

            </div>


                        
            <div class="o-layout__item u-2/3@md u-right@md">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="t-caption u-white--low-med">&copy; 2012-2020 F1000 Research Ltd. ISSN 2046-1402 | <a href="/about/legal" class="copyrightLegal">Legal</a> | Partner of <a target="_blank" href="http://www.who.int/hinari/en/">HINARI</a>  &bull; <a target="_blank" href="http://crossref.org/">CrossRef</a> &bull; <a target="_blank" href="http://about.orcid.org/">ORCID</a> &bull; <a target="_blank" href="http://www.fairsharing.org">FAIRSharing</a></p>

            </div>
        </div>
    </div>

</footer>            </div>
        
    </div>

            <div class="js-cookie-spacer"></div>
        <div class="cookie-warning">
            <div class="instruction">The F1000Research website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. <a class="js-scroll-to" href="/about/legal/privacypolicy#use-of-cookies" data-scroll-target="#use-of-cookies">Find out more &raquo;</a></div>
            <div class="close-button"></div>
        </div>
    
    <script>
                    R.templateTests.simpleTemplate = R.template('<p class="$variable.one">$text</p><p class="${variable.two}">$text</p><p class="$!variable.three">$text</p><p class="$!{variable.four}">$text</p><p class="${selector}.five">$text</p>');
            R.templateTests.runTests();
        
        var F1000platform = new F1000.Platform({
            name: "f1000research",
            displayName: "F1000Research",
            hostName: "f1000research.com",
            id: "1",
            editorialEmail: "research@f1000.com",
            infoEmail: "info@f1000.com",
            usePmcStats: true
        });

                    $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');});
            // $(function(){R.ui.dropdowns('.dropdown-for-referees');});

            $(document).ready(function () {
                if ($(".cookie-warning").is(":visible")) {
                    $(".sticky").css("margin-bottom", "35px");
                    $(".devices").addClass("devices-and-cookie-warning");
                }
                $(".cookie-warning .close-button").click(function (e) {
                    $(".devices").removeClass("devices-and-cookie-warning");
                    $(".sticky").css("margin-bottom", "0");
                });

                $("#tweeter-feed .tweet-message").each(function (i, message) {
                    var self = $(message);
                    self.html(linkify(self.html()));
                });

                $(".partner").on("mouseenter mouseleave", function() {
                    $(this).find(".gray-scale, .colour").toggleClass("is-hidden");
                });
            });
        
    </script>

            
<div class="sign-in-popup">
	<!-- <a href="#" class="sign-in shadow">Sign in <span class="sign-in-image-active"></span></a> -->
	<a href="#" class="sign-in ${locale}">Sign In <span class="arrow-closed sign-in-arrow-padding arrow-opened"></span></a>
	<div class="sign-in-form">

            <form action="https://f1000research.com/j_spring_oauth_security_check" id="googleOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/7-1566.html"/>
                            <input id="google-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-google" name="system" type="hidden" value="GOOGLE"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="facebookOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/7-1566.html"/>
                            <input id="facebook-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-fb" name="system" type="hidden" value="FACEBOOK"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="orcidOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/7-1566.html"/>
                            <input id="orcid-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-orcid" name="system" type="hidden" value="ORCID"/>
    </form>
		<form id="sign-in-form" class="login-container" action="https://f1000research.com/login" method="post" name="f">
           <div id="sign-in-form-gfb-popup"></div>

                                                            <input class="target-field" type="hidden" name="target" value="/articles/7-1566.html"/>
                            			<input type="text" name="username" id="signin-email-box" class="sign-in-input" placeholder="Email address" autocomplete="email">
			<input type="password" name="password" id="signin-password-box" class="sign-in-input" placeholder="Password" autocomplete="current-password">
			<div class="sign-in-remember">
                <div class="checkbox-wrapper">
    				<input type="checkbox" id="remember-me" name="remember_me" class="checkbox is-hidden">
                </div>
                <span class="checkbox-label">Remember me</span>
			</div>
			<a href="#" class="sign-in-link" id="forgot-password-link">Forgotten your password?</a>
			<div class="sign-in-button-container margin-top margin-left-20 margin-bottom">
				<button type="submit" id="sign-in-button" class="sign-in-buttons general-white-orange-button">Sign In</button>
				<button type="button" id="sign-in-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
				<div class="clearfix"></div>
			</div>
			<div class="sign-in-error">Email or password not correct. Please try again</div>
			<div class="sign-in-loading">Please wait...</div>
		</form>
		<div class="forgot-password-container">
			
<script type="text/javascript">
	$(function(){
		// Note: All the setup needs to run against a name attribute and *not* the id due the clonish
		// nature of facebox...
		$("a[id=googleSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("GOOGLE");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=facebookSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("FACEBOOK");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=orcidSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("ORCID");
            $("form[id=oAuthForm]").submit();
        });
	});
</script>

<span class="text first">
	If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.
    <p>The email address should be the one you originally registered with F1000.</p>
</span>
<input name="email" class="sign-in-input" id="email-forgot-password" type="text" placeholder="Email address">
<div class="forgot-password-email-error">
	Email address not valid, please try again
</div>
<div class="forgot-password-google-email-error">
    <p>You registered with F1000 via Google, so we cannot reset your password.</p>
	<p>To sign in, please click <a href="#" id="googleSignInButton">here</a>.</p>
    <p>If you still need help with your Google account password, please click <a href="https://www.google.com/accounts/recovery">here</a>.</p>
</div>
<div class="forgot-password-facebook-email-error">
    <p>You registered with F1000 via Facebook, so we cannot reset your password.</p>
    <p>To sign in, please click <a href="#" id="facebookSignInButton">here</a>.</p>
	<p>If you still need help with your Facebook account password, please click <a href="https://www.facebook.com/recover/initiate">here</a>.</p>
</div>
<div class="clearfix"></div>
<div class="forgot-password-captcha-error">
	Code not correct, please try again
</div>
<div class="clearfix"></div>
<div class="sign-in-button-container margin-left-20 margin-bottom">
	<button type="button" id="sign-in-reset-password" class="sign-in-buttons general-white-orange-button">Reset password</button>
	<button type="button" id="forgot-password-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
	<div class="clearfix"></div>
</div>
<span class="text last">
	<a href="mailto:">Email us</a> for further assistance.
</span>
<form action="https://f1000research.com/j_spring_oauth_security_check" id="oAuthForm" method="post" target="_top">
                        <input class="target-field" type="hidden" name="target" value="/articles/7-1566.html"/>
                <input id="oAuthSystem" name="system" type="hidden"/>
</form>
			<div class="forgot-password-server-error">Server error, please try again.</div>
			<div class="sign-in-success">
                <p>We have sent an email to <span id="email-value"></span>, please follow the instructions to reset your password.</p>
                <p>If you don't receive this email, please check your spam filters and/or contact .</p>
            </div>
			<div class="sign-in-loading">Please wait...</div>
		</div>

		<div class="sign-in-form-register-section">
			<div class="sign-in-button-container margin-left-20 margin-bottom">
				<a href="/register" title="Register"><button type="button" id="sign-in-register-button" class="sign-in-buttons general-white-orange-button">Register</button></a>
				<div class="clearfix"></div>
			</div>
		</div>

	</div>
</div>

<script type="text/javascript">
$(document).ready(function () {

    signIn.createSignInAsRow($("#sign-in-form-gfb-popup"));

    $(".target-field").each(function () {
        var uris = $(this).val().split("/");
        if (uris.pop() === "login") {
        	$(this).val(uris.toString().replace(",","/"));
        }
    });
});
</script>
        <div id="templateOverlay" class="is-hidden" hidden="hidden">
  <div class="o-overlay js-overlay is-hidden" hidden="hidden"></div>
</div>

<div id="templateExternalMessages" class="is-hidden" hidden="hidden">
  <div class="o-modal o-modal--auto@md js-external-messages is-hidden" hidden="hidden">
    <div class="o-modal__body">
      <section class="c-console">
        <div class="_mdl-layout c-console__bdy js-external-messages-body"></div>
        <footer class="_mdl-layout c-console__ftr o-flex o-flex--reverse js-external-messages-footer">
          <button type="button" class="mdl-button mdl-js-button mdl-button--raised mdl-button--colored c-console__btn js-external-messages-close" data-action="maintenance-close">I Understand</button>
        </footer>
      </section>
    </div>
  </div>
</div>

<script src="https://cdnjs.cloudflare.com/ajax/libs/moment.js/2.22.1/moment.min.js"></script>

<script src="/js/namespace.js"></script>
<script src="/js/constants.js"></script>
<script src="/js/utilities.js"></script>

<script>
                  F1000.ExtenalMaintenanceItems = [
    {
      start: '2018-12-10T14:21:00Z',
      end: '2018-12-13T16:00:00Z',
      msg: 'This site will be down for a short time on XX December. It is advisable not to start any submissions on that day or you may lose your work unless you save regularly.',
      cookieName: 'outage23122018',
      editor: false,
    }
  ];
</script>

<script src="/js/shared_scripts/cookie-helper.js"></script>
<script src="/js/shared_scripts/mdl-helper.js"></script>

<script src="/js/app/external-maintenance.js"></script>

                <script type="text/javascript">
            (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
            (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
            m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
            })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

            ga('create', 'UA-5646075-11', 'auto');
            ga('require', 'displayfeatures');
            ga('send', 'pageview');
        </script>
        
                <script type="text/javascript" src="/js/app/research.analytics.js"></script>

        <!-- Start of HubSpot Embed Code -->
        <script type="text/javascript" id="hs-script-loader" async defer src="//js.hs-scripts.com/4475190.js"></script>
        <!-- End of HubSpot Embed Code -->
    
            <script src="https://my.hellobar.com/4e0495c6f18cbd68731a1dc1978195a144e767ba.js" type="text/javascript" charset="utf-8" async="async"></script>
    </body>

</html>